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Abstract 
 
Cell-to-cell signaling molecules are an important class of endogenous molecules 
which are responsible for cell-to-cell communication within organisms. Small molecules 
and peptides work as neurotransmitters and neuromodulators in the nervous system and 
play important regulatory roles in a wide range of physiological events and animal 
behaviors, such as pain sensation, food intake, memory, circadian rhythm, tissue 
regeneration and drug addiction. Cell-to-cell signaling molecules are highly diverse in 
structure or sequence and their quantities are different at various time points or locations 
in the nervous system. In addition, cell-to-cell signaling molecules are usually expressed 
in relatively low abundance level in cells. All these features make the characterization of 
cell-to-cell signaling molecules a challenging task.   
Multiple methods have been successfully applied to study cell-to-cell signaling 
molecules in different animal models. Mass spectrometry (MS), with the assistance of 
improved sampling and separation techniques, can reveal identity and structure of cell-to-
cell signaling molecules and also provide insight into their changes in different biological 
processes.  
Various sample types are used in the study of cell-to-cell signaling molecules, 
such as cell releasates, tissues and biological fluids. This often requires an optimized use 
of an MS platform or a combination of them, depending on the practical situation and 
research goal. In this dissertation, four different MS platforms which cover both 
electrospray ionization (ESI) and matrix assisted laser desorption/ionization (MALDI) 
were used to characterize cell-to-cell signaling molecules secreted by or contained in 
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animal models of rotifers, mice and rats in both a targeted and untargeted manner. For 
targeted studies, a separation protocol or detection channel is established and optimized 
specifically for one or a few molecules of interest, whose functions or involvements in 
certain biological processes are known. For untargeted studies, MS is usually coupled 
with bioinformatics for peptide identification or integrated with statistics for comparative 
quantitation.  
Findings from these studies help facilitate our understanding of cell-to-cell 
communications in different animal models. In addition, the work presented in this 
dissertation also includes development of novel analytical methods and evaluation of 
different sampling methods, which represent a contribution in the aspect of methodology. 
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Chapter 1 
Introduction and Summary of Thesis Work 
 
1.1 Introduction to cell-to-cell signaling molecules 
Cell-to-cell signaling molecules play important roles in information transmission 
between different cells. They are ligands binding to receptors expressed by signal- 
receiving cells. Different types of molecules can work as cell-to-cell signaling molecules, 
ranging from small gas molecules like NO and amino acids to peptides and proteins, such 
as angiotensin and insulin.(1-4) Small molecules and neuropeptides are two primary 
classes of cell-to-cell signaling molecules. Here, both classes of cell-to-cell signaling 
molecules were introduced with an emphasis on neuropeptides as they are involved in 
most of the work presented in this dissertation. 
 
1.1.1 Introduction to small molecules as cell-to-cell signaling molecules 
Small molecules work as neurotransmitters in the nervous system. Common 
neurotransmitters include glutamate, serotonin, acetylcholine, norepinephrine, dopamine 
and γ-aminobutyric acid. These neurotransmitters are synthesized in the presynaptic 
neurons and released from their termini upon stimulation. After release, neurotransmitters 
bind to the receptors on the post-synaptic neurons, most of which are ligand-gated ion 
channels.(5-7) Once signal transmission is finished, the neurotransmitters left in the 
synaptic cleft are quickly removed by enzymatic degradation or recycled by nearby 
cells.(8, 9)  
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1.1.2 Introduction to neuropeptides 
Neuropeptides are a remarkable class of signaling molecules. Neuropeptides 
primarily function as neuromodulators in the nervous system.(10) In addition, some 
neuropeptides or signaling peptides are secreted into the circulatory systems like blood 
streams and act as hormones in the endocrine system.(11) Neuropeptides have been 
implicated in a broad range of biological and behavioral functions, such as blood pressure 
regulation, food intake, memory, depression, circadian rhythm, drug addiction and pain 
sensation.(12-18) 
Neuropeptides are enzymatic cleavage products of larger precursor proteins called 
prohormones.(19) In the production of neuropeptides, the initial precursor protein 
contains a signal peptide at its N-terminus, followed by the sequence of the prohormone. 
The short N-terminal signal peptide guides and translocates the preprohormone through 
rough endoplasmic reticulum (RER) and is then rapidly removed by a signal 
endopeptidase. Removal of the signal peptide is finished before the completion of mRNA 
translation. In the next step, prohormones are transferred to the Golgi networks and enter 
regulated secretory pathways. Prohormones are sorted away from other proteins by the 
Golgi networks and packed into secretory granules (SGs) and large dense-core vesicles 
(LDCVs). Enzymatic processing of prohormones also starts at the Golgi network and 
continues in SGs and LDCVs. Figure 1.1 shows the steps involved in prohormone 
processing. Prohormones are first processed by prohormone convertases (PCs), a group 
of enzymes that perform peptide bond cleavages at dibasic sites. Such cleavage can also 
occur at mono basic sites, sites following K/R[X]nK/R pattern (n=2, 4, 6) or even 
nonbasic sites, which are less common. The K or R residues left at the C-terminus of 
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cleavage products are removed by arginine or lysine carboxypeptidase. Some of these 
final cleavage products become bioactive neuropeptides that are released upon 
stimulation, while some are further modified by various enzymes to possess post- 
translational modifications (PTMs).(19, 20) PTMs can greatly affect the bioactivity and 
stability of neuropeptides and their binding affinity to receptors.(21, 22) Two important 
and common PTMs observed in neuropeptides are N-terminal pyroglutamination and C-
terminal amidation, which result in a mass shift of the neuropeptide by -17.03 Da and -
0.98 Da respectively. These two PTMs are also considered a hallmark of bioactive 
neuropeptides and used in the annotation of novel prohormones in species lacking 
sequenced genome.(19, 23, 24) Other PTMs seen on neuropeptides include acetylation 
(+42.01 Da), phosphorylation (+79.97 Da), disulfide bond (-2.02 Da) and oxidation 
(+15.99 Da).(25-28) The mature neuropeptides stored in SGs and LDCVs are released 
from neurons upon stimulation. Different from neurotransmitters, released neuropeptides 
can be present in the nervous system for longer duration, diffuse and bind to receptors, 
mostly G-protein coupled receptors (GPCRs), at a location distant from the cells where 
they are released.(29)   
The expression of neuropeptides has three important features impacting their 
characterization. First, neuropeptide expression is tissue-specific, which means that 
different sets of neuropeptides are produced from the same prohormone in different 
tissues or brain regions. For example, as shown in Figure 1.1, pro-opiomelanocortin 
(POMC) is cleaved into β-MCH and β-endorphin 1-27 in the hypothalamus but into γ-
LPH and ACTH peptides in the anterior pituitary.(30, 31) Related to the first feature, 
neuropeptides are functionally diverse. Even for the same neuropeptide, its biological 
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function can be completely different depending on where it is expressed and released. 
The third feature in neuropeptide expression is its dependence on time. Forms and 
quantities of neuropeptides are usually dynamic, changing between different 
developmental or pathological stages. For instance, somatostatin has a progressive 
postnatal increase in the rat hypothalamus and cortex.(32) The expression of 
neuropeptide Y is up-regulated in the striatum in Parkinson’s disease patients.(33) 
Because of these three features of neuropeptides, it is critical to accurately determine the 
identity, PTM and quantity of different neuropeptides in order to gain a better 
understanding of their roles in the nervous system. 
 
1.2 Introduction to model organisms  
To understand how the human brain works is challenging. An alternative way is 
to study signaling molecules using simplified animal models. In the Sweedler group, a 
broad range of animal models have been used, ranging from invertebrates like sea hare, 
Aplysia californica to vertebrates, like rodents. Here, a few organisms used in the work 
shown in this dissertation are briefly introduced.  
 
1.2.1 Rotaria rotatoria 
The rotifers are a group of aquatic micrometazoans under the phylum of 
microscopic and near-microscopic pseudocoelomate animals. They are small in size, 
usually less than one millimeter and can be found in freshwater and oceans. Rotifers are 
characterized by their wheel organs located in the cephalic region, which are used for 
movements and food intake.(34, 35) We study one species of rotifers, Roraria ratatoria 
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because this animal releases an unknown metabolite that paralyzes the parasitic flatworm, 
Schistosoma. 
 
1.2.2 Mus musculus 
Mus musclus is one of the most widely used animal models used in various types 
of experiments. Mice have many advantages over other animals in biological research. 
Compared with bacteria and invertebrates, mice are mammals. Therefore, many 
similarities with respect to genes and molecular functions are found between mice and 
human.(36) Many regions found in human brains are also conserved in mice. On the 
other hand, mice are inexpensive, easy to handle and maintain and have a short 
reproduction cycle as compared to other mammals like dogs and monkeys. The genome 
of mice is sequenced, which makes the protein and peptide identification easier. In the 
study of signaling molecules, male mice are used since they have smaller fluctuations in 
hormones. 
 
1.2.3 Rattus norvegicus 
Rattus norvegicus is another commonly used rodent animal model in the 
laboratory. Similar to mice, rats also possess the advantages mentioned in 1.2.2 and their 
genome has been sequenced as well. One difference between these two rodent models is 
their size. As a result, it is easier to isolate small and fine structures from rat brains. 
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1.3 Introduction to liquid chromatography 
Proteomics and peptidomics often require the extraction and preconcentration of 
proteins and peptides from bulk tissue or biological fluids such as serum and 
cerebrospinal fluid (CSF). A common challenge in analyzing such samples is their high 
chemical complexity, which suppresses the signal of peptides of interest and interference 
with mass spectrometry data interpretation.(27) Various liquid chromatography 
techniques have been used to separate or fractionate complex biological samples prior to 
MS analysis.(27, 37, 38) The most widely used technique is reverse phase liquid 
chromatography (RPLC). In a RP column, peptides are separated from each other 
primarily based on their hydrophobicity. Other factors like column resin particle size and 
pore size also can affect the separation efficiency. For our typical neuropeptidomics study, 
2~5 µm resin with 100  Å provides satisfactory separation performance. Peptides 
partitioned in the stationary phase can be eluted off the RP column through an increasing 
gradient of organic solvent. Methanol (MeOH) and acetonitrile (ACN) are two commonly 
used elution solvents. MeOH is more hydrophilic as compared with ACN. Therefore, 
peptides are eluted at a higher percentage of MeOH, which facilitates downstream 
electrospray ionization. However, H2O and MeOH mixture has a higher viscosity, 
resulting in an increase in pump and column pressure.(39) In addition, different acid 
additives are also added into mobile phases at a low concentration (e.g. 0.1%). The 
addition of acids lowers pH of solvents and can aid protonation of peptides during 
ionization, enhancing peptide signal intensity.(40, 41) Commonly used acids include 
formic acid (FA) and acetic acid (AA). Other acids such as trifluoroacetic acid (TFA), 
heptafluorobutyric acid (HFBA) and perfluorinated acids (PFA) not only promote 
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protonation but also work as ion paring reagent which improves peak shape, separation 
selectivity and efficiency. However, it is worth noticing that these fluorinated acids 
should be used at lower concentration, usually 0.01%, to avoid ion suppression during 
electrospray ionization.(41) 
To increase the peptide coverage in a complex sample, multidimensional HPLC 
approach can be employed, in which the 1
st
 stage HPLC has a separation principle 
different from RPLC. Strong cation chromatography (SCX) (42), affinity 
chromatography (AFC) (43), hydrophilic interaction chromatography (HILIC) (44) and 
size exclusion chromatography (SEC) (45) have been successfully used in the 1
st
 stage 
separation.  The fractions collected from the 1
st
 stage separation can be analyzed in online 
and offline mode. Online analysis means that peptides are eluted from 1
st
 column in 
stepwise manner and loaded onto RP column subsequently. In offline mode, fractions 
from 1
st
 LC are collected. Part or all of the collected fractions can be re-injected into RP 
column for analysis with or without further sample treatment between the 1
st
 and 2
nd
 
separations.   
 
1.4 Introduction to mass spectrometry 
Mass spectrometry is a technique measuring the mass to charge ratio (m/z) of 
analytes ionized into gas phase. In the post Genomics era, study of the entire set of 
metabolites, peptides and proteins becomes accessible due to the development of soft 
ionization methods and improvement in mass spectrometry instrumentation.(46-49) In 
this dissertation, different MS platforms were utilized to study signaling molecules with a 
focus on neuropeptides. These platforms include matrix-assisted laser 
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desorption/ionization (MALDI) time of flight (TOF) MS, electrospray ionization- (ESI) 
quadrupole-time of flight (QTOF) MS, ESI-Fourier transform ion cyclotron resonance 
(FT ICR) MS and ESI-triple quadrupole (QqQ) MS. Different MS platforms have their 
own features, which result in their different applications and affect the experiment 
results.(50, 51) The ionization techniques and mass analyzers used in the dissertation 
work are briefly introduced in the following content.  
 
1.4.1 Ionization methods 
1.4.1.1 Matrix-assisted laser desorption ionization 
Matrix-assisted laser desorption ionization is a soft ionization technique in mass 
spectrometry analysis. “Soft” means the analytes such as peptides, proteins and other 
biological molecules become ions and enter gas phase without much fragmentation, 
which could not be achieved using previous conventional ionization techniques like 
electron ionization.(52) As the name suggests, matrices are required in MALDI analysis. 
Common MALDI matrices include 2, 5-dihydroxybenzoic acid (DHB), α-cyano-4-
hydroxy cinnamic acid (CHCA) and sinapinic acid (SA). In MALDI analysis, samples 
are spotted on the target plate and mixed with matrix chemicals which have a strong laser 
absorption. After drying, the sample re-crystalized with matrix is radiated with a laser 
under vacuum. Analytes and matrix molecules are ionized upon laser application and are 
guided to and analyzed by downstream mass analyzer (Figure 1.2). Ions generated 
through MALDI are usually singly charged. In addition to protonated analytes, sodium 
and potassium adducts are also commonly observed in MALDI spectra, which 
correspond to M+H+22 Da and M+H+38 Da.  
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MALDI has several advantages over other ionization techniques. 1. Large 
biological molecules like peptides, lipids and DNAs are intact during ionization. As a 
result, the molecular weight as well as information about post-translational modifications 
is kept. 2. MALDI spectra are easier to interpret as most analytes are singly charged. 3. 
MALDI has an outstanding sensitivity which makes it the tool of choice for the analysis 
of low-abundance peptides, such as cell releasates and single cells.(53, 54) 4. MALDI is 
tolerant to salt so that sample loss is reduced due to simplified sample pretreatment. 5. 
MALDI is usually used in off-line manner. This allows real-time analytical parameter 
adjustment so quality of the spectra of a particular ion or mass range can be optimized. 
However, MALDI also has a few drawbacks. Firstly, MALDI has a poor 
reproducibility since the spectra quality is greatly affected by the sample and matrix 
crystallization, which is a process hard to control. Secondly, matrix also generates peaks 
in the low mass range (100-1000 Da). These peaks can inference or suppress signals from 
small biological molecules. Thirdly, pulsed nature of MALDI limits compatibility with 
many mass analyzers. Currently, most MALDI instruments employ TOF or FT ICR as 
mass analyzers.  
 
1.4.1.2 Electrospray ionization 
ESI is another important soft ionization technique for biological molecule analysis. 
It was first used for characterization of large biological molecules by Yamashita and 
Fenn back in 1980s.(55) In ESI, one or mixed volatile solvent is pumped through a small 
capillary and pushed out of a conductive spray tip maintained at a high voltage. At the tip 
end, a Taylor cone is formed due to the strong electric field formed between the spray tip 
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and MS inlet nozzle. Charged smaller droplets are generated and emitted from the Taylor 
cone and move towards the MS inlet nozzle (Figure 1.3).(56) Heated nebulizer gas (e.g. 
N2) is used to assist the evaporation of solvents insides these droplets during their 
migration. Smaller charged droplets are generated through Coulomb explosion when the 
surface tension cannot hold the droplet due to increased repulsion forces between ions 
inside. The same process is repeated until the eventual generation of gaseous ions. 
However, the mechanism for the final step, gaseous ion production, is not well 
understood. Both charged residue model and ion evaporation model have been 
proposed.(57, 58) Different from MALDI, ions formed through ESI often possess 
multiple charges. The distribution of different charge states depend on various factors, 
such as peptide sequence, solvent property and solvent additives. For peptide work, ESI 
is usually operated at positive mode. Diluted acids are added into solvents to enhance 
peptide protonation. In some cases, super charging reagents (e.g. m-nitrobenzyl alcohol 
(m-NBA) and dimethyl sulfoxide (DMSO)) are also added into solvents or post-column 
to further enhance the dominant change state peak intensity.(59, 60) ESI has its own 
merits: 1. Molecular integrity is preserved in ESI as it is a very gentle ionization method; 
2. ESI has a better reproducibility than MALDI since no hard-to-control crystallization 
process is involved. Thus it is widely used for quantitative experiments; 3. ESI can be 
coupled to different mass analyzers so that it has better adaptability for various types of 
research; 4. The ion generation is continuous and ions have high charge states and energy. 
These two features ensure that enough ions with high energy are generated and subject to 
collision induced dissociation. It facilitates the fragmentation of precursor ion, which is 
advantageous for identification and structure determination of analytes. A shortcoming of 
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ESI is its susceptibility to salt, detergent and other polymeric contaminants.(61, 62) 
These chemicals can affect stability of ESI or have strong suppression effects. Besides, 
ESI is usually used in LC-MS setup, so no data collection parameter can be optimized 
once the LC-MS injection gets started. 
 
1.4.2 Mass analyzers 
1.4.2.1 Quadrupole  
Quadrupole is one of the most widely used mass analyzer in chemical analysis. It 
can serve as the final mass analyzer or applied in other types of instruments as ion 
transmission optics. As its name suggests, the quadrupole is composed of two pairs of 
hyperbolic or cylindrical rods. A combination of a time-independent direct-current (DC) 
voltage and a time-dependent alternating-current (AC) voltage is applied on these two 
pairs of rods. The first pair in X-Z plane controls the highest m/z that can pass through 
while the other pair controls the lowest m/z. The operating principle makes quadrupole a 
great mass band filter, only allowing ions of interest to reach detector or downstream 
instrument components.(63, 64)  
A quadrupole instrument commonly used in metabolomics and peptidomics 
research is triple quadrupole (QqQ) MS. In QqQ MS, the first and third quadrupole work 
as mass filters, enabling isolation of ions of interest. The second quadrupole is the place 
where ion dissociation occurs. QqQ MS is a great tool for quantitative analysis. As shown 
in Figure 1.4, it can be operated at different modes for different scientific applications, 
such as single ion monitoring, neutral loss scan and multiple reaction monitoring 
(MRM).(65) In this dissertation, MRM mode is used in targeted peptide quantitation 
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study. Only the ions possessing m/z close to targeted peptides pass the first quadrupole 
and dissociate in the second one through colliding with neutral gases (e.g. N2). The third 
quadrupole filters all the fragments and only allows a few preselected structure or 
sequence-specific fragment ions to reach the detector.  
 
1.4.2.2 Time-of-flight 
The concept of time of flight (TOF) mass analyzer was first introduced by Prof. 
Stephens at University of Pennsylvania in 1946.(66) TOF, as its name implies, measures 
the time that ions fly in a field free drift tube before reaching the detector, then converts 
time data to m/z values through other algorithms. Ideally, ions have the same amount of 
kinetic energy after being accelerated in an electric field and entering the drift tube. The 
relationship between m/z and ion flight time can be described using the following 
equations. 
𝐸𝑘 =
1
2
𝑚𝑣2 =
1
2
𝑚(𝐿 𝑡⁄ )2 = 𝑧𝑉 (Equation 1) 
Equation 1 can be transformed to: 
𝑚/𝑧 = (2𝑉/𝐿2)𝑡2 (Equation 2) 
Ek, kinetic energy; m, mass; v, velocity; L, drift tube length; V, voltage; z, ion 
charge. 
As Equation 2 shows, the m/z of ions are in proportion to the square of flight time 
when ions are accelerated with a fixed voltage and fly in a drift tube with fixed length.  
TOF has multiple advantages over other types of mass analyzers. These 
advantages include:(1). TOF can record a mass spectrum in a few microseconds; (2). 
TOF is well suited for pulsed ionization method and used as a mass analyzer in most of 
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the MALDI instruments; (3). TOF has the highest practical working mass range as it 
measures time instead of m/z directly.(67) However, a well-recognized challenge in TOF 
is that its resolution is compromised by the velocity spread of ions entering the drift tube. 
Two solutions have been developed to address this issue. The first one is to use an 
electrostatic ion reflector named reflectron. Ions with different velocities penetrate into 
the reflectron by different extent. Faster ions take a longer path to reach the detector than 
slower ions, in which the spread of initial velocity is compensated (Figure 1.2).(68, 69) 
Another solution to improve resolution in TOF is to apply delayed ion extraction. In this 
method, ions enter an acceleration region located between ion source and TOF drift tube. 
After a short amount of time, voltages are applied across the acceleration region. Ions 
with low initial velocity are closer to the ion source and accelerated at a greater potential, 
which allows them to receive extra energy to catch up with faster ions.(70) 
 
1.4.2.3 Quadrupole time-of-flight 
The quadrupole time-of-flight (QTOF) is a common hybrid mass analyzer in the 
analysis of biological molecules. The quadrupole works as an ion transmission and 
focusing component and is installed in the orthogonal direction to the TOF drift tube. In 
MS/MS mode, the quadrupole is also used as the collision cell where dissociation of 
selected precursor occurs. Precursor or fragment ions enter the TOF part and are analyzed 
through the principle mentioned in 1.5.2.2.  
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1.4.2.4 Fourier-transform ion cyclotron resonance 
Fourier-transform ion cyclotron resonance (FT-ICR) MS is a powerful technique 
used in different chemical analysis. Its applications cover a broad range of fields such as 
metabolomics, peptidomics, proteomics, lipidomics and the analysis of glycan and 
petroleum since FT-ICR MS provides outstanding resolution and mass accuracy.(71-77) 
The resolving power of FT-ICR can reach 1×10
7
 which is even able to differentiate subtle 
mass differences such as N
15
H and O
16
. During data acquisition, ions are transmitted into 
an ICR cell which is made of three pairs of opposing metal plates, including trapping, 
excitation and detection plates. A homogenous magnetic field is applied in the ICR cell 
so that ions inside move in circular paths in the plane composed of excitation and 
detection plates. The frequency of such circular movement is only determined by the m/z 
of the ion and magnetic field strength. After ions being guided into the ICR cell, an 
electric field that oscillates at or near the cyclotron frequency of ions in the m/z range of 
interest is applied on the excitation plates for ion excitation. The excitation increases the 
radius of circular paths of ions without changing the angular frequency and eventually 
makes their circular trajectory in proximity to the detection plates. Every time when an 
ion packet passes detection plates, a charge movement is induced within the circuit 
between two detection plates and recorded. The recorded charge movement is time-
dependent and measured as a function of time. Information on the time domain can be 
extracted and converted into frequency and m/z through Fourier transformation (Figure 
1.5A).(78, 79) A concern about FT-ICR MS is the space charging effect in the ICR cell. 
However, it could be reduced by controlling the number of ions guided into the cell.(80) 
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1.4.2.5 Orbitrap 
Orbitrap is another mass analyzer that uses Fourier transform to convert 
information on time domain to frequency and m/z of analytes. The concept, orbital 
trapping, was first raised by Kingdon in 1923.(81) However, orbital trapping was not 
successfully applied into mass spectrometer until 2005. Different from FT-ICR, Orbitrap 
does not require the use of a magnetic field. The trap is composed of two parts, a central 
spindle electrode and an outer barrel-like electrode. In the radial direction, ions are 
trapped about the central electrode by the application of an electrostatic field. In the axis 
direction, ions possess harmonic ion oscillations along the axis of the central electrode. 
The frequency of the harmonic oscillation is determined by m/z but not related to spatial 
distribution and energy of the trapped ions. The time-domain of image current transients 
are subjected to Fourier transforms and converted to m/z of ions (Figure 1.5B).(82) 
Orbitrap is also a high resolution mass analyzer and can provide resolving power up to 
150K with 2-5 ppm mass accuracy. However, it does not require cryogenic liquids (e.g. 
liquid N2 and He) to maintain the superconducting magnet like FT-ICR. The current 
commercial Orbitrap instruments have a fast data collection speed and can perform 
tandem MS/MS through collision induced dissociation (CID), higher-energy collisional 
dissociation (HCD) and electron transfer dissociation (ETD).(83, 84) 
 
1.4.3 Tandem mass spectrometry  
Tandem mass spectrometry, commonly abbreviated as MS/MS, refers to a 
technique that breaks down the precursor ion of interest into smaller fragments and 
measures the m/z of these fragments. It is a useful technique widely used in analytical 
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laboratories as it can provide important structural or sequence-related information of the 
precursor ion. Up to date, various dissociation techniques have been developed and used 
for different applications. 
Among them, CID is the most commonly employed method to fragment the 
precursor ions. In CID, precursor ions are usually accelerated through an electric field to 
increase their kinetic energy and then collide with atoms of inert collision gas (e.g. He, 
N2, Ar and Ne). During collision, some kinetic energy is converted into the internal 
energy of precursor ions, which can result in the breakage of chemical bonds and 
fragmentation of precursor ions. The fragment pattern of analytes is influenced by many 
factors such as collision energy, type of collision gas, structure or sequence of analytes 
and charge states.(85) For small molecules, the fragmentation pattern prediction is 
challenging. However, for peptides dissociated with CID, the most common place where 
the breakage occurs is the C-N peptide bond between two different amino acid residues. 
Such breakage often generates two series of ions, b and y ions, which correspond to 
fragments with N- and C- terminus respectively (Figure 1.6). The mass differences 
between different b and y ions correspond to one or a combination of a few amino acid 
residues and are used in determining the peptide sequence. A low collision energy (25~40 
eV) is usually applied in peptide analysis. For targeted analysis of some peptides or 
proteins, higher energy can be used to gain more structurally informative fragments.(86) 
CID can be performed in quadrupole when ions pass through. For some types of MS such 
as FT-ICR, Orbitrap, ions are stored within an ion trap before detection. This working 
principle enables MS
n
, in which two or more cycles of ion isolation and fragmentation 
are performed.(87, 88) Although CID is the most widely used ion dissociation technique 
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used in ESI-MS and MALDI MS, it has a few shortcomings. First, the peptide bonds are 
not equally broken down in CID. It has been shown that peptide bond cleavage near the 
amino acids glutamic acid, aspartic acid and proline is preferred. This problem leaves 
ambiguity in peptide sequences and can be solved by using a different and 
complementary ion dissociation method.(89) Another issue is that increased internal 
energy in CID usually results in the breakage of the weakest chemical bond regardless of 
its location (peptide backbone or side chains). Therefore, some labile but biologically 
important post-translational modifications (PTMs) cannot be preserved in the dissociation 
step.(89, 90) 
Another common dissociation technique is ETD. In ETD, an electron is 
transferred from a radical anion to a multiply charged analyte. This process makes the 
analyte an unstable radical cation. For peptides, breakage occurs between the N-Cα bond 
on the peptide backbone, generating c and z series of fragment ions.(91) An important 
feature of ETD is that it leaves the PTMs intact, so ETD is widely used in the study of 
glycoproteomics and other PTM investigations.(92) 
In addition to CID and ETD, photodissociation (PD) represents another class of 
dissociation method in the analysis of biological molecules. Both infrared and ultraviolet 
are used in PD. PD occurs after the analytes absorb sufficient energy from the IR or UV 
laser. In infrared multiphoton dissociation (IRMPD), the dissociation is similar to low 
energy CID.(93) Different from IRMPD, analytes can become fragments directly from 
excited electronic states in ultraviolet photodissociation (UVPD). Thus, UVPD can yield 
a different set of fragment ions complementary to those generated in other dissociation 
methods.(94) 
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1.5 Dissertation overview 
The Sweedler group at University of Illinois at Urbana Champaign is always 
committed to develop novel and advanced analytical techniques to understand the 
complicated nervous system on the molecular level. The signaling molecules, including 
neuropeptides and small molecule neurotransmitters, are investigated from three 
perspectives: (1). Chemical aspect. What are the structures or sequences of signaling 
molecules? (2). Temporal aspect. How do the signaling molecules change at different 
points in a time frame? (3). Spatial aspect. How are signaling molecules distributed 
across the nervous system? To answer these three questions, a technique is required that 
can analyze signaling molecules fast and accurately from a complex chemical 
background. Mass spectrometry is the tool of choice as it has good sensitivity, selectivity 
and ability to provide structure/sequence information of analytes. In this dissertation, 
several research projects within the theme of mass spectrometric characterization of cell-
to-cell signaling molecules are presented. These projects include study of both small 
molecules and neuropeptides in qualitative and quantitative manner. 
Chapter 2 is an overview of the state of art mass spectrometry-based approaches 
used for studying signaling molecules, primarily neuropeptides. With a combination of 
these methods, the identity, spatial distribution and quantitative information of signaling 
molecules are characterized, which shed light on mechanisms of various biological 
processes and animal behaviors. Many of these approaches were applied in the work 
presented in chapter 3, 4, 5 and 6.  
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Chapter 3 is about the optimization of sampling methods for the study of 
endogenous peptides. In this project, the effects of different tissue stabilization methods 
on the outcome of neuropeptide identification and quantitation were investigated. ESI-
FT-ICR MS and ESI-QTOF MS were employed for the identification study. ESI-QqQ 
MS was used for targeted neuropeptide quantitation. The results showed that tissue 
stabilization through laser heating under vacuum preserves endogenous peptide content 
better. This method has been accepted as a new standard operating procedure for peptide-
related projects in the Sweedler group. 
Chapter 4 focuses on the investigation of neuropeptidome of a small rat brain 
nuclei, the habenula. This region has been shown to be involved in many biological 
functions such as nicotine addiction, reward control and circadian rhythm. A multifaceted 
mass spectrometric approach was used to explore the neuropeptide content within this 
region, which included ESI-Orbitrap, ESI-FT-ICR and MALDI MS. A combination of 
various MS platforms can provide complementary results. Two bioinformatics methods, 
PEAKS and ProsightPC, were also used to further expand the neuropeptide coverage. A 
high chemical heterogeneity was observed from the results and correlated well with 
recent findings in situ hybridization study.  
Chapter 5 presents the discovery of signaling peptides involved in two pain- 
related diseases, migraine and opioid induced hyperalgesia through label free LC-MS 
quantitation approach. According to neurobiological studies, these two diseases have 
partially overlapping signaling pathways, which might be an indication of overlapping 
molecular mechanisms. To discover the signaling peptides related to one or both of 
migraine and opioid induced hyperalgesia, a dual MS system-based peptide quantitation 
- 20 - 
 
approach was employed, which combined the advantages of two different mass analyzers, 
Orbitrap and QTOF. In addition to new peptide quantitation pipeline, bioinformatics and 
statistics were also applied in this project. Peptides that were significantly up-or down-
regulated in the animals with migraine or opioid induced hyperalgesia were revealed, 
which could be further validated through other experiments. 
Chapter 6 is a research project emphasizing on the purification and structure 
elucidation of an unknown natural product that paralyze a parasite, Schistosoma. To 
determine the structure and stereochemistry of the target molecule, a broad range of 
analytical techniques were employed, including LC, MS, nuclear magnetic resonance 
(NMR) and molecule modeling. The determined structure from NMR matches well with 
observations in other experiments. In addition, the preliminary results of biological 
experiments and literature search suggested that the target bioactive compound cause 
paralysis of Schistosoma by acting on serotonin receptors. 
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1.7 List of Figures 
 
 
Figure 1.1 Overview of prohormone processing. The prohormone is cleaved at basic sites. 
Basic amino acids are removed from the cleaved products, which are further processed 
into short neuropeptides. Some final cleaved products are post-translationally modified. 
In addition, such prohormone processing is cell and region-specific. For example, POMC 
prohormone above are processed into different set of neuropeptides in anterior pituitary 
and hypothalamus. Figure adapted from the following book chapter with permission, 
Yang N. et al. Neuropeptidomics: the characterization of neuropeptides and hormones in 
the nervous and neuroendocrine systems. International Neuroendocrine Federation (INF) 
Masterclass Series: ’Molecular Neuroendocrinology’, March 2016.  
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Figure 1.2 Schematic view of processes in matrix-assisted laser desorption/ionization 
time-of-flight analysis. Samples (blue, red and green) are mixed with matrix and ionized 
upon laser application. Ions are analyzed through TOF mass analyzer, in which their 
flight time used to reach detector is  recorded and transformed into m/z. The spread of 
initial velocity of different ions could be compensated using a reflectron. Figure adapted 
from website http://wln.nl/en/bacteria-quickly-identified-thanks-to-a-chemical-
fingerprint/. 
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Figure 1.3 Schematic view of electrospray ionization process. Charged droplets are 
formed from the small spray needle or tip and explode into smaller charged droplets with 
the assistance of heated gas. In the final step, gaseous ions are formed and guided into 
MS for analysis. Figure adapted from reference [56] with permission and modified. 
  
- 33 - 
 
 
 
 
Figure 1.4 Schematic representation of various modes in triple quadrupole MS. (A) 
Precursor ion scanning sets Q3 to transmit only one specific fragment ion to the detector. 
All the precursor ions that generate this fragment is scanned in the Q1. (B) Neutral loss 
scanning scans both analyzers in a synchronized manner, so that the mass difference of 
ions passing through Q1 and Q3 remains constant. The neutral loss scan is therefore used 
to detect those peptides in a sample that contain a specific functional group. (C) MRM 
consists of a series of short experiments in which one precursor ion and one specific 
fragment characteristic for that precursor are selected by Q1 and Q3 respectively. 
Typically, the instrument cycles through a series of transitions (precursor-fragment pair) 
and records the signal as a function of time (chromatographic elution). MRM is used for 
the quantitation of a specific analyte with known fragmentation properties in complex 
samples. Figure adapted from reference [60] with permission.  
  
A 
B 
C 
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Figure 1.5 Schematic diagram of working principle of FT-ICR and Orbitrap MS. Both 
types of MS measures the ion motion frequency and convert it to m/z. (A) In FT-ICR MS, 
excitation plates excite ions to larger orbitals so the induced currents can be detected and 
its frequency is recorded by the detector plates. (B) In Orbitrap, ions possess harmonic 
ion oscillations along the axis of the central electrode. The frequency of the harmonic 
oscillation is calculated from induced image current transient. Figure A adapted from 
website http://people.whitman.edu/~dunnivfm/C_MS_Ebook/CH5/5_5_6.html. Figure B 
adapted from reference [82] with permission.  
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Figure 1.6 Nomenclature of peptide fragment ions in tandem mass spectrometry. Figure 
adapted and modified from Roepstorff P.; Fohlman J., Proposal for a common 
nomenclature for sequence ions in mass spectra of peptides. Biomed. Mass Spectrom. 
1984, 11, 601. 
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Chapter 2 
Mass spectrometric approaches in neuropeptide discovery, 
identification and quantitation 
 
 
2.1 Notes and acknowledgements 
This chapter provides an overview of state of art mass spectrometric approaches 
used in the identification and quantitation of signaling molecules, primarily 
neuropeptides. Common and new mass spectrometric methods used in studying 
neuropeptide are introduced, some of which are applied in the work presented in later 
chapters. Other techniques such as bioinformatics, which are often used in combination 
with mass spectrometry, are also covered in this chapter. Part of content contained in this 
chapter is adapted from a book chapter entitled “Neuropeptidomics: The Characterization 
of Neuropeptides and Hormones in the Nervous and Neuroendocrine Systems” published 
by John Wiley & Sons, Ltd, 2016 (DOI: 10.1002/9781118760369.ch8). I would like to 
thank other authors, Samuel J. Irving, Elena V. Romanova, Jennifer W. Mitchell, Martha 
U. Gillette and Jonathan V. Sweedler for their contributions to the manuscript. This work 
was funded by the National Institutes of Health (NIH 2 P30 DA018310 B).  
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2.2 Introduction 
Neuropeptides are a remarkable group of polypeptides used in nervous and 
endocrine system for cell-to-cell communication. They are cleaved from large 
prohormones synthesized in the neurons and packed into large dense core vesicles 
(LDCVs). Upon stimulation, neuropeptides are released from axon termini and diffuse to 
other regions to take effects.(1) Neuropeptides are involved in a broad range of 
physiological events and animal behaviors.(2-4) The characterization of neuropeptides is 
challenging because of their features like high structural diversity and low abundance in 
complex chemical background. The following content in this chapter reviews the current 
progress in the development and improvement of sampling and analytical techniques for 
the characterization of endogenous neuropeptides in the nervous and endocrine system.  
 In the past decades, in situ hybridization, immunohistochemistry (5) and 
radioimmunoassay (6) have been successfully utilized to reveal the presence and 
distribution of some neuropeptides. However, these techniques are either focused on 
mRNA level or subject to limitation of antibodies. Since neuropeptides are highly diverse 
in structure, post-translation modification (PTMs) and function, it is critical to determine 
the unambiguous identity, chemical form and dynamic amount change of neuropeptides in 
the brain regions of interest.  
The advent of soft ionization techniques (ESI and MALDI) in mass spectrometry 
(MS) has started a new page on the chemical analysis of biological molecules, including 
neuropeptides.(7-9) Compared with mRNA or antibody-based techniques, bioanalytical 
MS has many advantages. MS is fast in analysis. For instance, thousands of peptides can 
be analyzed in a single LC-MS run, which typically takes less than 2 hours. Besides, MS 
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does not require the use of an antibody, so the time and money consuming antibody 
development process is avoided. Moreover, MS is able to unambiguously elucidate the 
sequence and PTMs of neuropeptides in the sample, so the exact chemical form of 
bioactive neuropeptides are revealed.(8) 
When using MS to study neuropeptides, a proper choice of MS platforms and 
analyzing methods is critical as it directly affects the experiment outcome. The selection 
of MS platform not only depends on the characteristics of different ionization methods 
and mass analyzers but also on the sample itself. What is the rough amount of 
neuropeptides in the sample? What are other interferencing compounds in the sample? 
What mass range do the neuropeptides of interest fall into?  How many samples are to be 
analyzed? Is quantitative information needed, or just qualitative? All these questions 
should be asked and addressed when choosing the right MS platform and method.   
 
2.3 Direct sample profiling 
Direct sample profiling refers to a technique to measure analytes, including 
peptides, directly from an intact tissue slice. It is a convenient method for peptide 
detection as it involves minimal sample handling and pretreatment and reduces sample 
loss. Steps in direct sample profiling are shown in Figure 2.1.(10) In direct sample 
profiling, tissues are carefully removed from animals so their native shapes are preserved. 
Isolated tissues are quickly frozen to arrest proteolytic activity and then cut into thin 
slices using a cryostat. An ideal slice thickness for direct profiling is 10–20 µm, in the 
order of the diameter of mammalian cells. As a result, most of the cells in the slice are cut 
open and their intracellular contents are exposed for analysis.(11, 12) Since no sample 
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homogenization is performed, samples are usually analyzed with MALDI MS in direct 
profiling. Common MALDI matrix can be applied onto the tissue slice through direct 
dropping (13) , sublimation (14) and air brush spray (15). In many cases, an ethanol wash 
step is added before matrix application to remove salts and other contaminant from the 
tissue surface. In addition to tissue slice, application of direct sample profiling has been 
successfully extended into samples with smaller size, such as ganglion, single cells and 
dense core vesicles, which leads to the discovery of many neuropeptides, such as 
neuropeptides derived from egg-laying hormone (ELH) and acidic peptide (AP) in 
Aplysia californica.(16) Direct sample profiling not only reveals the m/z of many analytes 
in the sample and their relative expression levels, it also helps determine the structure and 
sequence of peptides. Both collision induced dissociation (CID) and post-source decay 
(PSD) are employed to acquire tandem MS spectra on ions of interest and discover 
neuropeptides in insects and crustaceans.(17-19) 
 
2.4 Mass spectrometry imaging 
An important variant of direct sample profiling is mass spectrometry imaging 
(MSI) technique. In MSI, initial sample preparation is done in the same way as direct 
profiling, described in 2.3. During imaging process, the tissue section is shot by laser 
pulses at discrete locations in a predefined manner based on a rectangular x, y grid. 
Depending on laser resolution, each predefined point in the x, y grid is shot by the laser 
to generate a position-specific mass spectrum which works as an independent molecular 
profile. The whole dataset contains the information of all detected ions, including 
location and intensity, from which any particular ion, with or without identity known, can 
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be selectively extracted out and re-plotted according to the data acquisition coordinates 
(Figure 2.1). The re-mapped image of any selected ion shows its distribution across the 
whole tissue section with differential intensity represented by a gradient of color scale 
and exhibits the native presence of molecules of interests like neuropeptides in a 
straightforward way.(20)  
The MSI technique, as well as direct sample profiling, has multiple unique 
advantages in studying peptides. First of all, no peptide extraction, desalting and 
fractionation are required. This feature minimizes the amount of peptides lost in the 
sample handling and the probability of introducing contaminants into the sample.  
Besides, the shape of tissue samples is preserved in MSI. Minimized sample pretreatment 
also reduces the relocation of peptides in the frozen tissue slice. As a result, it is possible 
to connect the spatial information of peptides to the morphological and anatomical 
structures contained in the tissue section. Last but not least, MSI allows scientist to study 
the changes of peptides in both abundance level and spatial distribution as a response to 
certain behavioral or functional disorders (21, 22), stimulations and manipulations (23, 
24). 
 
2.5 Single cell analysis 
The brain is an organ of high structural and cellular heterogeneity and composed 
of different types of cells, including neurons, astrocytes and oligodendrocytes.(25, 26) 
Even for a small region in the brain, cells contained inside have distinct chemical 
contents and functions.(27) Useful chemical and functional information of cells is lost 
when the entire brain region of interest is analyzed since the data represent a 
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stochastically averaged result from bulk analysis. Analysis of neuropeptides and other 
neurotransmitters on single cell level, though experimentally challenging, can address 
this issue and provide a deeper understanding of cell-to-cell communication and function 
of individual cells.(28) 
Single cell analysis requires precise and fine isolation of target cells and sensitive 
analytical tools for their measurements. Various methods (e.g. manual isolation, flow 
cytometry and microfluidics) have been utilized to isolate and sort individual cells of 
interest.(29-31) MALDI MS and capillary electrophoresis (CE) MS are two common 
mass spectrometric technique for single cell analysis. In the former case, as shown in 
Figure 2.2 isolated cells are placed on the target plate, applied with matrix and 
analyzed.(32) Single cells have a lower chemical complexity but higher local 
concentration of neuropeptides as compared to bulk tissue or extracts, so recorded spectra 
tend to have a simpler background and are easier to interpret. This strategy has features of 
high sensitivity and throughput. It has been used for different research goals such as 
novel neuropeptides discovery (33) , prohormone processing pattern investigation (34) 
and rare cells identification (35). For CE-MS, intracellular contents are usually extracted 
before analysis. Analytes are packed into a sharp band in CE separation, so CE-MS has 
an extraordinary low detection limit, which enables the analysis of both small molecule 
neurotransmitters and neuropeptides contained in an individual cell.(36, 37) 
 
2.6 Analysis of extracted peptides 
LC-ESI-MS is a powerful analytical tool for the discovery and identification of 
neuropeptides. The use of liquid chromatography requires peptides to be extracted from 
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bulk tissues or preconcentrated from biological fluids prior to analysis. Although the 
spatial information of neuropeptides is lost in the extraction step, which requires tissue 
homogenization, more peptides can be detected and identified since less interferencing 
compounds in the tissue are present in the extracted peptides after proper sample 
treatment. Besides, extracted peptides are separated on LC columns before entering MS 
so the sample complexity at a certain time point is greatly reduced. Figure 2.3 shows the 
workflow of a general LC-MS experiment, including tissue isolation and stabilization, 
peptide extraction, sample pretreatment, LC-MS analysis and bioinformatics analysis of 
acquired data.  
One crucial issue compromising the analysis of native neuropeptides is the rapid 
post-mortem degradation of proteins. Such degradation starts immediately after the 
removal of brain from the skull and can change the form and amount of endogenous 
peptides within a few minutes. Moreover, the degraded products from abundant proteins 
increase the sample complexity, suppress the signal from endogenous peptides and add 
difficulty in the spectra interpretation.(38) Several methods have been used to stabilize 
the tissue after isolation and reduce post-mortem degradation, such as freezing (39), 
boiling (3) and focused microwave irradiation (40). Recently, Per and his coworkers 
developed a tissue stabilization device which heats up the fresh tissue sample under 
vacuum within 30~45 seconds using an energy input controllable laser.(41) With this 
new technique, the peptide identification results are significantly improved in stabilized 
tissues as compared to unstabilized tissues. Although methods mentioned above all help 
preserve endogenous peptide content, one must realize that a complete avoidance of post-
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mortem degradation is impossible and there will always be a certain amount of protein 
degradation products present in the sample. 
After tissue isolation and stabilization, the next step in LC-ESI-MS experiments is 
peptide extraction. Peptides together with other intracellular contents can be extracted out 
of cells and tissues with a variety of solutions during and after homogenization. 
Neuropeptides are highly diverse in sequence and structure, which results in a remarkable 
difference in their physical properties. For hydrophilic peptides such as substance P, 
neuropeptide Y and vasoactive intestinal polypeptide, dilute acids are extraction buffer of 
choice. Some neuropeptides like corticotropin-releasing hormone, neurokinin B are 
relatively hydrophobic, so they will be extracted with a high efficiency using organic 
solvents.(42) Multistage peptide extraction protocol can be adopted to increase the 
peptide coverage in the extraction step, in which the homogenized tissues are subjected to 
repeated extraction with different solvents. Common solvents include ice cold water, ice 
cold acidified water and acidified methanol or acetone. Several groups have compared 
the extraction protocols under different conditions such as solution composition, 
temperature. It is recommended that hot acid and detergent like SDS should be avoided. 
(43, 44) Hot extraction in an acidic environment induces a significant level of protein 
degradation, while the use of detergent causes signal suppression as it affects the 
ionization of peptides. Romanova et al. developed a one-step peptide extraction 
method.(45) The isolated tissues are directly immersed into saturated 2, 5-
dihydroxybenzoic acid (DHB) solution for long-term storage and peptide extraction. This 
method is simplified in the extraction step, but the excessive amount of DHB used must 
be removed by HPLC before LC-ESI-MS analysis. 
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Endogenous neuropeptides are extracted out of cells and tissues together with 
other large peptides, small proteins and lipids. Most of neuropeptides have a molecular 
weight less than 4000 Da, so molecular weight (MW) cut-off filters and C18 solid phase 
extraction (SPE) are used to pre-concentrate the low MW fraction.(46) Large peptides 
and proteins cannot pass the MW cut-off filters or retained on C18 SPE with 100 Å pore 
size. Pre-concentrated peptides are then injected into capillary or nano-scale HPLC for 
separation before MS analysis. They are first loaded onto a low back pressure trap 
column so a high flowrate can be used for fast peptide desalting. After desalting, the trap 
column is placed online with a longer analytical column for separation using a gradient of 
aqueous and organic solvent. Separated peptides from the column can be collected in 
different fractions and analyzed using MALDI MS in an offline setup or directly 
analyzed by MS platforms coupled to HPLC systems in an online setup. In many cases, 
extracted peptide mix has a high chemical complexity and requires fractionation prior to 
LC-MS analysis. The most common fractionation method in proteomics study, gel 
electrophoresis does not work well for neuropeptides since gel electrophoresis is not 
effective in separated proteins less than 10 kDa.(47, 48) A useful alternative method is 
multidimensional liquid chromatography. Strong cation exchange chromatography (SCX) 
is usually used as the first LC, orthogonal to reverse phase (RP) LC coupled to MS.(49-
51) In SCX, peptides retained on a SCX column are eluted in a stepwise manner using 
solvents with increasing salt content. Eluted fractions can be guided to RPLC directly 
through a 2D HPLC system or collected and reinjected for RPLC-MS analysis. Other LC 
techniques with a separation principle orthogonal to RPLC are also used in peptidomics 
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and proteomics studies, such as hydrophilic interaction chromatography (HILIC) and size 
exclusion chromatography (SEC).(52, 53) 
Peptides out of analytical columns are ionized and subject to MS analysis. In 
typical neuropeptidomics studies, both precursor and tandem spectra are collected so that 
peptides sequences and identities can be determined using bioinformatics during data 
interpretation. As extracted peptide samples are chemically complicated, MS data are 
usually collected rapidly in data-dependent mode (DDA). In this mode, a precursor MS 
scan is followed by 3 up to 10 tandem MS spectra of the most intense ions found in the 
precursor scan. Dynamic exclusion function is usually turned on in DDA mode, which 
prevents the repeated collection of tandem MS spectra of the same ion in a selected 
duration of time. Recently, improved MS instrumentation enables peptide identification 
in another MS operation mode, data-independent mode (DIA). In DIA mode, the entire 
mass range of interest is divided into many small m/z segments. MS in DIA mode collects 
tandem MS data of all the ions contained in each small specified m/z range rapidly and 
repetitively. In contrast to DDA, DIA is unrelated to prioritization of a precursor ion or 
its relative abundance in the mass spectrum and the fragment information of all the 
precursor ions are preserved and collected. However, tandem MS spectra in DIA mode is 
often more complex and difficult to interpret, which requires advanced algorithms. (54-
56) 
LC-MS/MS has an unsurpassed capability for peptide detection and identification. 
Normally, a few thousand of MS spectra are collected in a single experiment, which 
requires the aid of bioinformatics tools in the interpretation of collected data. Different 
web-based bioinformatics tools have been developed to perform database search and 
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peptide identification, including SeQuest (57), Mascot (58) and OMSSA (59). These 
tools compare the detected fragment ions of a peptide with the predicted fragment 
patterns of a protein sequence or subsequence contained in the database. For many 
organisms, their proteome databases have been well constructed and are available 
through SwissProt and NCBInr websites. Databases can also be built manually using 
some well evaluated algorithms. For instance, NeuroPred developed at UIUC predicts the 
expected peptides cleaved from a prohormone and successfully applied in the study of 
neuropeptides in a few animal species. (60-63) An alternative for peptide identification is 
de novo sequencing, which deduces peptide sequence by calculating mass differences 
between the fragment ions and comparing them to ion series composed of amino 
acids.(20) These deduced sequences are searched against a database for identity 
determination. A few commercial bioinformatics tools have been developed and 
implemented for de novo sequencing, such as PEAKS (64) and PepNovo (65). 
 
2.7 Neuropeptide quantitation  
Neuropeptides are associated with many diseases, such as obesity (2), 
hypertension (66), drug addiction (67), Alzheimer’s disease (68), hyperalgesia (69) and 
Parkinson’s disease (70). The changes in neuropeptide expression levels represent 
molecular responses to different functional and behavioral disorders within the nervous 
system. Therefore, investigation of neuropeptide quantities at different pathogenic states 
or between disease and normal animals facilitate the discovery of disease-related 
signaling peptides and their functions.  
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MS has been widely used in peptide quantitative study in the past decade. 
Absolute peptide quantitation requires the use of an internal standard and is often used for 
targeted peptide quantitation since it is impractical to have internal standards for every 
single peptide in a complex biological sample. Another more popular application of MS 
is the relative or comparative peptide quantitation. MS has the capability to detect 
thousands of peptides within the samples without the use of any antibody. Therefore, it is 
inherently a great tool for untargeted quantitative peptidomics study. Many MS-based 
approaches for peptide comparative quantitation have been developed and they can be 
divided into two main categories, isotopic labeling and label free methods. Figure 2.4 
shows the schematic workflow of common peptide quantitation strategies within these 
two categories.(71)  
Isotopic labeling quantitation requires the peptides in different sample groups to 
be isotopically modified through either chemical or metabolic way. For chemical labeling, 
samples are subject to a chemical reaction which adds light and heavy tags to peptides in 
experimental and control group respectively. These isotopic tags usually have features 
such as low cost, commercially availability and good chemical stability. For metabolic 
labeling, it refers to stable isotope labeling by amino acids in cell culture (SILAC). Cells 
in the experimental group are cultured in medium where natural (“light”) amino acids are 
replaced by stable isotope labeled (“heavy”) amino acids. These heavy amino acids are 
then incorporated into newly synthesized peptides through normal metabolic 
pathways.(72) Regardless of chemical or metabolic labeling, peptides in light and heavy 
forms are mixed and analyzed through LC-MS after the completion of labeling. Tags 
render sufficient mass shifts between light and heavy forms of labeled peptides, which 
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allow peaks in different samples to be differentiated and quantified through comparing 
integrated peak areas. The isotopic labeling quantitation can also be performed on tandem 
MS level using isobaric tags such as iTRAQ. Peptides in different samples still have the 
same mass after labeling and are selected for tandem MS simultaneously. During 
fragmentation, reporter groups, substructures of iTRAQ tags with distinct masses, are 
detached from the peptides and recorded by MS. Similarly to methods mentioned above, 
peptide abundances in different samples are determined and compared using peak 
intensity or integrated peak area of different reporter ions.(73) Other isobaric tags similar 
to iTRAQ but with higher throughput are developed. Li and her coworkers synthesized a 
series of DiLeu-tags and used them for quantitation of up to 12 Saccharomyces cerevisiae 
lysate samples.(74) 
Peptides in complex biological samples can also be quantified through label free 
approaches. Free from any tag, label free methods are not affected by many tag-related 
problems, such as extra sample loss in labeling step, increased sample chemical 
complexity, incomplete peptide labeling and excessive labeling reagents.(20) In addition, 
number of samples to be analyzed is not limited by the number of available tags. Every 
sample is analyzed independently through LC-MS in label free quantitation. A strength is 
that low abundant peptides can be detected since no sample mixing is needed and each 
LC-MS has a reduced sample complexity. However, this feature also makes label free 
quantitation more susceptible to run-to-run variations. Therefore, it is critical to keep 
sample preparation consistent, adjust and finalize LC and MS parameters before starting 
the experiments. Two common ways for label free quantitation are peak integration and 
spectra counting. In peak integration, ion chromatograms of peptides are extracted from 
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different LC-MS runs and corresponding peaks are integrated and compared. For spectra 
counting, the abundance of a peptide is represented by its number of tandem MS spectra 
collected. This method is based on the fact that abundant peptides have a higher 
probability to be selected for tandem MS.(71)  
Many exciting scientific findings have been discovered through comparative 
peptide quantitation. [H4] and [D4] succinic anhydride tags were used to reveal 
neuropeptide level changes in honey bees and correlated to their foraging behavior.(75) 
Potential biomarker candidates of Alzheimer’s disease was discovered through profiling 
peptides in cerebrospinal fluid using iTRAQ.(76) Label free quantitation was successfully 
employed to explore neuropeptides regulating circadian rhythm in rats.(3, 77) However, it is 
important to note that there is no perfect quantitation method well suited for all research 
applications. Isotopic labeling and label free method, each of them has its own strengths 
and shortcomings.  We believe that these quantitation methods will be further improved 
in the future.  
 
2.8 Conclusion and future perspectives 
In the past two decades, new and more powerful MS instruments have been 
developed, enabling fast acquisition of MS data with high accuracy and resolution. 
Assisted by the improved sampling and separation techniques, MS has boosted and 
reshaped the field of neuropeptide study. LC-MS/MS analysis of extracted peptides 
allows a comprehensive investigation of peptide contents in an organism or a defined 
region.(3, 63) Direct sample profiling can quickly reveals peptides in various types of 
samples, from a tissue slice (78) down to a cluster of or individual cells (13, 34). MSI 
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adds one dimension of analysis and uncovers the spatial distribution of neuropeptides in 
their original biological context.(79) 
Although a remarkable progress has been achieved, scientists are still facing 
challenges on the way to understand how the nervous system works thoroughly. In this 
post-genome era, genomics, transcriptomics and MS-based peptidomics give scientist 
access to information on gene, mRNA and protein level. However, better analytical 
methods and bioinformatics tools are required to combine, interpret and correlate the 
huge amount of data to certain physiological events and animal behaviors. In addition, no 
current MS-based approaches can cover chemical, temporal and spatial aspects of 
neuropeptide study simultaneously. Research on neuropeptides is still limited to well-
characterized animal models and many neuropeptides still remain undiscovered due to 
alternative slicing or unannotated genes.(9, 80)  
Nevertheless, we envision a continuously increasing use of MS in answering 
neuropeptide related questions. In the future, the emergence and fusion of better sampling, 
detecting and data processing methods, as well as breakthroughs in genomics and 
transcriptomics, will definitely broaden our knowledge of neuropeptides and enhance our 
understanding of cell-to-cell communications. 
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2.10 List of Figures 
 
 
Figure 2.1 Overview of direct tissue profiling and MALDI imaging. Frozen tissue slice 
was prepared and transferred to MALDI target plate. MALDI matrix was applied through 
direct dropping or other methods like spraying. In tissue profiling, MS spectra were 
acquired on selected locations across the tissue slice. In MSI, MS spectra were acquired 
from the entire tissue slice in a predefined manner or array. Information of m/z of interest 
was extracted and processed into ion distribution image. Figure adapted from reference 
[10] with permission. Copyright © 2004 American Chemical Society. 
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Figure 2.2 Overview of single-cell analysis through MALDI MS. (a) Individual cells are 
isolated from tissues in physiological saline or matrix solution and placed on MALDI 
plate with matrix application followed. (b) Process of sample molecule ionization and 
analysis in MALDI MS. (c) A cultured neuron and matrix crystals visible. Figure adapted 
from [32] with permission from Elsevier © 2000. 
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Figure 2.3 Schematic workflow of LC-MS analysis of extracted peptides. Tissues were 
isolated from animals and stabilized through ice-cold saline, freezing or heat. Peptides 
were extracted, cleaned up, preconcentrated and then subject to LC-MS analysis. MS and 
MS/MS data were searched against databases using bioinformatics tools. Figure adapted 
from reference [46] with permission and modified. Copyright © 2008 by Annual Reviews. 
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Figure 2.4 Mass spectrometry-based strategies for quantitation of endogenous 
peptides.(A) Workflow of typical isotopic labeling quantitation. Samples were labeled 
with different tags, mixed and analyzed using LC-MS. Peak intensity or area of heavy 
and light peptides were calculated for quantitation. (B) Workflow of label free peptide 
quantitation. Peak intensity, area or number of MS/MS spectra in different samples were 
used for quantitation. Figure adapted from reference [71] with permission and modified. 
Copyright © 2013 by Annual Reviews. 
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Chapter 3 
Evaluation of effects of heat-based tissue stabilization methods on 
neuropeptide identification and quantitation  
 
3.1 Notes and acknowledgements 
This chapter is about the systematic comparison and evaluation of performances 
of different tissue stabilization methods on the identification and quantitation of 
neuropeptides in the mammalian brain tissues. The content in this chapter is adapted from 
the manuscript in preparation, entitled “Mass Spectrometry-based Investigation of 
Neuropeptide Identification and Quantitation in Heat Stabilized Mammalian Tissues”, co-
authored by Krishna, D.B. Anapindi, Stanislav, S. Rubakhin and Jonathan V. Sweedler. 
Dr. Stanislav, S. Rubakhin and Prof. Jonathan Sweedler initiated this project and 
provided useful advice. My role in this project is to design and perform the mass 
spectrometry-based measurements, analyze acquired data and write the manuscript. 
Krishna D.B. Anapindi assisted in the sample preparation and peptide measurement. Dr. 
Erik, Jansson helped in stabilization instrument transportation, setup and instruction. Dr. 
Stanislav, S. Rubakhin performed rat dissection and isolated hypothalamus and 
suprachiasmatic nucleus. The research presented in this chapter was funded by the 
National Institutes of Health (NIH 2 P30 DA018310 B). 
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3.2 Introduction 
Neuropeptides are a remarkable class of signaling molecules responsible for cell-
to-cell communications in the central and peripheral nervous systems. They are actively 
involved in a broad range of physiological and endocrine processes such as pain 
sensation, food intake, circadian rhythm, depression, tissue regeneration and drug 
addiction by acting as neuromodulators, neurotransmitters and hormones. (1-6) Because 
of the important roles they play in the functioning of an organism, scientists have started 
the study of neuropeptides using radioimmunoassay and immunohistochemistry decades 
ago.(7, 8) However, in the past two decades, study of neuropeptides has been greatly 
facilitated by improvements in mass spectrometric techniques, including new ionization 
methods and better instrumentation.(9-12) 
 In qualitative studies, mass spectrometry not only can identify neuropeptides 
from tissues and biological fluidics but also has pushed detection limit of neuropeptide 
down scale to single cell level.(13-15) For quantitative studies, no antibody or enzyme-
linked immunosorbent assay (ELISA) need to be developed for peptides of interest. 
Instead, all of the peptides in the sample can be quantified within the timeframe of 
several LC-MS experiments. Various approaches such as SILAC, iTRAQ and label free 
methods have been developed and successfully applied to unveil neuropeptides 
underlying different physiological events and diseases.(16-19) Although neuropeptide 
study has benefited from the development and improvement in analytical techniques and 
methods, challenges compromising the reliability of mass spectrometry data are still 
present. 
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One such challenge is the post-mortem degradation of peptides and proteins 
during sample preparation step.  It has been reported that many endogenous enzymes will 
continue to function after removal of tissues from their original environment.(20-22) The 
peptides formed ex vivo can disrupt the endogenous status of peptidome and proteome, 
which may lead to incorrect or biased conclusions about a specific sample. Signals from 
low abundant molecules like neuropeptide could also be masked by the presence of ex 
vivo fragments from the high abundant proteins. To preserve the endogenous peptide and 
protein status, several approaches have been developed to stabilize the tissue.(23-27) 
Application of focused microwave radiation has been proven effective in arresting 
enzymatic activities, but it cannot be utilized on samples other than rodent brain.(27) 
Moreover, it is used before dissection, which makes isolation of smaller brain regions 
difficult. Though post-dissection stabilization methods like freezing or conventional 
microwave treatments have been reported earlier, they do have their own drawbacks. 
Freezing has been shown less efficient in stopping peptide and protein degradation than 
heat, while microwave treatment is hard to control total energy input into the sample and 
has non-uniform heat distribution in the tissue. To overcome the drawbacks of tissue 
stabilization methods mentioned above, Per Andren and his coworkers developed 
Stabilizor, an instrument for controlled heating of the tissues at reduced pressures.(28) 
This instrument can stabilize both fresh and frozen samples quickly and uniformly with 
an energy input controllable laser. In addition, it can be used on other types of biological 
tissues than brain. 
This technique has been reported to successfully preserve endogenous proteome 
and peptidome. However, most comparisons were performed between Stabilizor treated 
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samples and unstabilized or snap frozen samples.(21) Though Li et al. evaluated the 
performance of Stabilizor and other heat stabilization methods, they only focused on 
crustaceans, which used a different set of enzymes in neuropeptide production and 
modification.(29) In this study, we investigated the effects of two different heat 
stabilization methods on the mass spectrometric study of mammalian neuropeptidome. 
The first method is heat stabilization by the Stabilizor mentioned above and the second is 
an immediate hot water treatment of tissues after isolation, which does not require special 
equipment and can be easily performed in any lab. We first compared LC-MS based 
identification results from samples treated with the two methods. We also examined the 
effect of these two heat stabilization methods in quantitative experiments.  
 
3.3 Experimental 
3.3.1 Chemicals 
All the reagents were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO) 
and ThermoFisher Scientific (Waltham, MA). 
 
3.3.2 Animals 
Male Sprague Dawley rats were used for the experiments. All the animal 
procedures were carried out according to protocols approved by the Institutional Animal 
Care and Use Committee, University of Illinois at Urbana-Champaign and in full 
compliance with the Principles of Laboratory Animal Care. The brain was quickly 
removed after decapitation and kept cold on ice. Hypothalamus and suprachiasmatic 
nucleus (SCN) were isolated and subjected to Stabilizor or hot water treatment.  
- 68 - 
 
3.3.3 Total protein assay and peptide identification 
Hypothalamus regions were isolated from 6 rats immediately after decapitation. 
Three were heat stabilized with Stabilizor (Gothenburg, Sweden) and three were placed 
in hot water (preheated to 95°C) for 10 min. The samples were then homogenized on ice 
and subjected to a 3 stage peptide extraction procedure consisting of ice-cold water, 
acidified acetone (40:5:5, acetone: water: acetic acid) and water containing 0.25% (v/v) 
acetic acid. Sample desalting and pre-concentration were performed on the combined 
extracts using C18 spin column (Thermo, MA). 20% of the final eluent from spin column 
was used for total protein assay using a commercial BCA protein assay kit (Thermo, CA). 
The remaining eluent was dried in SpeedVac (Genevac, UK) and stored at -20°C until 
analysis.  
Each of the samples was reconstituted using water with 0.1% (v/v) formic acid 
(FA) in water and injected onto a Dionex Ultimate3000 nanoLC system (Thermo, MA) 
coupled to Bruker Maxis IMPACT qTOF mass spectrometer. Extracted peptides were 
first loaded onto a PepMap™ 100 pre-column trap (C18, 5µm, 100 Å) and separated on 
PepMap™ RSLC nanoviper column (75 µm x 15 cm, C18, 2µm, 100Å). The flow rate 
was maintained at 300 nl/min.  Water with 0.1% FA and acetonitrile with 0.1% FA were 
used as solvent A and B respectively. The flow gradient conditions were: 0-3 min, 4-4% 
B; 3-50 min, 4-50% B; 50-55 min, 50-95% B; 55-58 min, 95-95% B; 58-65 min, 95-4% 
B; 65-75 min, 4-4% B. Data was acquired over a full scan range of m/z 300-3000. 
MS/MS acquisition was performed in data-dependent manner with collision-induced 
dissociation (CID) and top 5 most intense peaks were selected for fragmentation from the 
full scan. Dynamic exclusion was turned on and precursor ions were released after 60 sec.  
- 69 - 
 
 
3.3.4 Identification comparison between fresh and frozen tissues 
Hypothalamus tissues were isolated from 12 rats, pooled into 4 groups with 3 
biological replicates. Tissues from group 1 and 2 were snap-frozen immediately after 
isolation and stabilized by Stabilizor and hot water respectively. Group 3 and 4 were 
immediately stabilized with Stabilizor and hot water respectively. Peptide extraction and 
clean-up were performed using the protocol described above. The eluents from spin 
column were dried in SpeedVac (Genevac, UK) and stored at -20°C until analysis. 
The samples were reconstituted using water with 0.1% (v/v) formic acid (FA) and 
injected into Eksigent 1D NanoLC plus system (Dublin, CA) equipped with a PicoFrit™ 
ProteoPep™ II column (C18, 5µm, 100Å). The mass spectra data were collected using a 
11 Tesla FT-ICR mass spectrometer (LTQ-FT Ultra, Thermo, MA). Solvent A (water 
with 0.1% FA) and B (acetonitrile with 0.1% FA) were operated at 300 nl/min with the 
following gradients: 0–80 min, 30% B; 80–105 min, 30–45% B; 105–120 min, 45–60% 
B; 120–125 min, 60–85% B; 125–130 min, 85–85% B; 130–145 min, 85–0% B. The MS 
acquisition was set to scan at m/z 300–2000 with an m/z 10 precursor isolation window 
for CID. Data-dependent precursor selection was restricted to top three most intense ions. 
Dynamic exclusion was enabled with 3 repeat counts and 120 s exclusion duration. 
 
3.3.5 Database search 
PEAKS software (version 7.5, Bioinformatics Solutions Inc., Canada) was used 
for peptide identification. The data from Bruker Maxis IMPACT QqTOF were converted 
to Mascot generic format using Bruker Data Analysis (version 4.2) before loading into 
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PEAKS software. Data from Thermo ESI-LTQ-FTMS was directly loaded onto PEAKS 
for identification. The search was performed against a rat proteome database downloaded 
from Uniprot. The search parameters include: 20 ppm precursor mass tolerance, 0.1 Da 
fragment mass tolerance, no enzymatic cleavage, variable PTMs including acetylation, 
amidation, phosphorylation, half-disulfide bond, pyroglutamination and Met oxidation. 
Maximum number of variable PTM per peptide was 3. Filtering criteria of 1% false 
discovery rate is used on the final peptide spectral matches. 
 
3.3.6 Targeted neuropeptide quantitation  
Left and right lobes of SCN were isolated from 6 rats. From this pool of 12 SCN 
lobes, 6 were picked randomly and stabilized using Stabilizor and the remaining 6 were 
stabilized using hot water. Peptides were extracted and desalted using methods described 
above. The eluents were dried in SpeedVac (Genevac, UK) and stored at -20°C. 
Peptide extracts were reconstituted in 30 µl of water with 0.1% FA and analyzed 
with a UHPLC QqQ mass spectrometer (Bruker, MA). Kinetex column packed with 1.7 
µm C18 resin (Phenomenex, CA) was used with a flow rate of 300 µl/min for separation. 
MRM channels for little SAAS, neuropeptide-glutamic acid-isoleucine, neurosecretory 
protein VGF [491-507] and AVPRGEAAGAVQEL were established based on the top 
four most intense ions from the tandem MS product ion scan. Peptide intensity was 
calculated by integrating peak area of the top most intense fragment ion.  
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3.4 Results 
3.4.1 Total protein assay and peptide identification 
We used BCA total protein assay to investigate the amount of peptides extracted 
from rat hypothalamus stabilized with Stabilizor and hot water treatment method. A 
significant difference in extracted peptide amount was observed between Stabilizor and 
hot water treated group (Student’s t test, p = 0.0061). As shown in Figure 3.1A, 
concentration of peptides extracts from hot water stabilized hypothalamus (49.4 µg/ml) 
was nearly twice higher than Stabilizor stabilized hypothalamus (26.7 µg/ml).  
We also analyzed peptide extracts from the two groups using LC-MS/MS and 
performed peptide identification. On average, 224.0 and 103.7 peptides per sample were 
identified in peptide extracts prepared from hot water and Stabilizor treated group (Figure 
3.1B). This correlated well with the total protein assay results. As neuropeptides were the 
class of molecules we focused on, we examined the number of prohormone-derived 
peptides identified per sample in two groups of hypothalamus. In contrast to the peptide 
identification results, only 58.3 prohormone-derived peptides per sample were identified 
in hot water treated group, but 83.7 could be identified from each of the Stabilizor treated 
hypothalami. To understand what type of peptides contributed to higher peptide 
extraction efficiency in the hot water group, we checked the identity of peptides 
exclusively identified in hot water treatment group. 87% of them were from non-
prohormone proteins, which are primarily composed of cytosolic, energy-related, 
transcription/translation-related and structural proteins.  
For most neuropeptides, arginine and/or lysine should be found at both termini in 
the prohormone sequence as mono or dibasic sites are where prohormone convertases act. 
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To understand whether these prohormone-derived peptides are produced endogenously or 
ex vivo, we further examined the amino acid residue before and after the N and C-
terminus of the identified neuropeptides in the prohormone sequence. On average, 61.3 
and 37.3 prohormone-derived peptides have endogenous cleavage sites found at both 
termini in Stabilizor and hot water treated group and they should be endogenous 
neuropeptides. For both the stabilization methods we investigated, we found peptides 
resulting from non-endogenous cleavage. However, a smaller fraction of such non-
endogenous prohormone-derived peptides were observed in hypothalamus stabilized 
utilizing Stabilizor (29.8%) than hot water method (36.0%).  
 
3.4.2 LC-MS/MS identification on fresh and frozen hypothalamus 
To investigate whether the two stabilization methods perform differently in frozen 
and fresh tissues, we conducted identification experiments on four groups of rat 
hypothalamus as mentioned in methods section. Figure 3.2 showed the average number 
of neuropeptides (cleavage sites checked) identified per sample between fresh and frozen 
hypothalamus treated with two different methods. It is obvious that neuropeptide number 
per sample was higher in Stabilizor treated groups than hot water treated groups 
regardless of the tissue status, fresh or frozen (group 1 and 3, p = 1.9e-3; group 2 and 4, p 
= 6.1e-4). No difference was observed between fresh and frozen hypothalamus stabilized 
with Stabilizor. In contrary, more neuropeptides was identified per sample in frozen 
tissue than in fresh tissue when hot water was employed as stabilization method.  
The average number of neuropeptides identified per fresh or frozen hypothalamus 
treated with Stabilizor was 51.0 and 54.7, which were nearly the same. We also checked 
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the identities of neuropeptides identified from these two groups. In total, 77 and 78 
different neuropeptides were identified from Stabilizor treated fresh and frozen sample 
groups respectively. 53 neuropeptides were identified in both groups, leaving 24 and 25 
neuropeptides exclusively detected in the two sample groups.  
 
3.4.3 Targeted peptide quantitation   
Figure 3.3 shows the intensity of selected neuropeptides in Stabilizor and hot 
water treated SCN tissues. For the three selected neuropeptides, the signal intensities in 
Stabilizor treated SCNs were higher than hot water treated SCNs. Little SAAS and 
neuropeptide-glutamic acid-isoleucine among these three had a p value < 0.05.  
To test our hypothesis that fewer neuropeptides were degraded in Stabilizor 
treated groups, we also monitored the peak intensity for one N-terminus truncated peptide 
derived from proSAAS (AVPRGEAAGAVQEL) using MRM. Signal from this peptide 
was observed in hot water treated SCNs but not in Stabilizor treated SCNs. 
 
3.5 Discussion 
Interference from degraded peptides and proteins is a common challenge in both 
qualitative and quantitative proteomics and peptidomics studies. With post mortem 
proteolytic activities present, proteome and peptidome states are modified by ex vivo 
factors after samples are removed from their natural environment. It is an essential step to 
stabilize the tissue and keep biomolecules in their endogenous form and amount. We 
evaluated the performance of Stabilizor in preserving peptide content of tissues as 
compared to hot water, a lab-friendly heat stabilization method.  
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As the BCA assay results showed, more peptides were extracted from hot water 
treated samples. This observation correlated well with the results of experiment that 
peptide identifications in hot water treated group were nearly twice as much as the 
Stabilizor treated group. For hot water treated samples, higher extracted peptide amount 
and peptide identification number could be due to increased amount of degradation 
products and/or endogenous peptides. The latter facilitates identification of neuropeptides 
which are usually at low concentrations as their tandem MS spectrum quality gets 
improved. In contrast to the BCA assay and peptide identification results, the hot water 
group had less prohormone derived peptides identification. In addition, over 80 % of 
peptides exclusively identified in hot water groups are from cytosolic, mitochondrial, 
structural and other proteins, including peptidyl-prolyl cis-trans isomerase, cytochrome c 
oxidase, tubulin, ribosomal protein and hemoglobin etc. Indications from results above 
are two-fold. First, the increased peptide amount extracted from hot water samples was 
caused by (cytosolic) protein degradation products instead of higher extraction efficiency 
of endogenous peptides. In addition, detection of prohormone-derived peptides were 
suppressed or complicated by greater sample complexity in hot water treated samples. 
Heat stabilization irreversibly inactivates enzymes and other proteins because of 
secondary and tertiary structure of proteins are disrupted in high temperature 
condition.(28) Stabilization of rat hypothalamus using Stabilizor was completed within 
35 sec, while it could take long for the entire bulk tissue to reach thermal equilibrium 
with preheated water in hot water method. Enzymes can continue to work before fully 
denatured and result in more protein degradation. Another important reason is that 
hydrolysis of peptide bond between some residues are promoted in hot aqueous 
- 75 - 
 
environment. Che et al. found that elevated temperature should be avoided for samples in 
diluted acidic buffer to prevent ex vivo protein degradation.(30) Although we stabilized 
samples in water (pH=7), a higher temperature (95°C) was used than Che and his 
coworkers (70°C).  For both methods, there is a decrease in identification number from 
prohormone-derived peptides to neuropeptides which have endogenous cleavage sites at 
both termini. Smaller decrease in percentage was found in Stabilizor treated samples as 
compared to hot water method, which suggests less degradation of endogenous 
neuropeptides occurs in the former group.  
Stabilizing fresh tissues has a positive effect on the outcome, compared to no 
stabilization.(28, 31-33) In fact, frozen samples are more commonly used due to many 
practical reasons, such as sample transferring and difficulties in dissection. We evaluated 
the performance of Stabilizor and hot water treatment on neuropeptide identification 
using frozen samples. Firstly, we found that nearly same number of peptides and 
neuropeptides were identified from Stabilizor treated frozen and fresh samples. This 
finding is in agreement with previous results from identification experiments using a 
different animal and brain region, the mouse striatum.(28) Li’s laboratory discovered that 
neuropeptide identification was not affected by use of Stabilizor and hot water method 
even though additional complexity was observed in hot water treated blue crab 
pericardial organs.(29) This indicates a difference in necessity of sample stabilization for 
mammalian and crustacean animal models. Secondly, more neuropeptides were detected 
in Stabilizor treated frozen samples than in hot water treated ones. This is similar to our 
results from fresh tissues, suggesting Stabilizor can also effectively stop enzymatic 
activities and introduce less degradation in frozen tissues as compared to hot water.  
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Post-mortem degradation of neuropeptides distorts their original levels within 
samples.(21) Besides, added sample complexity affects accuracy of neuropeptide 
quantitation due to different extents of suppression and interference during data 
collection. Svensson et al. has reported that selected endogenous peptides were detectable 
only in Stabilizor treated mouse striatum as compared to unstabilized tissues using 
MALDI-MS.(28) To monitor how neuropeptide signals change in tissues stabilized with 
different methods, we quantified three neuropeptides in rat SCNs using MRM. Little 
SAAS, neuropeptide-glutamic acid-isoleucine from proMCH and neurosecretory protein 
VGF [491-507] were selected for targeted quantitation because previous studies have 
shown their expressions in the rat SCN.(3, 34) For little SAAS and neuropeptide-
glutamic acid-isoleucine, intensities were significantly higher in the Stabilizor treated 
samples. It suggests that Stabilizor preserves neuropeptides better with less signal 
suppression induced by increased sample complexity. For some neuropeptides like 
neurosecretory protein VGF [491-507], they can be preserved equally by Stabilizor and 
hot water method as no significant difference can be found between different treatments. 
This is understandable since different peptides resist enzymatic digestion and hydrolysis 
differently.(35) For example, peptides with N-terminal proline have extended lifetime 
than other peptides upon action of aminopeptidase M.(36, 37) Figure 3.3 also shows 
lower or similar standard deviation for Stabilizor treated samples compared to hot water, 
suggesting smaller sample to sample variation in Stabilizor treated groups. This can be 
attributed to the controlled heating at low pressure by the Stabilizor. In addition to 
intensity, peptide MRM chromatography had a higher background signal in hot water 
group, which affected peptide quantitation accuracy (Figure 3.4). The elevation in 
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background signal could be caused due to added protein degradation products given the 
results of identification experiments discussed above. Moreover, certain amount of other 
molecules like fatty acids can also be extracted and are hard to be completely removed by 
the peptide extraction and clean-up protocol used in this study. Hot water treated samples 
with such increased chemical complexity have a higher chance to include interfering ions, 
of which m/z fall into isolation window of target peptides. In the channel for peptide 
AVPRGEAAGAVQEL, target peptide peaks were detected in hot water treated but not in 
Stabilizor treated samples (Figure 3.5). This peptide is a C-terminal truncated peptide 
derived from ProSAAS. The endogenous peptide sequence should have one more alanine 
at the C-terminal and located in between mono or dibasic cleavage sites. Exclusive 
presence of truncated form in samples stabilized through hot water suggests more severe 
degradation occurs during hot water treatment. Although only selected peptides were 
investigated here, results correlated with findings from identification experiments. Fewer 
proteins and peptides were degraded in Stabilizor treated samples, from which improved 
endogenous peptide identification and quantitation were observed. The improvement is 
likely due to the fact that stabilizing tissues through hot water treatment is a prolonged 
process with hot aqueous condition. Proteins and peptides are more susceptible to 
degradation in hot water treatment because of slow enzyme inactivation and weak 
thermal stability of certain peptide bonds.  
 
3.6 Conclusion 
Tissue stabilization through heat is a common way to halt the post mortem protein 
deterioration and capture endogenous states of peptidome and proteome. Findings in this 
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study presented here suggest rapid heat treatment through Stabilizor has an improved 
effect on outcome of neuropeptide studies compared to hot water treatment and can be 
applied to both fresh and frozen samples. More neuropeptides were detected from 
Stabilizor treated samples even though they have less extracted peptide material and 
peptide identifications. Degradation of endogenous peptides was observed in Stabilizor 
treated samples as well, but not as prominent as in hot water treated samples. For 
neuropeptide quantitation, results from Stabilizor treated tissues exhibit protected 
neuropeptide integrity and less background inference. Our results are consistent with 
findings in previous stabilization studies, although we were comparing Stabilizor to hot 
water instead of freezing or no stabilization and explored performance of Stablizor in 
quantitation in addition to identification. However, some of our findings differ from the 
results of similar studies on crustaceans. This indicates how various animal tissues react 
to different methods of stabilization. It is wise to choose the stabilization method 
depending on the experimental goal and the animal models being used.  
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3.8 List of Figures 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Results of BCA assay and peptide identification using fresh brain tissues. 20% 
and 80% of peptides extracted from Stabilizor and hot water treated hypothalami (n=3) 
were subjected to BCA total protein assay and LC-qTOF analysis for peptide 
identification respectively. The error bars in panel A and B are standard deviations for 
total extracted protein amount and number of identified (neuro)peptides/prohormone-
derived peptides respectively. (A) Less total peptides (26.7 µg/ml) were extracted from 
Stabilizor treated hypothalami than hot water treated hypothalami (49.4 µg/ml) with p = 
0.0061.  (B) More peptides per sample were identified from hot water treated 
hypothalami. In contrast, more prohormone-derived peptides and neuropeptides per 
sample were detected in Stabilizor treated samples. 
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Figure 3.2 Results of peptide identification using fresh and frozen tissues. The figure 
shows the number of neuropeptides identified per sample in four different hypothalamus 
groups using ESI-FT ICR MS. No significant difference was observed between Stabilizor 
treated frozen and fresh hypothalami and number of neuropeptides identified from these 
two groups were higher than hot water treated frozen and fresh groups (group 1 and 3, p 
= 1.9e-3; group 2 and 4, p = 6.1e-4). The error bars are standard deviations of 
neuropeptide identification number in different sample groups. 
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Figure 3.3 Neuropeptide quantitation results acquired through multiple reaction 
monitoring. The figure shows the comparison of peak intensity (integrated peak areas on 
MRM channels) of little SAAS, neuropeptide-glutamic acid-isoleucine, neuroVGF [491-
507] between Stabilizor and hot water treated SCNs. Intensity of Little SAAS and 
neuropeptide glutamic acid-isoleucine were significantly higher in Stabilizor treated 
samples as compared with hot water treated samples (little SAAS, p = 0.018; neuropeptide 
glutamic acid-isoleucine, p = 0.012). The error bars are standard deviations of signal 
intensity for the three selected neuropeptides.  
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Figure 3.4 Comparison of MRM chromatograms of neuropeptide neuroVGF [491-507] 
between Stabilizor and hot water treated brain tissues. Higher background signals were 
observed in hot water treated SCNs (top three panels) but not Stabilizor treated SCNs 
(bottom three panels). 
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Figure 3.5 MRM chromatograms of truncated neuropeptide derived from proSAAS 
(AVPRGEAAGAVQEL). Peaks of this C-terminal truncated peptide were only observed 
in hot water treated SCNs (top panel) but not Stabilizor treated SCNs (bottom panel). 
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Chapter 4 
Neuropeptidomics of the rat habenula nuclei  
 
4.1 Notes and acknowledgements 
Chapter 4 includes the comprehensive study of neuropeptides contained in the rat 
habenula nuclei. The coverage of neuropeptide identification in the habenula was 
expanded through the application of different MS platforms. This chapter is adapted from 
the manuscript in preparation, entitled “Neuropeptidomics Study of the Rat Habenula 
Nuclei” and authored by Ning Yang; Krishna D.B. Anapindi; Stanislav S. Rubakhin and 
Jonathan V. Sweedler. Prof. Paul J. Kenny at Icahn School of Medicine at Mount Sinai 
and Prof. Jonathan V. Sweedler initiated our study of habenula. Dr. Stanislav S. 
Rubakhin performed animal dissection and isolated habenula region. With assistance 
from Krishna D.B. Anapindi, I prepared samples, performed peptide measurements, data 
analysis and wrote the manuscript. In addition, I would thank Dr. Xian Chen, Dr. Cong 
Wu, Prof. Peter M. Yau, Dr. Brian S. Imai and Dr. Yu Chen for instrument training and 
maintenance. This work was funded by the National Institutes of Health (NIH 2 P30 
DA018310 B).  
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4.2 Introduction 
The habenula nuclei are a pair of small structures located above the posterior end 
of thalamus, linking the forebrain and the midbrain. It is phylogenetically conserved in 
the vertebrates and regarded as a part of the epithalamus.(1) The habenula has two 
substructures, the medial and lateral subnuclei, connecting to different brain regions.(2) 
Neglected before, research on habenula was slow for two decades. However, the 
discovery of involvement of habenula in the reward system in the past decade has 
sparked scientists’ interests and investments in this small old brain region.(3-6) So far, 
habenula has been found to play important roles in a wide range of physiological 
processes and animal behaviors, including sleep, reward-based decision-making, 
avoidance of punishment, depression and nicotine addiction.(7-10) The first step to 
understand these biological events and behaviors is to elucidate the signaling molecules, 
including neuropeptides, contained in the habenula region. In addition, there are orphan 
G-protein coupled receptors (GPCRs) densely or exclusively expressed in the 
habenula,(11, 12) knowing the neuropeptide content in the habenula also helps uncover 
the endogenous ligands for these GPCRs, which is meaningful for agonist or antagonist 
drug development.  
Neuropeptides in the nervous systems are important cell-to-cell signaling 
molecules and play behavioral, cognitive and homeostatic functions in various 
physiological events, such as food intake, pain sensation, circadian rhythms, drug 
addiction and tissue regeneration.(13-17) These signaling peptides are produced after 
their large precursor proteins, named prohormones, go through enzymatically selective 
cleavages at mono or di-basic sites. To become biologically functional peptides, many 
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neuropeptides undergo different post-translational modifications (PTMs).(18, 19) The 
development of modern mass spectrometry techniques, aided by improvements in sample 
preparation, has changed the way how peptide identification and quantitation is 
performed. Different from previous methods like Edman degradation (20) and antibody-
based techniques (21, 22), mass spectrometry can rapidly discover, sequence and identify 
peptides with or without PTMs in complex biological samples. The speed, sensitivity and 
sequencing ability of mass spectrometry makes it a powerful tool in characterizing 
neuropeptides localized across heterogeneous brain regions. In the past decade, hundreds 
of neuropeptides have been discovered and identified through MALDI-MS from different 
forms of samples, including brain slices, single neurons and cultured neuron 
releasates.(23-25) ESI-MS, working complementary to MALDI-MS, also contributed to 
the identification and characterization of large amount of neuropeptides in various 
neuronal region homogenates.(26-28) Here, we used a multifaceted mass spectrometric 
approach to study peptides present in the habenula nuclei of rat brain. 
Results from in situ mRNA hybridization and immunohistochemistry have shown 
the presence of a few neuropeptides and their receptors in the habenula region, such as 
pro-orexin derived peptides and neuropeptide Y.(29, 30) However, there is no systematic 
investigation of neuropeptide content in this small but functionally critical brain region. 
Here, we combined sample heat stabilization, multiple high accuracy and high resolution 
mass spectrometry and bioinformatics to perform the peptidomic characterization of the 
rat habenula region. In our study, 263 and 177 peptides from 27 and 20 prohormones 
were identified in the medial and lateral habenula respectively. 38 and 36 peptides in 
medial and lateral habenula possess PTMs, including amidation, pyroglutamylation, 
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acetylation, disulfide bond and phosphorylation. This study presented here is the first 
comprehensive study of neuropeptides contained in vertebrate habenula. The 
neuropeptide content discovered in habenula here can be used as a basis to better 
understand the role of these peptides in different biological processes.  
 
4.3 Experimental 
4.3.1 Materials  
All solvents used were LC-MS grade and obtained from Thermo Fisher Scientific 
(Waltham, MA). Triethylamine, acetone and hydrochloric acid were obtained from 
Sigma-Aldrich (St. Louis, MA).  
 
4.3.2 Habenula isolation and stabilization 
Sprague Dawley rats were sacrificed by decapitation in compliance with protocols 
approved by the University of Illinois Institutional Animal Care and Use Committee and 
in accordance with all state and federal regulations. The brain was quickly removed and 
cooled down in ice cold mGBSS buffer. For LC-FT ICR MS analysis, the medial and 
lateral habenula regions were isolated from 10 rats, stabilized in boiling water for 10 min 
and pooled respectively. For LC-Orbitrap analysis, 6 rats were sacrificed. The isolated 
medial and lateral habenula regions were stabilized with Stabilizor (Denator, Sweden) 
and pooled respectively. For LC-MALDI MS analysis, the entire habenula regions from 3 
rats were stabilized with Stabilizor and pooled.   
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4.3.3 Extraction of endogenous peptides 
The isolated and stabilized habenula were homogenized in 200 µL ice cold water 
and placed on ice for 1 hour. Supernatants were saved in a new microcentrifuge tube after 
centrifugation at 14000 × g for 10 min. The tissue pellets were subjected to two more 
stages of peptide extraction with acidified acetone (acetone:water:HCl 40:6:1) and 0.25% 
acetic acid solution respectively in a similar manner. The supernatants saved from three 
extractions were combined.  
Combined supernatant was concentrated to about 20 µL to remove HCl and 
acetone used in extraction step through a SpeedVac device (GeneVac, UK) and desalted 
with a C18 spin column (ThermoFisher, MA). For LC-Orbitrap and LC-MALDI MS 
analysis, peptides were eluted from the C18 spin column using acidic buffer as 
recommended by the manufacturer. For LC-FT ICR MS analysis, peptides retained on the 
C18 spin column were eluted using 70/30, 50/50 and 20/80 water/acetonitrile (ACN) 
solutions with pH adjusted to 11.0. Each eluent fraction was collected, dried using 
SpeedVac and stored in -20 °C freezer until LC-MS analysis. 
 
4.3.4 LC-Orbitrap MS analysis 
The peptides extracted from rat habenula regions were analyzed using a nanoLC 
system (Ultimate 3000, ThermoFisher, MA) coupled to an Orbitrap Fusion mass 
spectrometer (ThermoFisher, MA). The samples were reconstituted in loading solvent 
(95%/5% water/ACN with 0.1% formic acid, FA) and loaded into a trap column (). Water 
with 0.1% FA and ACN with 0.1% FA were used as solvent A and B. The loaded 
peptides were separated on a 15 cm Pepmap Acclaim analytical column packed with 2 
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µm particle sizes (100 Å pore sizes) obtained from Thermo Fisher Scientific (MA) at 300 
nl/min flowrate. The gradient for peptide elution range is as followings: 3-6 min, 1-10% 
B; 6-90 min, 10-70% B. Data acquisition was accomplished on an Orbitrap fusion mass 
spectrometer (ThermoFisher, MA) in top speed data-dependent mode. Other parameters 
include: precursor scan AGC, 2e+5; MS/MS scan AGC, 5e+4; isolation window, 1.6 Da; 
normalized collision energy, 35%; activation Q, 0.25. 
 
4.3.5 LC-FT-ICR MS analysis 
The three dried eluent fractions were reconstituted in 10 µl of 95%/5% H2O/ACN 
solution and injected into a Eksigent 1D Plus nanoLC system (Eksigent, MA) coupled to 
a 11 Tesla FT-MS (LTQ FT Ultra, ThermoFisher, MA) respectively. The peptides were 
first loaded onto a peptide trap column (150 μm ID ×2 cm length, 5 μm Magic AQ 
particles, 100 Å pore size, New Objective, MA). The trap column was then placed in-line 
with the analytical column (PicoFrit column, 75 μm ID × 15 cm length, 5 μm Magic AQ 
particles, 100 Å pore size, New Objective, MA). 95%/5% H2O/ACN and 5%/95% 
H2O/ACN with 0.1% FA were used as solvent A and B. The sample was eluted with a 
flow rate of 300 nl/min over a gradient as following: 0-10min, 0-20% solvent B; 10-
65min, 20-55% solvent B; 65-75min, 55-85% solvent B; 75-80min, 85-85% solvent B; 
80-85min, 85-0% solvent B; 85-90min, 0-0% B. MS acquisition parameters include mass 
scan at m/z 300-2000. Data-dependent precursor selection was restricted to the top five 
most intense ions with following parameters: precursor isolation window, m/z 10; 
activation Q, 0.25; activation time, 50ms; collision energy 35eV. Dynamic exclusion was 
enabled with a repeat count of 2 and exclusion duration of 180s. 
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4.3.6 Peptide identification 
4.3.6.1 Untargeted database search 
The raw files acquired on LC-Orbitrap fusion MS were loaded into PEAKS 
software (Version 7.5, Canada). The loaded files were first processed with de novo 
function in the software and then searched against a rat proteome database downloaded 
from Uniprot. The mass error tolerance was set to 20 ppm for precursor ion and 0.1 Da 
for fragment ions. No enzyme digestion was selected and up to 3 variable PTMs were 
allowed for each peptide. Identified peptides in the database search results were filtered 
by -10logP value cut-offs, which corresponding to 1% false discovery rate (FDR).  
The raw files acquired on LC-FT ICR MS were processed with cRAWler 
algorithm in ProsightPC (Version 2.0, ThermoFisher, MA), which outputs .puf files.  
The .puf files generated after cRAWler processing contained deconvoluted monoisotopic 
masses of precursor and fragment ions. The .puf files were then loaded into ProsightPC 
and searched against a lab-built rat proteome database downloaded from Uniprot. The 
database search was conducted in Biomarker search mode with precursor and fragment 
mass error tolerance set at 81 Da and 10 ppm respectively. In biomarker search mode, 
detected precursor mass was compared with all the possible subsequences in the database. 
For the subsequences whose masses are within 81 Da tolerance of a precursor mass, 
detected fragment masses are then matched with theoretical fragment masses from these 
candidate subsequences. Identified peptides with p value lower than 1e-4 were kept. 
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4.3.6.2 Targeted database search 
The .raw files from Orbitrap MS analysis were also searched against a lab-built 
rat neuropeptide database that contains prohormone sequences in FASTA format. The 
same precursor and fragment ion mass error tolerance value were used as described 
above. Up to 7 variable PTMs were allow for each peptide, so that the neuropeptides with 
multiple PTMs missed in the first round of database search could be discovered and 
identified in the second round targeted search. FDR value was controlled at a stricter 
level of 0.1%. 
 
4.3.7 LC-MALDI MS analysis 
Peptide extracts were injected into a Dionex capLC system equipped with a 
capillary C18 column (300 µm ID × 150 mm, 100 Å, ThermoFisher). Solvent A and B 
were water with 0.1% FA and ACN with 0.1% FA operated at 4 µl/min. Peptides were 
separated and eluted over a 45 min gradient with solvent B from 1% B up to 50% B. 
Fractions were collected every 3 min. Collected fractions were dried with SpeedVac and 
reconstituted in 5 µl of water. 1 µl of sample from each fraction was spotted on MALDI 
target plate, mixed with 50 mg/ml 2, 5-Dihydroxybenzoic acid matrix and dried at room 
temperature. The dried samples were analyzed with a MALDI-FT MS (Bruker, MA) over 
a mass range of 200 to 4000 m/z. The identity of peaks in MALDI spectra was assigned 
by matching m/z of detected peaks to known neuropeptides contained in the SwePep rat 
database within 0.1 Da mass error. 
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4.4 Results and discussion 
The habenula is a small brain region conserved in the vertebrates. It works as a 
structure linking the forebrain and midbrain and has been reported to play important roles 
in different physiological processes such as reward-based decision-making and 
depression.(1, 9, 31) Therefore, investigating the signaling peptides contained inside the 
habenula region is expected to facilitate our understanding of molecular mechanisms of 
these physiological events and animal behaviors. Scientists have used immunological 
methods and in situ hybridization to study the distribution of different neuropeptide or 
their mRNAs across the central nervous systems, some of which were reported to be 
present in the habenula region.(32) Here, we employed a combination of high resolution 
mass spectrometry platforms to explore the neuropeptidome of the habenula region 
isolated from rat brains. 
Habenula is a small structure composed of lateral and medial nuclei, each of 
which can be further divided into multiple smaller subnuclei. Due to limitations in 
isolating these subnuclei during dissection, we investigated the lateral and medial 
habenula nuclei respectively. Figure 4.1 showed the workflow of the multifaceted mass 
spectrometric approach used in this study. In total, 263 neuropeptides were identified 
from medial habenula using LC-FT MS and LC-Orbitrap MS. These neuropeptides were 
derived from 27 prohormones (Table 4.1). For lateral habenula, 177 neuropeptides 
derived from 20 prohormones were identified using the two mass spectrometry platforms 
(Table 4.2). The diversity of prohormones in this small brain nuclei displays a high 
molecular heterogeneity which is in agreement with morphological heterogeneity 
revealed by previous transcriptome study.(33) For .raw files acquired using Orbitrap MS, 
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we performed de novo sequencing and PEAKS database search in both untargeted and 
targeted mode. In the latter case, a neuropeptide library was used instead of a proteome 
database. Moreover, up to 7 PTMs on a single peptide were allowed, which can help 
discover neuropeptides possessing multiple PTMs. For example, orexin-A has 
pyroglutamination at N-terminus, two disulfide bonds and amidation at C-terminus. In 
our results, 6 neuropeptides from lateral habenula region, which were missing in the 
initial untargeted search, were identified and rescued in the targeted database search. 
Among the identified neuropeptides, 134 of them were detected in both medial and lateral 
habenula. 7 prohormones were exclusively detected from medial habenula, including pro-
opiomelanocortin, gastrin-releasing peptide, insulin-like growth factor-binding protein 5, 
neuropeptide S, neuroendocrine protein 7B2, corticoliberin and tachykinin-3. These 
observations indicate that the medial and lateral habenula uses different sets of signaling 
peptides, at least partially, to communicate in the neuronal network and have different 
biological functions. We also investigated the habenula using MALDI-MS. Most of the 
peaks, even with high intensity and good peak shape, could not be matched to any 
peptides. It is not surprising because the current database only includes reported/known 
neuropeptides. Many peaks could correspond to peptides possessing endogenous 
cleavage sites at both termini but not included in the database. Nevertheless, we detected 
24 neuropeptides in MALDI-MS data (Table 4.3) through mass matching of detected 
peaks to known neuropeptides. Majority of them were also identified in ESI-MS analysis. 
2 neuropeptides from osteostatin and pro-FMRFamide-related neuropeptide were 
detected only using MALDI. However, the presence of these two peptides needs further 
validation since no MS/MS spectra were acquired in MALDI-MS analysis.  
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Our study represents the first neuropeptidomics study of the habenula nuclei. In 
the following content, presence and functions of some neuropeptides in the habenula are 
discussed. Tandem MS of selected important neuropeptides were shown in Figure 4.2.  
Prohormone protachykinin-1 belongs to the tachykinin family and its presence has 
been reported in the medial habenula region.(34) Multiple neuropeptides cleaved at mono 
or di-basic sites from tachykinin-1 have been identified in our peptidomic study, 
including substance P, neurokinin A, short neuropeptide K, C-terminal flanking peptide, 
protachykinin[111-118]. Cells containing substance P and neurokinin B have been found 
in the medial habenula with axons projecting to interpeducular nucleus (IPN) and ventral 
tegmental area (VTA) using immunocytochemistry and in situ hybridization, which is in 
agreement of our identification results.(35) Recently, the neurokinin signaling composed 
of substance P, neurokinin B and their receptors have been discovered to facilitate 
nicotine-induced excitability enhancement of neurons within medial habenula.(36) 
However, biological functions of other neurokinin peptides identified in the habenula are 
not clear. Further research on these neurokinin peptides can lead to a better understand of 
nicotine addiction mechanism and promote neurokinin signaling based therapies.  
Neuropeptide Y (NPY) is a 36-amino acid signaling peptide found in the nervous 
system. NPY has been found to be involved in regulating different physiological events 
such as food intake, stress and depression.(37, 38) Immunohistochemistry showed that 
NPY-positive fibers were detected in both lateral and medial habenula regions.(39) In our 
study, we identified the complete form of NPY and its C-terminal flanking peptide. 
Besides, a shortened NPY peptide (YPSKPDNPGEDAPAEDMA.R) was also identified 
confidently with 34.0 for -10logP score. This shortened NPY has an arginine at its C-
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terminal, a common cleavage site in prohormone processing, suggesting that it is likely 
an endogenous neuropeptide instead of a NPY degradation product generated post-
mortem. McBride and his coworkers discovered that mRNA of NPY was significantly 
reduced in the medial habenula of alcohol-preferring rats, which indicates the potential 
function of NPY in the habenula in ethanol intake control.(40) However, the experiments 
were performed on mRNA level, which cannot distinguish which form of NPY is 
depleted in the habenula region of alcohol-preferring rats. Using a MS-based strategy, 
previously overlooked peptides, the shortened NPY in this case, can be discovered, which 
reduces the probability of missing important functional targets. It will be interesting to 
determine the accurate form and identity of bioactive neuropeptide regulating ethanol 
intake through other biological methods. 
Habenula is anatomically close to the pineal gland which affects sleep pattern and 
composes the epithalamus together with pineal gland.(8) It also receives extrinsic 
circadian signals sent from the main circadian pacemaker, the suprachiasmatic nucleus 
(SCN).(41) It has been revealed that orexin A and B modulate sleep by regulating 
melatonin synthesis and secretion through orexinergic neuron-pineal gland circuit in 
zebrafish and rat and influence neuron activities in the lateral habenula.(42, 43) In our 
peptidomic results, full length orexin-B and its C-terminal peptide were identified in the 
lateral habenula. However, orexin-A was not identified in our results. It is possible that 
the ionized amount of orexin-A is below the instrument limit or not sufficient for a high 
quality MS/MS spectra. In addition, orexin-A has two disulfide bonds, pyroglutamated at 
N-terminal and amidated at C-terminal. The 6 PTMs on a peptide of 3500 Da can also 
complicate the de novo sequencing and database search even in targeted search mode. 
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Although orexin-A was not confidently identified, peaks of m/z corresponding to +4, +5 
and +6 charged orexin-A were observed, with low intensity yet (Figure 4.3). The low 
intensity might also account for the missing of orexin-A in the identification results since 
insufficient ions resulted in tandem MS spectra with poor quality. Besides, the 
identification of orexin-B indicates pro-orexin was translated and processed within the 
habenula neurons, roles of orexin peptides in the modulation of circadian signals could be 
investigated later. 
Two pituitary adenylate cyclase-activating polypeptide derived neuropeptides, 
PACAP[111-128] and [130-143], were identified in the habenula region. Cleavage sites 
are found on N and C-terminals of both peptides. Previous study of PACAP distribution 
in the brain has shown that both peptide and its receptors were present in the medial and 
lateral habenula.(44, 45) Habenular neurons can be activated by stress-inducing stimuli 
and PACAP has been reported to be associated with stress and anxiety-like behaviors.(8, 
31) A recent study showed a significant increase of serum corticosterone and decrease in 
c-fos expression in the habenula after fear conditioning in rats.(46) Follow-up function 
study of PACAP in stress modulation can facilitate future pharmacological treatment 
approaches. 
Multiple pain-related peptides were detected including nociceptins, somatostatin 
and opiates peptides from pro-enkephalin-A and pro-dynorphin.(47-49) Those peptides 
bind to various classes of opioid and nociception receptors and are involved in pain 
signaling.(50) Findings of pain-related peptides in the habenula are consistent with results 
from preclinical study that habenula plays an important role in pain and analgesia.(51) 
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Besides, somatostatin in the zebrafish habenula was reported to likely affect stress 
response in both experience-dependent and independent way.(52) 
Our peptidome study also identified other neuropeptides not reported or only 
discovered in habenula at mRNA level previously, including CART, neurosecretory 
protein VGF and secretogranins.(53) However, their potential roles in the habenula are 
not reported. It is meaningful to investigate what physiological processes the 
neuropeptide participate and their molecular mechanisms, given that habenula is a 
convergence site of inputs from forebrain and expected to have different functions. Other 
than neuropeptides, some orphan GPCRs were discovered and they display a distinct 
expression pattern in the habenula region.(11, 12) Our results are useful in determining 
endogenous ligands for the receptors and display a potential in developing drugs for 
diseases relevant to these receptors. 
 
4.5 Conclusion 
Our peptidomic analysis combined tissue stabilization, high-resolution mass 
spectrometry and bioinformatics and allowed the identification of 263 and 177 
neuropeptides in the rat medial and lateral habenula region respectively. The first 
comprehensive peptidome characterization of habenula presented here provided ample 
information of neuropeptides in the small nuclei. In neuroscience perspective, although 
many early prohormone distribution studies suggested the presence of heterogeneous 
cells expressing neuropeptides in the habenula, data at peptide level was either missing or 
incomplete. Our study confirmed the prohormone expressions and revealed the accurate 
forms of neuropeptides. Many behaviors and pathological states with involvement of 
- 102 - 
 
habenula were investigated since the habenula receives neuronal input from different 
brain regions and acts as a bridge between fore-brain and mid-brain. Results of our 
peptidomic study can help shed light on identities of neuroactive peptides in the habenula 
neurons that project into other parts of the brain and discovery of endogenous ligands for 
disease-related orphan GPCRs.   
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4.7 List of Figures and Tables 
 
 
 
 
 
Figure 4.1 Workflow of neuropeptidomics study of the rat habenula. The medial and 
lateral habenula were isolated and analyzed using ESI-Orbitrap and ESI-FTMS with 
fractionation respectively. The entire habenula region was fractionated with capLC and 
analyzed by MALDI-FTMS.  
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Figure 4.2 Representative tandem MS spectra of selected important neuropeptides in the 
habenula. (A) Substance P. (B) Neuropeptide Y. (C) Orexin-B. (D) PACAP [111-128]. 
(E) Beta-neoendorphin.  
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Figure 4.3 Putative signals from orexin-A at different charge states. Putative Orexin-A 
signal was observed between retention time 18.52 and 18.83 on LC-MS. The isotopic 
patterns of putative orexin-A at different charge states (+4, +5, +6) were shown. Isotopic 
peaks from orexin-A isotopic profile were labeled with red dot.  
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Table 4.1 Neuropeptide identification results from the medial habenula. For PEAKS 
database search, peptides with -10lgP score higher than 1% and 0.1% FDR threshold 
values in untargeted and targeted search were kept. For ProsightPC database search, 
peptides with p value lower than 1e-4 were kept. 
Prohormone Peptide -10lgP or p 
value 
theoretic
al mass 
mass error 
(ppm) 
detected 
mass 
Orbitr
ap 
FT-
ICR 
Cerebellin-1  R.SGSAKVAFSAIRSTN.H 58.09 1494.77
91 
-3 1494.7746 X  
Cerebellin-1  R.SGSAKVAFSAIRSTNH.E 40.91 1631.83
79 
-2.2 1631.8341 X  
Cerebellin-1  S.GSAKVAFSAIRSTN.H 33.56 1407.74
69 
-2.7 1407.743 X  
Cerebellin-1  S.GSAKVAFSAIRSTNH.E 61.18 1544.80
59 
-2.5 1544.802 X  
Cholecystokinin  A.Q(pyro)PVVPVEAVDPMEQRAE
EAPRRQL.R 
42.31 2726.38
09 
-3.1 2726.3721 X  
Chromogranin A  R.MDQLAKELTAE.K 28.06 1247.60
67 
1 1247.6078 X  
Chromogranin A  W.SRMDQLAKELTAE.K 23.99 1490.73
99 
1.8 1490.7423 X  
Chromogranin A  G.FRDPGPQL.R 18.69 928.476
6 
-2.4 928.4744 X  
Chromogranin A  R.AYGFRDPGPQL.R 34.19 1219.59
85 
-2.6 1219.5952 X  
Chromogranin A  R.LEGEDDPDRSM.K 30.81 1262.50
84 
-1.6 1262.5064 X  
Chromogranin A  R.LEGEDDPDRSMKLSF.R 46.58 1737.78
8 
-2.6 1737.7833 X  
Chromogranin A  R.LEGEDDPDRSMKLSFRARAYG
FRDPGPQL.R 
28.31 3322.61
52 
-2.6 3322.6065 X  
Chromogranin A  R.WSRMDQLAKELTAE.K 28.14 1676.81
92 
-2.8 1676.8143 X  
Chromogranin A  Y.GFRDPGPQL.R 23.41 985.498
1 
-1.4 985.4966 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
A.Q(pyro)EDAELQP.R 16.04 911.387
2 
1.5 911.3885 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
A.Q(pyro)EDAELQPR.A 43.67 1067.48
83 
-2.4 1067.4856 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
G.AQEDAELQP.R 21.31 999.450
9 
-1.9 999.449 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
R.ALDIYSAVDDAS(phos)HEKEL
PR.R 
23.03 2208.01 -2.1 2208.0051 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
R.ALDIYSAVDDASHEKELPR.R 29.64 2128.04
37 
1.9 2128.0476 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
R.APGAVLQIEALQEVLKKLKS.K 30.52 2134.27
25 
2.1 2134.2768 X  
Cocaine- and 
amphetamine-
regulated 
transcript protein  
R.IPIYE.K 22.35 633.337
3 
-1.2 633.3366 X  
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Table 4.1 (cont.) 
Cocaine- and 
amphetamine-
regulated 
transcript protein  
R.Q(pyro)LRAPGAVLQIEALQEV
LKKLKS.K 
23.46 2514.48
97 
1.1 2514.4924 X  
Corticoliberin R.GAEDALGGHQGALE.R 27.74 1323.60
55 
-4.1 1323.6 X  
Corticoliberin R.GAEDALGGHQGALERE.R 56.86 1608.74
91 
-2.9 1608.7443 X  
Galanin peptides R.GWTLNSAGYLLGPHAIDNHRS
FSDKHGLT(amide).G 
31.88 3162.57
47 
-2.7 3162.566 X  
Gastrin-releasing 
peptide  
R.GSHWAVGHLM(amide).G 28.79 1092.52
87 
-1.9 1092.5266 X  
Insulin-like 
growth factor-
binding protein 5  
R.HMEASLQEFKASPRMVP.R 17.52 1956.95
5 
11 1956.9765 X  
Insulin-like 
growth factor-
binding protein 5 
R.ISELKAEAV.K 25.02 958.533
4 
-3.1 958.5304 X  
Neuroendocrine 
protein 7B2  
K.SVPHFS(phos)EEEKEPE 21.88 1622.65
01 
-2.1 1622.6466 X  
Neuroendocrine 
protein 7B2 
K.SVPHFSEEEKEPE 21.97 1542.68
37 
-1.7 1542.681 X  
Neuropeptide S R.SFRNGVGSGVKKTSF.R 52.46 1569.82
63 
-2.1 1569.8229 X  
Neurosecretory 
protein VGF  
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKD.D 
28.02 3241.57
52 
2.8 3241.584 X  
Neurosecretory 
protein VGF  
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEV(amide).R 
21.49 3866.88
23 
-4.4 3866.8652 X  
Neurosecretory 
protein VGF  
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEV.R 
31.36 3867.86
62 
0.2 3867.8672 X X 
Neurosecretory 
protein VGF  
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEVRA.A 
32.26 4095.00
44 
0.4 4095.006 X  
Neurosecretory 
protein VGF  
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEVRAA.R 
30.26 4166.04
15 
3.8 4166.0574 X X 
Neurosecretory 
protein VGF  
G.VSSPKTHLGETLTPLSKAYQS.
L 
16.64 2243.17
97 
1.5 2243.1828 X  
Neurosecretory 
protein VGF  
K.NAPPEPVPPPR.A 47.14 1169.61
93 
-2.9 1169.6158 X  
Neurosecretory 
protein VGF  
K.NAPPEPVPPPRAAPAPT.H 47.08 1677.88
38 
-2 1677.8804 X  
Neurosecretory 
protein VGF  
K.NAPPEPVPPPRAAPAPTHV.R 33.97 1914.011
1 
1.8 1914.0144 X  
Neurosecretory 
protein VGF  
K.NAPPEPVPPPRAAPAPTHVR.S 25.82 2070.11
23 
1.4 2070.1152 X  
Neurosecretory 
protein VGF  
N.APPEPVPPPRAAPAPTHV.R 53.09 1799.96
81 
-1.5 1799.9652 X  
Neurosecretory 
protein VGF  
R.AQEEADAEERRLQEQEELENY
IEHVLLHRP 
19.09 3672.77
66 
0.2 3672.777 X  
Neurosecretory 
protein VGF  
R.ARQNALLFAEEEDGEAGAED.
K 
21.47 2133.94
51 
1.6 2133.9486 X  
Neurosecretory 
protein VGF  
R.DLGGRGLQETQQERENEREEE
AEQE.R 
27.58 2958.31
86 
-4.1 2958.3063 X  
Neurosecretory 
protein VGF  
R.GLQETQQERENEREEEAEQE.R 23.35 2460.06
37 
2.1 2460.0687 X  
Neurosecretory 
protein VGF  
R.KKNAPPEPVPPPRAAPAPTHV.
R 
18.18 2170.20
09 
1 2170.2028 X  
Neurosecretory 
protein VGF  
R.LEGSFLGGSEAGERLLQQGLA
QVEA(amide).G 
21.73 2557.31
35 
3.2 2557.3215 X X 
Neurosecretory 
protein VGF  
R.LEGSFLGGSEAGERLLQQGLA
QVEAGRRQAEATR.Q 
27.19 3583.84
55 
0.3 3583.8465 X  
Neurosecretory 
protein VGF  
R.MSENVPLPETHQFGEGVSSPK
THLGETLTPLSKAYQS.L 
25.27 3995.95
75 
0.9 3995.961 X  
Neurosecretory 
protein VGF  
R.MSENVPLPETHQFGEGVSSPK
THLGETLTPLSKAYQSLSAPFPK
V.R 
34.86 4835.44
78 
-1.5 4835.44 X  
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Table 4.1 (cont.) 
Neurosecretory 
protein VGF  
R.Q(pyro)QETAAAETETRTHTLTR
VNLESPGPER.V 
35.48 3104.51
22 
1.1 3104.5156 X  
Neurosecretory 
protein VGF  
R.Q(pyro)QETAAAETETRTHTLTR
VNLESPGPERVW.R 
39.66 3389.65
99 
2.2 3389.6672 X  
Neurosecretory 
protein VGF  
R.QQETAAAETETRTHTLTRVNL
ESPGPERVW.R 
23.46 3406.68
65 
-4.7 3406.6704 X  
Neurosecretory 
protein VGF  
R.QRDLGGRGLQETQQERENER
EEEAEQE.R 
34.71 3242.47
83 
1.7 3242.4836 X  
Neurosecretory 
protein VGF  
R.THTLTRVNLESPGPER.V 29.67 1805.93
84 
1.3 1805.9404 X  
Neurosecretory 
protein VGF  
R.THTLTRVNLESPGPERVW.R 32.49 2091.08
62 
0.7 2091.0876 X  
Neurosecretory 
protein VGF  
R.VPERAPLPPSVPSQFQ.A 33.67 1747.92
57 
4.5 1747.9334 X  
Neurosecretory 
protein VGF  
R.VPERAPLPPSVPSQFQARMSE
NVPLPETHQFGEG.V 
20.32 3727.84
16 
0.4 3727.8428 X  
Neurosecretory 
protein VGF  
S.LSAPFPKV.R 22.68 857.501 0.8 857.5016 X  
Neurotensin K.IPYIL.K 18.5 617.378
8 
1.5 617.3797 X  
Neurotensin R.Q(pyro)LYENKPRRP.Y 15.63 1282.67
82 
1.7 1282.6803 X  
Neurotensin R.Q(pyro)LYENKPRRPYIL.K 31.05 1671.90
97 
1.8 1671.9126 X  
Orexin  R.RPGPPGLQGRLQ.R 47.57 1274.72
07 
-2.5 1274.7174 X  
Orexin  R.RPGPPGLQGRLQRLLQANGN
HAAGILTM(amide).G 
45.54 2934.61
99 
-2.2 2934.6132 X  
Pituitary 
adenylate 
cyclase-
activating 
polypeptide  
A.AAVDDRAPLT.K 26.26 1027.52
98 
-1.4 1027.5282 X  
Pituitary 
adenylate 
cyclase-
activating 
polypeptide  
R.GMGENLAAAAVDDRAPLT.K 36.85 1770.85
71 
1.5 1770.8596 X X 
Prepronociceptin  R.DAEPEADAEPVADEADEVEQK
QLQ.K 
20.99 2625.15
65 
-1.1 2625.1536 X  
Prepronociceptin  R.FGGFTGARKSA.R 21.06 1097.56
18 
-2.7 1097.5587 X  
Prepronociceptin  R.FGGFTGARKSARKLANQ.K 31.52 1807.98
05 
-1.7 1807.9773 X  
Proenkephalin-A  K.DADEGDTLANSSDLLKELLGT
GDNRAKDSHQQESTNNDEDSTS
.K 
7.25E-25 4592.01 -0.93 4592.01  X 
Proenkephalin-A  K.MDELYPVEPEEEANGGEIL.A 1.05E-12 2132.95 -1.91 2132.95  X 
Proenkephalin-A  G.RPEWWMDYQ.K 35.11 1309.55
49 
1.9 1309.5574 X  
Proenkephalin-A  K.YGGFM.K 47.1 573.225
7 
-2.7 573.2241 X  
Proenkephalin-A  P.Q(pyro)LEDEAKELQ.K 44.26 1184.55
6 
-2.4 1184.5532 X  
Proenkephalin-A  Q.LEDEAKELQ.K 27.39 1073.52
4 
-2.8 1073.521 X  
Proenkephalin-A  R.FAESLPSDEEGESYSKEVPEM.
E 
18.73 2359.00
49 
-1.2 2359.002 X  
Proenkephalin-A  R.SPQLEDEAKEL.Q 35.87 1257.60
88 
1.8 1257.611 X  
Proenkephalin-A  R.SPQLEDEAKELQ.K 39.02 1385.66
74 
1.6 1385.6694 X X 
Proenkephalin-A  R.VGRPEWWMDYQ.K 30.98 1465.64
49 
-3.5 1465.6396 X  
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Proenkephalin-A  R.YGGFL.K 22.12 555.269
3 
-2.6 555.2678 X  
Proenkephalin-A  R.YGGFMKKMDELYPVEPEEEA
NGGEILA.K 
14.95 3015.38
82 
2.1 3015.3945 X  
Proenkephalin-A  R.YGGFMRF 37.36 876.395
2 
1.6 876.3966 X  
Proenkephalin-A  R.YGGFMRGL.K 28.25 899.432
3 
1.1 899.4332 X  
Proenkephalin-A  V.GRPEWWMDYQ.K 30.22 1366.57
64 
-1 1366.575 X  
Proenkephalin-A  Y.GGFMRF 23.38 713.331
9 
-1.9 713.3304 X  
Proenkephalin-B  R.SQENPNTYSEDLDV 30.93 1609.67
43 
-1.3 1609.6722 X  
Proenkephalin-B  R.SSEMAGDEDRGQDGDQVGHE
DLY.K 
33.06 2508.99
34 
2.8 2509.0005 X  
Proenkephalin-B  R.YGGFL.R 22.12 555.269
3 
-2.6 555.2678 X  
Proenkephalin-B  R.YGGFLRKYP.K 26.88 1099.58
14 
-2.5 1099.5786 X  
Proenkephalin-B  R.YGGFLRKYPK.R 32.34 1227.67
64 
2.6 1227.6796 X  
Proenkephalin-B  R.YGGFLRRQFKVVT.R 25.91 1569.87
79 
-0.9 1569.8763 X  
Pro-MCH  R.EIGDEENSAKFPI(amide).G 32.38 1446.69
9 
0.9 1446.7002 X X 
Pro-MCH  R.EIGDEENSAKFPIG.R 25.95 1504.70
45 
1.5 1504.7068 X  
Pro-MCH  R.NVEDDIVFNTFRMGKAFQKE
DTAE.R 
23.37 2803.31
23 
1.1 2803.3152 X  
Pro-neuropeptide 
Y  
G.YPSKPDNPGEDAPAEDMAR.Y 33.91 2058.89
53 
1.6 2058.8985 X  
Pro-neuropeptide 
Y  
G.YPSKPDNPGEDAPAEDMARY
YSALRHYINLITRQRY(amide).G 
21.46 4269.08
11 
-0.6 4269.0781 X  
Pro-neuropeptide 
Y  
R.SSPETLISDLLMRESTENAPRT
RLEDPS.M 
23.09 3143.54
05 
-0.8 3143.538 X  
Pro-neuropeptide 
Y  
R.SSPETLISDLLMRESTENAPRT
RLEDPSM(oxidation)W 
16.36 3476.65
5 
1 3476.6584 X  
Pro-neuropeptide 
Y  
R.SSPETLISDLLMRESTENAPRT
RLEDPSMW 
34.57 3460.66
02 
2.4 3460.6684 X X 
Pro-
opiomelanocortin  
R.AEEETAGGDGRPEPSPRE(amid
e).G 
55.32 1881.84
52 
-2.5 1881.8406 X  
Pro-
opiomelanocortin  
R.ELEGEQPDGLEHVLEPDTEKA
DGPYRVEHFRWGNPPKD.K 
27.62 4385.06
25 
1 4385.0665 X  
Pro-
opiomelanocortin  
R.SYSMEHFRWGKPV(amide).G 30.11 1621.78
23 
-1.8 1621.7793 X  
Pro-
opiomelanocortin  
R.YGGFM.T 21.87 573.225
7 
-2.7 573.2241 X  
ProSAAS  A.ASAPLAETSTPLRL.R 1.26E-28 1425.78 -0.47 1425.78  X 
ProSAAS  R.AVDQDLGPEVPPENVLGALL.
R 
5.11E-39 2045.07 -0.13 2045.07  X 
ProSAAS  A.ASAPLAETSTPL.R 53.44 1156.59
75 
-2.8 1156.5942 X  
ProSAAS  A.ASAPLAETSTPLRL.R 35.6 1425.78
27 
1.4 1425.7848 X  
ProSAAS  A.RPVKEPR.S 44.3 880.524
2 
-2.3 880.5222 X  
ProSAAS  A.SAPLAETSTPL.R 35.52 1085.56
04 
0 1085.5604 X  
ProSAAS  A.VPRGEAAGAVQELAR.A 31.18 1522.82
15 
1.7 1522.824 X  
ProSAAS  D.PPLAPDDDPDAPAAQLAR.A 34.09 1828.89
55 
-0.1 1828.8951 X  
ProSAAS  G.SSEPEAAPAPRRL.R 20.83 1379.71
57 
-1.8 1379.7132 X  
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ProSAAS  L.AETSTPLRL.R 22.4 986.539
6 
1.7 986.5412 X  
ProSAAS  L.ENSSPQAPARRLLPP 42.66 1631.87
43 
-2 1631.871 X  
ProSAAS  L.GRILTGSSEPEAAPAPRRL.R 43.15 1977.07
54 
-1 1977.0732 X  
ProSAAS  L.SAASAPLAETSTPL.R 58.33 1314.66
66 
-2.4 1314.6634 X  
ProSAAS  L.SAASAPLAETSTPLRL.R 34.85 1583.85
18 
1.7 1583.8544 X  
ProSAAS  P.LAETSTPLRL.R 33.03 1099.62
37 
-0.2 1099.6234 X  
ProSAAS  R.ALAHLLEAERQE.R 38.33 1378.72
05 
1.6 1378.7226 X  
ProSAAS  R.ALAHLLEAERQER.A 35.83 1534.82
15 
1.4 1534.8237 X  
ProSAAS  R.ALAHLLEAERQERARAEAQE
AEDQQAR.V 
35.57 3088.53
98 
3.6 3088.5508 X  
ProSAAS  R.ASDPPLAPDDDPDAPAAQLAR
.A 
29.28 2101.99
15 
3.1 2101.998 X  
ProSAAS  R.AVDQDLGPEVPPENVL(amide).
G 
20.21 1689.85
73 
1.9 1689.8606 X  
ProSAAS  R.AVDQDLGPEVPPENVLGA.L 20.15 1818.89
99 
1.3 1818.9022 X X 
ProSAAS  R.AVDQDLGPEVPPENVLGALLR
V.K 
35.63 2300.23
75 
1.5 2300.241 X X 
ProSAAS  R.AVPRGEAAGAVQEL.A 25.73 1366.72
05 
-5 1366.7136 X  
ProSAAS  R.AVPRGEAAGAVQELA.R 20.03 1437.75
76 
1.5 1437.7596 X  
ProSAAS  R.AVPRGEAAGAVQELAR.A 41.16 1593.85
86 
2.4 1593.8624 X  
ProSAAS  R.AVPRGEAAGAVQELARALAH
LLEAERQE.R 
38.55 2954.56
86 
-0.2 2954.568 X  
ProSAAS  R.AVPRGEAAGAVQELARALAH
LLEAERQER.A 
36.46 3110.66
97 
1.4 3110.674 X  
ProSAAS  R.AWGSPRASDPPLAPDDDPDAP
AAQLAR.A 
40.88 2756.31
54 
1.3 2756.319 X  
ProSAAS  R.ILTGSSEPEAAPAPR.R 39.39 1494.76
78 
1.5 1494.77 X  
ProSAAS  R.ILTGSSEPEAAPAPRRL.R 18.14 1763.95
29 
1.3 1763.955 X  
ProSAAS  R.LENSSPQAPARRLL.P 17.45 1550.85
28 
-1.8 1550.85 X  
ProSAAS  R.LENSSPQAPARRLLP.P 23.71 1647.90
56 
-1.9 1647.9024 X  
ProSAAS  R.LENSSPQAPARRLLPP 27.91 1744.95
84 
1.7 1744.9614 X X 
ProSAAS  R.PVKEPR.S 25.46 724.423
2 
-2.1 724.4216 X  
ProSAAS  R.SLSAASAPLAETSTPL.R 41.39 1514.78
27 
1.8 1514.7854 X  
ProSAAS  R.SLSAASAPLAETSTPLRL.R 43.23 1783.96
79 
1.2 1783.97 X X 
ProSAAS  S.AASAPLAETSTPL.R 25.92 1227.63
46 
1.9 1227.6368 X  
ProSAAS  S.APLAETSTPL.R 20.51 998.528
4 
0.4 998.5288 X  
ProSAAS  S.ARPVKEP.R 24.45 795.460
3 
-2 795.4587 X  
ProSAAS  S.ARPVKEPR.S 27.55 951.561
3 
-2.5 951.5589 X  
ProSAAS  S.ARPVKEPRSLS.A 42.57 1238.70
95 
-3.2 1238.7054 X  
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ProSAAS  S.ARPVKEPRSLSAASAPLAETST
PL.R 
32.05 2448.33
35 
1.8 2448.3376 X X 
ProSAAS  S.ARPVKEPRSLSAASAPLAETST
PLR.L 
36.22 2604.43
46 
2.1 2604.44 X  
ProSAAS  S.ARPVKEPRSLSAASAPLAETST
PLRL.R 
38.19 2717.51
88 
1 2717.5212 X X 
ProSAAS  Y.LLGRILTGSSEPEAAPAPRRL.R 36.86 2203.24
37 
2.1 2203.248 X  
Protachykinin-1  R.ALNSVAYE.R 23.58 865.418
1 
-2.6 865.4158 X  
Protachykinin-1 R.ALNSVAYERSAMQNYE.R 60.06 1844.83
63 
-3.5 1844.8298 X  
Protachykinin-1 R.DADSSIEKQVALLKALYGHGQ
IS.H 
28.07 2442.27
54 
1.8 2442.2796 X  
Protachykinin-1 R.DADSSIEKQVALLKALYGHGQ
ISH.K 
42.56 2579.33
42 
1.3 2579.3376 X  
Protachykinin-1 R.HKTDSFVGLM(amide).G 46.17 1132.56
99 
-1.2 1132.5686 X  
Protachykinin-1 R.RPKPQQFFGLM(amide).G 18.02 1346.72
81 
2.3 1346.7312 X  
Protachykinin-3  R.NSQPDTPADVVEENTPSFGVL.
K 
7.43E-48 2215.03 0.74 2215.03  X 
Prothyroliberin  A.LPEAAQEEGAVTPDLPGLENV
QVRPE.R 
29.1 2757.38
21 
1.3 2757.3855 X X 
Prothyroliberin  R.ALGHPC(dehydro)GPQGTC(deh
ydro)GQTGLLQLLGDLSRGQETL
VKQSPQVEPWDKEPLE.E 
63 5007.48
58 
0.6 5007.4885 X  
Prothyroliberin  R.EEEEKDIEAEERGDLGEGGAW.
R 
27.1 2347.00
88 
-3.3 2347.0008 X  
Prothyroliberin  R.EEEEKDIEAEERGDLGEGGAW
RL.H 
29.7 2616.19
38 
0.6 2616.1956 X  
Prothyroliberin  R.EEEEKDIEAEERGDLGEGGAW
RLH.K 
36.83 2753.25
27 
9.4 2753.2784 X  
Prothyroliberin  R.FIDPELQRSWEEKEGEGVLMP
E.K 
20.5 2617.23
68 
1.4 2617.2405 X X 
Prothyroliberin  R.GQETLVKQSPQVEPWDKEPLE
E 
20.54 2565.25
98 
-0.4 2565.2586 X  
Prothyroliberin  R.SFPWMESDVT.K 24.84 1197.50
12 
-2.3 1197.4984 X  
Prothyroliberin  S.FPWMESDVT.K 15.65 1110.469
2 
1.1 1110.4704 X  
Prothyroliberin  W.FSDVPQV.K 25.05 790.386
1 
2.2 790.3878 X  
Secretogranin-1 G.RRPLSEERKHAAGESKDANVA
TANLGE.K 
23.63 2905.47
53 
-2.2 2905.469 X  
Secretogranin-1 K.HAAGESKDANVATANLGE.K 25.02 1753.82
3 
1 1753.8246 X  
Secretogranin-1 L.DEGHDPVHESPVDTA.K 19.6 1603.67
5 
-2.4 1603.671 X  
Secretogranin-1 L.LDEGHDPVHESPVDTA.K 20.79 1716.75
9 
-1.8 1716.756 X  
Secretogranin-1 L.SEERKHAAGESKDANVATANL
GE.K 
22.84 2383.13
62 
-1.4 2383.1328 X  
Secretogranin-1 R.APHLDL.K 26.52 664.354
4 
1.3 664.3552 X  
Secretogranin-1 R.DPSDASVGRWASSREETGAPV
EDSPGQAKVDNEEWTGGGGHS(
amide)(phos).R 
19.07 4389.87
94 
-4.4 4389.86 X  
Secretogranin-1 R.EAVDDQESLHPSNQQVS.K 30.56 1881.83
4 
-1.8 1881.8306 X  
Secretogranin-1 R.EAVDDQESLHPSNQQVSKEA.
K 
50 2210.00
88 
-1.5 2210.0055 X  
Secretogranin-1 R.EPGAYPALDSRQE.K 20.51 1431.66
3 
-2.7 1431.6592 X  
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Secretogranin-1 R.GGKEEEEEEGKIYPKGEHRGD
AGEE.K 
27.79 2758.23
17 
-1.4 2758.2276 X  
Secretogranin-1 R.GREPGAYPALDSRQE.K 36.98 1644.78
55 
1.6 1644.7881 X  
Secretogranin-1 R.GRGREPGAYPALDSRQE.K 31.87 1857.90
81 
2.2 1857.912 X X 
Secretogranin-1 R.HSEERGGKEEEEEEGKIYPKG
EHRGDAGEE.K 
26.46 3396.50
88 
-3.1 3396.498 X  
Secretogranin-1 R.KHAAGESKDANVATANLGE.K 25.48 1881.91
8 
1.7 1881.921 X  
Secretogranin-1 R.KHAAGESKDANVATANLGEK
R.G 
32.39 2166.11
4 
1.8 2166.1176 X  
Secretogranin-1 R.LGALFNPYFDPLQWKNSDFE.
K 
33.81 2400.14
26 
0.8 2400.1446 X X 
Secretogranin-1 R.LLDEGHDPVHESPVD.T 18.38 1657.75
83 
-2.1 1657.7547 X  
Secretogranin-1 R.LLDEGHDPVHESPVDT.A 40 1758.80
6 
2 1758.8094 X  
Secretogranin-1 R.LLDEGHDPVHESPVDTA.K 37.82 1829.84
31 
1.9 1829.8464 X X 
Secretogranin-1 R.NHPDSELES(phos)TANRHSEET
EEERSYEGAKGRQH.R 
44.66 3788.60
47 
-2.6 3788.595 X  
Secretogranin-1 R.NHPDSELEST(phos)ANRHSEE
TEEERSYEGAKGRQ.H 
25.92 3651.54
59 
-0.9 3651.5425 X  
Secretogranin-1 R.NHPDSELEST(phos)ANRHSEE
TEEERSYEGAKGRQH.R 
24.44 3788.60
47 
-2.8 3788.594 X  
Secretogranin-1 R.NHPDSELESTANRHS(phos)EET
EEERSYEGAKGRQ.H 
25.7 3651.54
59 
-2.6 3651.5365 X  
Secretogranin-1 R.NHPDSELESTANRHS(phos)EET
EEERSYEGAKGRQH.R 
48.22 3788.60
47 
-2.2 3788.5962 X  
Secretogranin-1 R.NHPDSELESTANRHSEET(phos)
EEERSYEGAKGRQH.R 
27.46 3788.60
47 
-1.9 3788.5974 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
.S 
35.83 2595.10
69 
2.1 2595.1124 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
SYEGAKGRQ.H 
25.63 3571.57
96 
3.7 3571.5925 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
SYEGAKGRQH.R 
59.91 3708.63
84 
-2.3 3708.63 X  
Secretogranin-1 R.PFSEDVNW.G 22.76 992.424 0.7 992.4246 X  
Secretogranin-1 R.PFSEDVNWGYE.K 21.89 1341.55
13 
2.7 1341.5548 X X 
Secretogranin-1 R.Q(pyro)YDDGVAELDQLLHY.R 46.36 1760.78
93 
-2.9 1760.7842 X X 
Secretogranin-1 R.QYDDGVAELDQLLHY.R 24.67 1777.81
58 
2 1777.8192 X X 
Secretogranin-1 R.RPLSEERKHAAGESKDANVAT
ANLGE.K 
22.03 2749.37
43 
2.6 2749.3812 X  
Secretogranin-1 R.SYEGAKGRQHRGRGREPGAYP
ALDSRQE.K 
46.96 3127.54
08 
-1.3 3127.5365 X  
Secretogranin-1 R.YPQSKWQEQE.K 51.58 1321.59
39 
-2.7 1321.5902 X  
Secretogranin-2 R.TNEIVEEQYTPQSLATLESVFQ
ELGKLTGPSN.Q 
1.05E-30 3521.74 1.17 3521.74  X 
Secretogranin-2 A.ASFQRNQLLQKEPDLR.L 43.11 1942.03
85 
2 1942.0424 X  
Secretogranin-2 A.GSLKNEDTPNRQYLDEDMLL
KVLEYLNQEQAEQGREHLA.K 
26.38 4586.23
49 
-3.5 4586.2185 X  
Secretogranin-2 A.NQIPKVAWIPDVESR.Q 22.5 1750.93
65 
1.7 1750.9392 X  
Secretogranin-2 A.SFQRNQLLQKEPDLR.L 34.98 1871.00
13 
1.6 1871.0044 X  
Secretogranin-2 E.YLNQEQAEQGREHLA.K 24.25 1784.84
41 
-1.8 1784.8407 X  
Secretogranin-2 F.QELGKLTGPSNQ.K 22.28 1270.65
17 
-2.3 1270.6488 X  
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Secretogranin-2 G.ISVPLQLKENGEESHLAESSR.
D 
35.17 2322.18
14 
1.2 2322.184 X  
Secretogranin-2 H.MRFPLMYEENSRENPF.K 26.4 2058.92
92 
1.3 2058.9318 X  
Secretogranin-2 K.YPELMNTNQL.K 25.38 1221.56
99 
1.5 1221.5718 X  
Secretogranin-2 L.EYLNQEQAEQGREHL.A 24.54 1842.84
96 
-3 1842.8439 X  
Secretogranin-2 L.EYLNQEQAEQGREHLA.K 19.23 1913.88
67 
-1.6 1913.8836 X  
Secretogranin-2 M.YEENSRENPF.K 24.15 1283.54
17 
-5.6 1283.5344 X  
Secretogranin-2 P.LMYEENSRENPF.K 35.72 1527.66
64 
0.8 1527.6676 X  
Secretogranin-2 Q.IPKVAWIPDVES.R 28.68 1352.73
4 
2.1 1352.7368 X  
Secretogranin-2 R.ANQIPKVAWIPDVES.R 33.77 1665.87
26 
0.7 1665.8738 X  
Secretogranin-2 R.ANQIPKVAWIPDVESR.Q 33.34 1821.97
36 
0.5 1821.9744 X  
Secretogranin-2 R.DKALLRLPYGPGKS.R 33.95 1513.86
16 
2.5 1513.8654 X  
Secretogranin-2 R.DKALLRLPYGPGKSR.A 39.36 1669.96
26 
0.9 1669.964 X  
Secretogranin-2 R.DSKENTEKNEQINEEM.K 45.03 1936.83
2 
-1.8 1936.8285 X  
Secretogranin-2 R.FPLM(oxidation)YEENSRENPF.
K 
18.72 1787.78
25 
3.8 1787.7892 X  
Secretogranin-2 R.FPLMYEENSR.E 23.01 1284.58
08 
3.6 1284.5854 X  
Secretogranin-2 R.FPLMYEENSRENPF.K 39.15 1771.78
75 
0.5 1771.7884 X  
Secretogranin-2 R.IPAGSLKNEDTPN.R 35.17 1354.67
29 
-2.6 1354.6692 X X 
Secretogranin-2 R.IPAGSLKNEDTPNR.Q 40.94 1510.77
39 
1.7 1510.7766 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQ.Y 27.64 1638.83
25 
-2.2 1638.8289 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQY.L 58.43 1801.89
59 
-2.5 1801.8915 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQYLDEDM
LLKVLEYLNQEQAEQGREHL.A 
39.14 4796.37
16 
2.5 4796.3832 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQYLDEDM
LLKVLEYLNQEQAEQGREHLA.
K 
39.04 4867.40
87 
-0.3 4867.4075 X X 
Secretogranin-2 R.LLERPLDSQSIYQLIEISR.N 19.1 2272.24
27 
1.2 2272.2453 X  
Secretogranin-2 R.LPYGPGKSRANQIPKVAWIPD
VES.R 
23.49 2621.39
65 
1.4 2621.4 X  
Secretogranin-2 R.LPYGPGKSRANQIPKVAWIPD
VESR.Q 
34.26 2777.49
76 
4.8 2777.5108 X  
Secretogranin-2 R.NQLLQKEPDLR.L 33.26 1352.74
12 
1.5 1352.7432 X  
Secretogranin-2 R.Q(pyro)APYDNLNDKDQELGE
YLARMLVKYPELMNTNQL.K 
24.86 4008.92
36 
-2.3 4008.914 X  
Secretogranin-2 R.QAPYDNLNDKDQELGEYLAR.
M 
35.31 2351.10
28 
1.1 2351.1051 X  
Secretogranin-2 R.SGHLGLPDEGN.R 46.43 1094.49
93 
-2.8 1094.4962 X  
Secretogranin-2 R.SGHLGLPDEGNR.K 35.62 1250.60
03 
1.8 1250.6025 X  
Secretogranin-2 R.SGHLGLPDEGNRKESKDQLSE
DASKVIT.Y 
28.12 3009.50
02 
-3.2 3009.4905 X  
Secretogranin-2 R.SGHLGLPDEGNRKESKDQLSE
DASKVITY.L 
49.57 3172.56
35 
-0.6 3172.5612 X  
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Table 4.1 (cont.) 
Secretogranin-2 R.SGHLGLPDEGNRKESKDQLSE
DASKVITYL.R 
27.81 3285.64
77 
1.9 3285.654 X  
Secretogranin-2 R.TNEIVEEQYTPQS.L 33.27 1536.69
43 
1.6 1536.6968 X  
Secretogranin-2 R.TNEIVEEQYTPQSLATLESVFQ
ELGKLTGPSNQ.K 
23.01 3649.79
98 
-3.5 3649.7868 X X 
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGS(phos)SQEMEKL
AKVS.K 
25.37 4526.00
83 
-3.9 4525.9904 X  
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGSS(phos)QEMEKL
AKVS.K 
21.33 4526.00
83 
-3.2 4525.9936 X  
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGSSQEMEKLAK.V 
28.02 4259.94
14 
1.1 4259.946 X  
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGSSQEMEKLAKVS.
K 
28.58 4446.04
2 
-1.2 4446.0368 X  
Secretogranin-2 R.VPSPGSSEDDLQEEEQLEQAIK
EHLGQGSSQEMEKLAK.V 
38.01 4179.97
51 
0.9 4179.979 X  
Secretogranin-2 R.VPSPGSSEDDLQEEEQLEQAIK
EHLGQGSSQEMEKLAKVS.K 
38.52 4366.07
57 
0.4 4366.0775 X X 
Secretogranin-2 S.VFQELGKLTGPSNQ.K 37.55 1516.78
86 
1.8 1516.7912 X  
Secretogranin-2 Y.LNQEQAEQGREHLA.K 18.73 1621.78
08 
-3.7 1621.7748 X  
Secretogranin-3  A.FPKPEGSQDKSLHN.R 38.09 1582.77
39 
1.7 1582.7766 X  
Secretogranin-3  A.FPKPEGSQDKSLHNRELSAER
PLNEQ.I 
19.23 3005.49
54 
-4.6 3005.4812 X  
Secretogranin-3 A.FPKPEGSQDKSLHNRELSAER
PLNEQIAEAEAD.K 
27.86 3704.80
3 
2.1 3704.8105 X  
Secretogranin-3 A.FPKPEGSQDKSLHNRELSAER
PLNEQIAEAEADKI.K 
37.54 3945.98
19 
1.4 3945.9875 X  
Secretogranin-3 L.LKAITEKETVEKAKQS.I 26.14 1802.01
49 
-10.5 1801.996 X  
Secretogranin-3 R.ELSAERPLNEQ.I 47.02 1284.63
1 
-2.4 1284.6278 X  
Secretogranin-3 R.ELSAERPLNEQIAEAE.A 19.96 1797.87
44 
-3 1797.869 X  
Secretogranin-3 R.ELSAERPLNEQIAEAEADKI.K 38.92 2225.11
74 
1.1 2225.1198 X  
Secretogranin-3 R.SSPFDNRLNVDDADSTKNR.K 32.09 2149.99
88 
1.1 2150.001 X  
Somatostatin  G.APSDPRLRQFLQKSLAAATGK
QELAKYFLAELLSEPNQTENDA
LEPEDLPQAAEQDEMRLELQ.R 
42.45 7093.56
15 
-7.6 7093.5072 X  
Somatostatin  R.SANSNPAMAPRE.R 31.35 1243.56
15 
-2.3 1243.5586 X  
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Table 4.2 Neuropeptide identification results from the lateral habenula. For PEAKS 
database search, peptides with -10lgP score higher than 1% and 0.1% FDR threshold 
values in untargeted and targeted search were kept. For ProsightPC database search, 
peptides with p value lower than 1e-4 were kept. 
Prohormone Peptide -10lgP or p 
score 
Theoreti
cal mass 
mass error 
(ppm) 
Detected 
mass 
Orbitr
ap 
FT- 
ICR 
Cerebellin-1 R.SGSAKVAFSAIRSTNHEPS.E 18.55 1944.96
5 
2.7 1944.971 X  
Cerebellin-1 S.GSAKVAFSAIRSTN.H 42.15 1407.74
7 
2.3 1407.75 X  
Cerebellin-1 S.GSAKVAFSAIRSTNH.E 48.1 1544.80
6 
2.1 1544.809 X X 
Cerebellin-1 R.SGSAKVAFSAIRSTN.H 42.92 1494.77
9 
1.9 1494.782 X X 
Cerebellin-1 R.SGSAKVAFSAIRSTNH.E 53.91 1631.83
8 
2.3 1631.842 X X 
Cerebellin-1 R.SGSAKVAFSAIRSTNHE.P 40.99 1760.88
1 
1.6 1760.883 X  
Cholecystokinin A.Q(pyro)PVVPVEAVDPMEQRAE
EAPRRQL.R 
32.42 2726.38
1 
-2.1 2726.375 X  
Chromogranin-A M.DQLAKELTAE.K 26.01 1116.566 3.9 1116.571 X  
Chromogranin-A R.LEGEDDPDRSM(oxidation)KLS
F.R 
20.44 1753.78
3 
1.4 1753.785 X  
Chromogranin-A R.LEGEDDPDRSM(oxidation)KLS
FR.A 
22.21 1909.88
4 
1.7 1909.887 X  
Chromogranin-A R.LEGEDDPDRSMKLSF.R 33.37 1737.78
8 
1.5 1737.791 X  
Chromogranin-A R.LEGEDDPDRSMKLSFRA.R 32.92 1964.92
6 
2.3 1964.93 X  
Chromogranin-A R.LEGEDDPDRSMKLSFRAR.A 30.73 2121.02
7 
2.4 2121.033 X  
Chromogranin-A R.LEGEDDPDRSMKLSFRARAYG
FRDPGPQL.R 
32.12 3322.61
5 
3.9 3322.628 X  
Chromogranin-A R.MDQLAKELTAE.K 37.01 1247.60
7 
1.4 1247.608 X  
Chromogranin-A W.SRM(oxidation)DQLAKELTAE.
K 
30.52 1506.73
5 
1.5 1506.737 X  
Chromogranin-A W.SRMDQLAKELTAE.K 32.62 1490.74 1.3 1490.742 X  
Cocaine-
amphetamine 
regulated 
transcript 
R.APGAVLQIEALQEVLKKLKS.K 28.26 2134.27
3 
-1.4 2134.269 X  
Galanin peptides *R.GWTLNSAGYLLGPHAIDNHR
SFSDKHGLT(amide).G 
36.66 3162.57
5 
-13.4 3162.532 X  
Neurosecretory 
protein VGF 
A.APPGRSDVYPPPLGSEHNGQV
AEDAVS(phos)RPK(actyl)DDSVPE
.V 
25.46 3890.77
5 
18.6 3890.847 X  
Neurosecretory 
protein VGF 
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKD.D 
33.15 3241.57
5 
-2.3 3241.568 X  
Neurosecretory 
protein VGF 
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEV.R 
45.37 3867.86
6 
1.6 3867.872 X X 
Neurosecretory 
protein VGF 
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEVRA.A 
35.47 4095.00
4 
1.4 4095.01 X X 
Neurosecretory 
protein VGF 
A.APPGRSDVYPPPLGSEHNGQV
AEDAVSRPKDDSVPEVRAA.R 
34.14 4166.04
2 
1.8 4166.049 X X 
Neurosecretory 
protein VGF 
E.HNGQVAEDAVSRPKDDSVPEV.
R 
37.39 2248.07
2 
1.4 2248.075 X  
Neurosecretory 
protein VGF 
E.HNGQVAEDAVSRPKDDSVPEV
RAA.R 
29.62 2546.24
7 
2.6 2546.254 X  
Neurosecretory 
protein VGF 
K.NAPPEPVPPPRAAPAPTH.V 23.61 1814.94
3 
1.8 1814.946 X  
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Table 4.2 (cont.) 
Neurosecretory 
protein VGF 
K.NAPPEPVPPPRAAPAPTHV.R 39.09 1914.01
1 
1.4 1914.014 X X 
Neurosecretory 
protein VGF 
K.NAPPEPVPPPRAAPAPTHVR.S 26.97 2070.11
2 
1.3 2070.115 X  
Neurosecretory 
protein VGF 
N.APPEPVPPPRAAPAPTHV.R 35.85 1799.96
8 
1.4 1799.971 X  
Neurosecretory 
protein VGF 
R.AQEEADAEERRLQEQEELENY
IEHVLLHRP 
35.03 3672.77
7 
1.9 3672.784 X  
Neurosecretory 
protein VGF 
R.ASWGEFQARVPERAPLPPSVP
SQFQ.A 
33.02 2780.40
3 
0.2 2780.404 X  
Neurosecretory 
protein VGF 
R.DLGGRGLQETQQERENEREEE
AEQE.R 
43.67 2958.31
9 
1.2 2958.322 X  
Neurosecretory 
protein VGF 
R.GLQETQQERENEREEEAEQE.R 41.4 2460.06
4 
1.8 2460.068 X  
Neurosecretory 
protein VGF 
R.KKNAPPEPVPPPRAAPAPTHV.
R 
43.43 2170.20
1 
1.9 2170.205 X X 
Neurosecretory 
protein VGF 
R.LEGSFLGGSEAGERLLQQGLA
QVEA(amide).G 
28.2 2557.31
4 
-4.3 2557.302 X X 
Neurosecretory 
protein VGF 
R.MSENVPLPETHQFGEGVSSPK
THLGETLTPLSKAYQSLSAPFPK
V.R 
39.25 4835.44
8 
0.7 4835.451 X X 
Neurosecretory 
protein VGF 
R.Q(pyro)QETAAAETETRTHTLT.
R 
38.43 1869.87
1 
1.3 1869.873 X  
Neurosecretory 
protein VGF 
R.Q(pyro)QETAAAETETRTHTLTR
.V 
36.98 2025.97
2 
1.7 2025.975 X  
Neurosecretory 
protein VGF 
R.Q(pyro)QETAAAETETRTHTLTR
VNLESPGPER.V 
42.76 3104.51
2 
1 3104.515 X  
Neurosecretory 
protein VGF 
R.Q(pyro)QETAAAETETRTHTLTR
VNLESPGPERVW.R 
28.28 3389.66 0.9 3389.663 X  
Neurosecretory 
protein VGF 
R.QQETAAAETETRTHTLTRVNL
ESPGPERVW.R 
39.02 3406.68
7 
1.1 3406.69 X  
Neurosecretory 
protein VGF 
R.QRDLGGRGLQETQQERENER
EEEAEQE.R 
42.25 3242.47
8 
2.2 3242.485 X  
Neurosecretory 
protein VGF 
R.SPQPPPPAPARDELPDWNEVLP
PWDREEDEVFPPGPYHPFPNYIR
P.R 
25.65 5356.56
8 
-2.8 5356.553 X  
Neurosecretory 
protein VGF 
R.THTLTRVNLESPGPERVW.R 24.43 2091.08
6 
2.3 2091.091 X  
Neurosecretory 
protein VGF 
R.VPERAPLPPSVPSQFQ.A 39.63 1747.92
6 
0.3 1747.926 X  
Neurosecretory 
protein VGF 
S.LSAPFPKV.R 24.24 857.501 1.4 857.5022 X  
Neurotensin R.Q(pyro)LYENKPRRP.Y 21.08 1282.67
8 
1.9 1282.681 X  
Neurotensin R.Q(pyro)LYENKPRRPYIL.K 26.44 1671.91 1.3 1671.912 X  
Neurotensin R.QLYENKPRRPYIL.K 23.39 1688.93
6 
1.1 1688.938 X X 
Orexin *R.AGAELEPYPC(dehydro)PGRR
C(dehydro)PTATATALAPR.G 
32.19 2666.30
6 
2.1 2666.311 X  
Orexin *R.RPGPPGLQGRLQRLLQANGN
HAAGILTM(amide).G 
36.06 2934.62 2.9 2934.628 X  
Pituitary 
adenylate 
cyclase-
activating 
polypeptide 
*R.GMGENLAAAAVDDRAPLT.K 42.9 1770.85
7 
-2.4 1770.853 X  
Prepronociceptin R.DAEPEADAEPVADEADEVEQK
QLQ.K 
25.95 2625.15
7 
1.8 2625.161 X  
Prepronociceptin R.FGGFTGARKSARKLANQ.K 37.72 1807.98
1 
1.6 1807.983 X  
Proenkephalin-A G.RPEWWM.D 28.73 903.406
1 
1.3 903.4072 X  
Proenkephalin-A G.RPEWWMDYQ.K 35.7 1309.55
5 
-1 1309.554 X  
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Table 4.2 (cont.) 
Proenkephalin-A K.DADEGDTLANSSDLLKELLGT
GDNRAKDSHQQESTNNDEDSTS
.K 
31.62 4592.01
4 
-2.9 4592.001 X  
Proenkephalin-A P.Q(pyro)LEDEAKELQ.K 31.52 1184.55
6 
1.9 1184.558 X  
Proenkephalin-A R.SPQLEDEAKEL.Q 39.4 1257.60
9 
1.2 1257.61 X  
Proenkephalin-A R.SPQLEDEAKELQ.K 43.16 1385.66
7 
1.6 1385.669 X X 
Proenkephalin-A R.VGRPEWWMDYQ.K 25.49 1465.64
5 
-3.3 1465.64 X  
Proenkephalin-A R.YGGFMRF 39.63 876.395
2 
1.6 876.3966 X  
Proenkephalin-A R.YGGFMRGL.K 35.47 899.432
3 
1.4 899.4336 X  
Proenkephalin-A V.GRPEWWMDYQK(actyl)RY(pho
s)GG.F 
21.86 2049.85
6 
10.2 2049.877 X  
Proenkephalin-B R.SQENPNTYSEDLDV 32.93 1609.67
4 
1.1 1609.676 X  
Proenkephalin-B R.SSEM(oxidation)AGDEDRGQD
GDQVGHEDLY.K 
18.27 2524.98
9 
2.2 2524.994 X  
Proenkephalin-B R.SSEMAGDEDRGQDGDQVGHE
DLY.K 
27.09 2508.99
3 
0.3 2508.994 X  
Proenkephalin-B R.YGGFLRKYPK.R 25.62 1227.67
6 
0.7 1227.677 X  
Pro-MCH E.IGDEENSAKFPI(amide).G 28.1 1317.65
6 
1.8 1317.659 X  
Pro-MCH R.EIGDEENSAKFPI(amide).G 38.51 1446.69
9 
2.3 1446.702 X  
Pro-MCH R.EIGDEENSAKFPIG.R 32.04 1504.70
5 
1.8 1504.707 X  
Pro-neuropeptide 
Y 
R.SSPETLISDLLMRESTENAPRT
RLEDPSMW 
35.11 3460.66 -2.6 3460.651 X  
ProSAAS A.ASAPLAETSTPL.R 34.65 1156.59
8 
0.8 1156.598 X  
ProSAAS A.RALAHLLEAERQE.R 31.71 1534.82
2 
3.1 1534.826 X  
ProSAAS A.SAPLAETSTPL.R 38.07 1085.56 2.1 1085.563 X  
ProSAAS A.VPRGEAAGAVQELAR.A 28.93 1522.82
2 
0.6 1522.822 X  
ProSAAS L.ENSSPQAPARRLLPP 22.62 1631.87
4 
2.2 1631.878 X  
ProSAAS L.GRILTGSSEPEAAPAPRRL.R 31.64 1977.07
5 
2.3 1977.08 X  
ProSAAS L.SAASAPLAETSTPL.R 44.01 1314.66
7 
1.3 1314.668 X  
ProSAAS L.SAASAPLAETSTPLRL.R 30.37 1583.85
2 
2.8 1583.856 X  
ProSAAS R.ALAHLLEAERQE.R 41.44 1378.72
1 
1.7 1378.723 X  
ProSAAS R.AVDQDLGPEVPPENVL(amide).
G 
17.62 1689.85
7 
2.3 1689.861 X  
ProSAAS R.AVDQDLGPEVPPENVLGALLR
V.K 
27.06 2300.23
8 
1.8 2300.242 X  
ProSAAS R.AVPRGEAAGAVQEL.A 22.09 1366.72
1 
1.5 1366.722 X  
ProSAAS R.AVPRGEAAGAVQELA.R 24.35 1437.75
8 
2 1437.76 X  
ProSAAS R.AVPRGEAAGAVQELAR.A 42.19 1593.85
9 
1.7 1593.861 X  
ProSAAS R.AVPRGEAAGAVQELARALAH
LLEAERQE.R 
47.13 2954.56
9 
0.9 2954.571 X X 
ProSAAS R.LENSSPQAPARRLLP.P 24.21 1647.90
6 
1.8 1647.908 X  
- 123 - 
 
Table 4.2 (cont.) 
ProSAAS R.LENSSPQAPARRLLPP 32.41 1744.95
8 
1.7 1744.961 X X 
ProSAAS R.SLSAASAPLAETSTPL.R 42.95 1514.78
3 
1.4 1514.785 X  
ProSAAS R.SLSAASAPLAETSTPLRL.R 47.04 1783.96
8 
1.3 1783.97 X X 
ProSAAS S.AASAPLAETSTPL.R 38.4 1227.63
5 
1.1 1227.636 X  
ProSAAS S.APLAETSTPL.R 27.45 998.528
4 
1.6 998.5298 X  
ProSAAS S.ARPVKEPR.S 30.02 951.561
3 
-2.6 951.5589 X X 
ProSAAS S.ARPVKEPRSLSAASAPLAETST
PL.R 
33.96 2448.33
4 
2.4 2448.339 X  
ProSAAS S.ARPVKEPRSLSAASAPLAETST
PLR.L 
35.2 2604.43
5 
1.8 2604.439 X  
ProSAAS S.ARPVKEPRSLSAASAPLAETST
PLRL.R 
41.42 2717.51
9 
2 2717.524 X X 
ProSAAS V.PRGEAAGAVQELARALAHLLE
AERQE.R 
3.43E-09 2784.46 -0.56 2784.46  X 
Protachykinin-1 R.DADSSIEKQVALLKALYGHGQ
IS.H 
39.54 2442.27
5 
-1.6 2442.271 X  
Protachykinin-1 R.DADSSIEKQVALLKALYGHGQ
ISH.K 
55.07 2579.33
4 
2.2 2579.34 X X 
Protachykinin-1 R.RPKPQQFFGLM(amide)(oxidatio
n).G 
41.58 1362.72
3 
2.1 1362.726 X  
Protachykinin-1 K.TDSFVGLM(amide).G 26.18 867.416 3.1 867.4187 X  
Protachykinin-1 R.ALNSVAYERSAMQNYE 
.R 
39.42 1844.83
6 
-0.5 1844.835 X  
Prothyroliberin A.LPEAAQEEGAVTPDLPGLENV
QVRPE.R 
32.17 2757.38
2 
1.2 2757.385 X  
Prothyroliberin R.ALGHPC(dehydro)GPQGTC(deh
ydro)GQTGLLQLLGDLSRGQETL
VKQSPQVEPWDKEPLE.E 
33.85 5007.48
6 
-3.3 5007.469 X  
Prothyroliberin R.EEEEKDIEAEERGDLGEGGAW
RLH.K 
44.09 2753.25
3 
0.6 2753.254 X  
Prothyroliberin R.SFPWMESDVT.K 19.89 1197.50
1 
0.8 1197.502 X  
Secretogranin-1 K.SGKEVKGEEKGENENSKFEVR
LL.R 
34.05 2605.33
5 
3 2605.342 X  
Secretogranin-1 L.LDEGHDPVHESPVDTA.K 31.12 1716.75
9 
2.5 1716.763 X  
Secretogranin-1 R.APHLDL.K 26.36 664.354
4 
1.6 664.3554 X  
Secretogranin-1 R.DPSDASVGRWASSREETGAPV
EDSPGQAKVDNEEWTGGGGHS.
R 
33.04 4310.89
7 
-0.6 4310.895 X  
Secretogranin-1 R.EAVDDQESLHPSNQQVSKEA.
K 
39.27 2210.00
9 
2.3 2210.014 X  
Secretogranin-1 R.GGKEEEEEEGKIYPKGEHRGD
AGEE.K 
30.15 2758.23
2 
1.9 2758.237 X  
Secretogranin-1 R.GREPGAYPALDSRQE.K 40.41 1644.78
6 
1.3 1644.788 X  
Secretogranin-1 R.GRGREPGAYPALDSRQE.K 38.39 1857.90
8 
1.2 1857.91 X  
Secretogranin-1 R.LGALFNPYFDPLQWKNSDFE.
K 
2.95E-17 2400.14 0.64 2400.14  X 
Secretogranin-1 R.LLDEGHDPVHESPVDT.A 34.92 1758.80
6 
2.3 1758.81 X  
Secretogranin-1 R.LLDEGHDPVHESPVDTA.K 40.76 1829.84
3 
1.7 1829.846 X X 
Secretogranin-1 R.NHPDSELEST(phos)ANRHSEE
TEEERSYEGAKGRQ.H 
25.62 3651.54
6 
2.4 3651.555 X  
Secretogranin-1 R.NHPDSELEST(phos)ANRHSEE
TEEERSYEGAKGRQH.R 
28.29 3788.60
5 
2.3 3788.614 X  
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Secretogranin-1 R.NHPDSELESTANRHS(phos)EET
EEERSYEGAKGR.Q 
30.65 3523.48
7 
2.8 3523.497 X  
Secretogranin-1 R.NHPDSELESTANRHS(phos)EET
EEERSYEGAKGRQ.H 
25.6 3651.54
6 
2.2 3651.554 X  
Secretogranin-1 R.NHPDSELESTANRHS(phos)EET
EEERSYEGAKGRQH.R 
34.97 3788.60
5 
1.7 3788.611 X  
Secretogranin-1 R.NHPDSELESTANRHS(phos)EET
EEERSYEGAKGRQHR.G 
18.13 3944.70
6 
3.8 3944.721 X  
Secretogranin-1 R.NHPDSELESTANRHSEET(phos)
EEERSYEGAKGRQH.R 
35.85 3788.60
5 
1.5 3788.61 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEE.
R 
21.41 2439.00
6 
1.8 2439.01 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
SYEGAKGR.Q 
40.2 3443.52
1 
0.2 3443.522 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
SYEGAKGRQ.H 
32.47 3571.58 2.2 3571.588 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
SYEGAKGRQH.R 
38.39 3708.63
8 
1.6 3708.644 X  
Secretogranin-1 R.NHPDSELESTANRHSEETEEER
SYEGAKGRQHR.G 
29.55 3864.74 2.6 3864.75 X  
Secretogranin-1 R.QYDDGVAELDQLLHY.R 30.6 1777.81
6 
-3 1777.81 X X 
Secretogranin-1 R.RPLSEERKHAAGESKDANVAT
ANLGE.K 
35.88 2749.37
4 
2.3 2749.38 X  
Secretogranin-1 G.REPGAYPALDSRQE.K 34.08 1587.76
4 
2 1587.767 X  
Secretogranin-1 K.HAAGESKDANVATANLGE.K 33.05 1753.82
3 
1.4 1753.826 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQYLDEDM
LLKVLEYLNQEQAEQGREHL.A 
43.34 4796.37
2 
-4.3 4796.351 X X 
Secretogranin-2 R.IPAGSLKNEDTPNRQYLDEDM
LLKVLEYLNQEQAEQGREHLA.
K 
35.63 4867.40
9 
0.8 4867.412 X X 
Secretogranin-2 R.KLKHMRFPLMYEENSRENPF.
K 
37.76 2565.26
2 
2.9 2565.269 X  
Secretogranin-2 R.NQLLQKEPDLR.L 22.64 1352.74
1 
2 1352.744 X  
Secretogranin-2 R.Q(pyro)APYDNLNDKDQELGE
YLARMLVKYPELMNTNQ.L 
0.00000247 3895.84 -0.86 3895.84  X 
Secretogranin-2 R.Q(pyro)APYDNLNDKDQELGE
YLARMLVKYPELMNTNQL.K 
3.41E-17 4008.92 1.63 4008.93  X 
Secretogranin-2 R.SGHLGLPDEGNRKESKDQLSE
DASKVIT.Y 
41.89 3009.5 5.5 3009.517 X  
Secretogranin-2 R.SGHLGLPDEGNRKESKDQLSE
DASKVITY.L 
44.02 3172.56
4 
1.4 3172.568 X  
Secretogranin-2 R.SGHLGLPDEGNRKESKDQLSE
DASKVITYL.R 
47.06 3285.64
8 
1.2 3285.652 X  
Secretogranin-2 R.TNEIVEEQYTPQS.L 35.89 1536.69
4 
1.7 1536.697 X  
Secretogranin-2 R.TNEIVEEQYTPQSLATLESVFQ
ELGKLTGPSNQ.K 
24.64 3649.8 -4.3 3649.784 X X 
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGS(phos)SQEMEKL
AKVS.K 
30.34 4526.00
8 
-2.7 4525.996 X  
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGSS(phos)QEMEKL
AKVS.K 
28.13 4526.00
8 
-1.5 4526.002 X  
Secretogranin-2 R.VPSPGS(phos)SEDDLQEEEQLE
QAIKEHLGQGSSQEMEKLAKVS.
K 
32.75 4446.04
2 
-2.5 4446.031 X X 
Secretogranin-2 R.VPSPGSSEDDLQEEEQLEQAIK
EHLGQGSSQEMEKLAKVS.K 
40.83 4366.07
6 
0.9 4366.08 X X 
Secretogranin-2 Y.LDEDMLLK.V 32.94 975.494
6 
1.7 975.4962 X  
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Table 4.2 (cont.) 
Secretogranin-2 A.ASFQRNQLLQKEPDLR.L 45.19 1942.03
9 
1.5 1942.041 X  
Secretogranin-2 A.SFQRNQLLQKEPDLR.L 33.73 1871.00
1 
2.5 1871.006 X  
Secretogranin-2 E.IVEEQYTPQSLATLESVFQELG
KLTGPSNQ.K 
24.58 3305.66
7 
-1.4 3305.662 X  
Secretogranin-2 E.YLNQEQAEQGREHLA.K 33.61 1784.84
4 
1.9 1784.847 X  
Secretogranin-2 F.QELGKLTGPSNQ.K 24.43 1270.65
2 
2.6 1270.655 X  
Secretogranin-2 K.VLEYLNQEQAEQGREHL.A 19.51 2055.00
2 
2.6 2055.008 X  
Secretogranin-2 R.ANQIPKVAWIPDVES.R 29.89 1665.87
3 
1.4 1665.875 X  
Secretogranin-2 R.FPLMYEENSRENPF.K 35.94 1771.78
8 
1.5 1771.79 X  
Secretogranin-2 R.IPAGSLKNEDTPN.R 36.55 1354.67
3 
2.1 1354.676 X X 
Secretogranin-2 R.IPAGSLKNEDTPNR.Q 44.01 1510.77
4 
1.8 1510.777 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQY.L 43.01 1801.89
6 
1.4 1801.898 X  
Secretogranin-2 R.IPAGSLKNEDTPNRQYLDEDM
LLK.V 
28.67 2759.38 16.4 2759.425 X  
Secretogranin-3 A.FPKPEGSQDKSLHN.R 40.88 1582.77
4 
1.9 1582.777 X X 
Secretogranin-3 A.FPKPEGSQDKSLHNRELSAER
PLNEQIAEAEAD.K 
18.32 3704.80
3 
2 3704.811 X  
Secretogranin-3 A.FPKPEGSQDKSLHNRELSAER
PLNEQIAEAEADKI.K 
39.01 3945.98
2 
0.9 3945.985 X  
Secretogranin-3 R.ELSAERPLNEQIAEAE.A 25.9 1797.87
4 
1.8 1797.878 X  
Secretogranin-3 R.ELSAERPLNEQIAEAEADKI.K 39.21 2225.11
7 
2.3 2225.123 X  
Secretogranin-3 R.SSPFDNRLNVDDADSTKNR.K 20.05 2149.99
9 
1.6 2150.002 X  
Somatostatin A.AEQDEMRLELQ.R 34.92 1360.62
9 
1.5 1360.631 X  
Somatostatin G.APSDPRLRQFLQ.K 23.59 1426.76
8 
1.6 1426.77 X  
Somatostatin G.APSDPRLRQFLQK.S 18.67 1554.86
3 
2.5 1554.867 X  
Somatostatin *G.APSDPRLRQFLQKSLAAATG
KQELAKYFLAELLSEPNQTEND
ALEPEDLPQAAEQDEMRLE.L 
51.62 6852.41
9 
-2.3 6852.403 X  
Somatostatin *G.APSDPRLRQFLQKSLAAATG
KQELAKYFLAELLSEPNQTEND
ALEPEDLPQAAEQDEMRLELQ.R 
65.03 7093.56
2 
-1.2 7093.553 X X 
Somatostatin K.SLAAATGKQELAKY.F 25.77 1449.78
3 
2 1449.785 X  
Somatostatin R.SANSNPAMAPRE.R 0.00000164 1243.56 -0.21 1243.56  X 
Somatostatin R.SANSNPAMAPRERKAGC(dehy
dro)KNFFWKTFTSC(dehydro) 
24.65 3146.46
4 
1.3 3146.468 X  
*: Peptides identified in targeted neuropeptide database search 
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Table 4.3 Neuropeptide discovered in MALDI MS analysis. m/z of peaks on MALDI 
were compared with known neuropeptides in SwePep database. Peak identity was 
assigned when the difference between detected m/z and known neuropeptides were within 
0.1 Da. 
Prohormone Peptide sequence Theoretical m/z 
(M+H) 
Detected m/z 
(M+H) 
Mass error 
(ppm) 
Cerebellin-1 R.SGSAKVAFSAIRSTNH.E 1632.8894 1632.8452 -27.069 
Cerebellin-1 S.GSAKVAFSAIRSTNH.E 1545.8972 1545.8132 -54.337 
Chromogranin A R.AYGFRDPGPQL.R 1220.6162 1220.6058 -8.5203 
Parathyroid hormone-related 
protein 
R.TRSAWPGTTGSGLLEDPQPHTSPTS
TSLEPSSR.T 
3437.7158 3437.6567 -17.192 
Proenkephalin-A R.DMHDFFVGLMamide.K 1210.533 1210.5384 4.46084 
Proenkephalin-A R.YGGFMRF 877.4094 877.4025 -7.8641 
Proenkephalin-A R.YGGFMRGL.K 900.4433 900.4396 -4.1091 
Proenkephalin-A  R.SPQLEDEAKEL.Q 1258.6063 1258.6161 7.78639 
Proenkephalin-A  R.VGRPEWWMDYQ.K 1466.665 1466.6521 -8.7955 
Pro-FMRFamide-related 
neuropeptide FF 
R.EFWSLAAPQRFamide.G 1350.7431 1350.6953 -35.388 
Pro-MCH R.EIGDEENSAKFPIamide.G 1447.7259 1447.7063 -13.538 
Pro-opiomelanocortin  R.YGGFMTSEKSQTPLVTL.F 1858.9303 1858.9255 -2.5821 
ProSAAS R.LENSSPQAPARRLLPP 1745.9261 1745.9656 22.6241 
ProSAAS  R.AVDQDLGPEVPPENVLGALLRV.K 2301.2174 2301.2448 11.9067 
ProSAAS  R.SLSAASAPLAETSTPL.R 1515.7801 1515.79 6.53129 
ProSAAS  R.SLSAASAPLAETSTPLRL.R 1784.9748 1784.9752 0.22409 
ProSAAS  S.ARPVKEP.R 796.421 796.4676 58.5118 
Protachykinin-1 R.ALNSVAYERSAMQNYE.R 1845.8325 1845.8436 6.01355 
Protachykinin-1 R.HKTDSFVGLMamide.G 1133.5923 1133.5772 -13.32 
Protachykinin-1 R.RPKPQQFFGLMamide.G 1347.7419 1347.6505 -67.817 
Secretogranin-1 R.GRGREPGAYPALDSRQE.K 1858.9303 1858.9154 -8.0154 
Secretogranin-1 R.LLDEGHDPVHESPVDTA.K 1830.8284 1830.8504 12.0164 
Somatostatin  R.SANSNPAMAPRE.R 1244.6177 1244.5688 -39.289 
 
  
- 127 - 
 
Chapter 5 
Discovery of migraine and opioid induced hyperalgesia-related peptides 
through a dual mass spectrometry system-based label-free quantitation 
approach 
 
5.1 Notes and acknowledgements 
Work presented in Chapter 5 is focused on discovering signaling peptides involved in 
two pain-related diseases, the migraine and opioid induced hyperalgesia (OIH), via label-
free comparative peptide quantitation approach. This project was initiated by Prof. 
Amynah A. Pradhan at University of Illinois at Chicago. My role in this project is to 
optimize peptide quantitation method, perform peptide measurement and analyze the data. 
Prof. Amynah A. Pradhan and her students established migraine and OIH mouse model 
and prepared mice with migraine and OIH. Together with Dr. Elena V. Romanova and Dr. 
Stanislav S. Rubakhin, they performed animal dissection and isolated regions of interest. 
Krishna D.B. Anapindi helped in sample preparation, optimization of peptide quantitation 
method and data analysis. Dr. Peter M. Yau, Dr. Yu Chen and Dr. Brian S. Imai assisted 
in Orbitrap instrument training, operation and maintenance. Prof. Jonathan V. Sweedler, 
Prof. Amynah A. Pradhan, Dr. Stanislav S. Rubakhin and Dr. Elena V. Romanova 
provided useful suggestions in experiment design and data analysis. This project is still 
ongoing and more experiments are being performed under the direction of Krishna D.B. 
Anapindi. The work was funded by National Institutes of Health and Nation Institute on 
Drug Abuse (NIH 2 P30DA018310 B). 
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5.2 Introduction 
Neuropeptides are chemical messenger molecules employed by the nervous 
system for communication between cells. The association of neuropeptides with various 
diseases has been investigated and confirmed.(1-4) One of these diseases is migraine, a 
pain sensation-related disorder characterized by its recurrent moderate to severe 
headaches. Migraine is a prevalent disease affecting 2% of the entire population all over 
the world.(5) In US, an average of 16.6% of population suffers from migraine during 
their lifetime.(6) Besides, migraine is costly as over 1 billion dollar is spent in the direct 
medical treatment and care for migraine care every year. Therefore, migraine is a 
common public health problem resulting in a considerable loss of healthcare resource and 
workforce.(7) 
The precise mechanism of migraine is not fully understood, but some chemical 
factors have been found implicated in migraine.(8) Ashina et al. discovered an increase of 
Calcitonin gene-related peptide (CGRP) concentration in the migraine patients’ plasma.(9)   
The level of this peptide in the plasma was found further elevated during migraine attack 
and decreased after pain relief.(10, 11) In addition, it has been reported that substance P, 
a well-known neuropeptide playing in pain sensation, was released from neurons in the 
trigeminal ganglion, a region playing critical role in migraine signaling.(12) Pituitary 
adenylate cyclase-activating polypeptide (PACAP) was also found in the trigeminal 
ganglion neurons and infusion of peptide, PACAP-38, delayed migraine-like attack in 
patients.(13) Other signaling peptides, including neurokinin-A (NKA), cholecystokinin 
(CCK), vasoactive intestinal peptide (VIP) were also reported to be involved in the 
pathogenesis of migraine.(10, 14, 15)  
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An intriguing clinical discovery is that patients who seek migraine treatment 
through opioid drugs could ultimately become more susceptible to pain stimuli.(16) In 
fact, opioids are widely used as the first line treatment for migraine attack, but the 
excessive or chronic use of opioids eventually leads to refractory headaches and 
chronification of migraine.(17-20) Another adverse consequence of opioid overuse is the 
formation of a nociceptive sensitization state, known as opioid-induced hyperalgesia 
(OIH).(16, 21, 22) The exact mechanism underlying OIH is not clear, but three possible 
mechanisms have been proposed based on preclinical studies: the central glutaminergic 
system, the spinal dynorphin and the descending facilitation mechanism. Neuropeptides 
play important roles in any of the proposed mechanisms by either enhancing nociceptive 
inputs or activating the descending pain facilitation.(23-27) Some of such neuropeptides 
include CGRP, substance P and opioid peptides like dynorphin. Evoked CGRP release 
was observed in the rat spinal cord after prolonged administration of opioids.(28) 
Moreover, evidences have been found that substance P enhanced nociceptive 
sensitization after morphine treatment in the spinal cord.(29)  
It is interesting to observe an overlapping set of neuropeptides found to be 
involved in OIH and migraine. Another intriguing finding is that a few brain regions 
located in the migraine signaling pathway are also lying across the OIH signaling route.  
The unique relationship between migraine and OIH in terms of the chemical messengers 
used and signaling pathway raises two important questions. What are the signaling 
peptides underlying migraine and OIH respectively? Whether it is possible that these two 
pain-related diseases have an overlapping molecular mechanism, at least partially, likely 
due to changes in neuropeptides? 
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Although some neuropeptides have been confirmed to affect nociception in 
migraine and/or OIH, conclusions of current studies were mostly drawn from data 
acquired using antibody- or mRNA-based techniques. Neither of them is able to reveal 
the exact form of a bioactive signaling peptide, which could lead to the loss and 
misinterpretation of important information. For instance, full length CGRP peptide, 
CGRP[1-37], is a critical player in migraine as its antagonist has been developed into 
drugs for migraine treatment.(30, 31) The epitopes of CGRP[1-37] for different 
antibodies are located at either the C-terminus or between residue [13-19].(32) Recently 
discovery suggested the presence of two endogenous cleavage sites at serine17 and 
asparagine26 in the CGRP[1-37].(33) Therefore it is hard to determine whether it is full 
length CGRP or shorten forms that are released upon pain stimulation and have 
bioactivity.   
Here, we employed mass spectrometry to quantify peptides in the brain regions of 
interest and discovered signaling peptides involved in migraine and/or OIH using mice 
migraine and OIH model. With mass spectrometry, the cross contamination issue met in 
antibody-based methods was avoided. Moreover, hundreds of peptides were quantified 
simultaneously in a time frame of several LC-MS runs. To accurately quantify as many 
peptides as possible, we used a label-free peptide quantitation pipeline combining the 
strengths of two different mass analyzers, the Orbitrap fusion and QTOF MS. 30 Peptides 
were found changed, either up-or down-regulated, in 4 of the 7 brain regions investigated, 
including mouse hypothalamus, nucleus accumbens, trigeminal ganglia, trigeminal nuclei, 
rostral ventromedial medulla (RVM), periaqueductal gray (PAG) and dorsal horn. 
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5.3 Experimental 
5.3.1 Animal model establishment and tissue isolation 
5 groups of animals were prepared, including migraine, migraine control, OIH, 
OIH control and naïve group. Each group contained 15 male c57bl6J mice. For migraine 
model, mice in migraine and migraine control group were injected with 10 mg/kg IP of 
nitroglycerin (NTG) and saline vehicle every other day for 9 days (5 injections in total) 
respectively. For OIH model, mice in OIH and OIH control group were injected with 20 
mg/kg SC of morphine and saline vehicle for the first three days and 40 mg/kg SC of 
morphine and saline vehicle for day 4, twice daily. No injections were performed on mice 
in naïve group.  
All the animal procedures were carried out according to protocols approved by the 
Institutional Animal Care and Use Committee, University of Illinois at Chicago and in 
full compliance with the Principles of Laboratory Animal Care. The brain and spinal 
cord were quickly removed after decapitation, kept cold on ice and cut into slices using a 
stainless steel neonatal mouse brain slicer matrix. Pouches of 7 regions of interest, the 
mouse hypothalamus, nucleus accumbens, trigeminal ganglia, trigeminal nuclei, rostral 
ventromedial medulla, periaqueductal gray and dorsal horn were isolated from the 
prepared slices, stabilized with Stabilizor device and snap frozen for sample transport and 
long-term storage.  
 
5.3.2 Peptide sample preparation 
For each region, five groups (migraine and migraine control, OIH and OIH 
control, naïve group) were prepared from 75 mice with n = 3 in each group. 
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Microcentrifuge tubes containing frozen tissues were taken out from -80 °C freezer and 
placed on ice. Tissues were homogenized using a pellet pestle cordless motor after 200 µl 
of ice cold LC-MS water were added into each vial. The homogenized tissue suspensions 
were placed on ice for 30 min for 1st stage peptide extraction. Samples were centrifuged 
at 14000 × g for 10 min and supernatants were saved in clean microcentrifuge tubes. 
Tissue pellets containing vials were vortexed for 30 sec after adding 200 µl of ice cold 
acidified methanol (methanol: glacial acetic acid, and water; 90:9:1) and placed on ice for 
30 min for 2nd stage peptide extraction. The procedure was repeated again for 3rd stage 
peptide extraction in which 200 µl of ice cold acetic acid water solution (0.25%) was 
used as extraction buffer. The supernatant saved from all extraction steps were combined 
and dried using a SpeedVac system.  
Dried peptide extract samples were reconstituted in 200 µl of water and loaded to 
pre-equilibrated C18 spin columns for desalting. After clean-up, peptides were eluted in 
200 µl of H2O and acetonitrile (ACN) solution with 0.1 % formic acid (FA) and 0.01 % 
trifluoroacetic acid (TFA). For different regions, either 5 or 10% of the eluted peptides 
were taken out from each of the 15 samples, pooled and saved in another clean tube. All 
samples were evaporated to dryness using a SpeedVac system.  
 
5.3.3 Peptide LC-MS/MS analysis 
For each region, the pooled sample was subjected to LC-MS/MS analysis for 
peptide identification. The sample was first reconstituted in 10 µl of 99%/1% H2O/ACN 
solution with 0.1 % FA and then loaded onto an Acclaim PepMap100 C18 trap cartridge 
trap column (Thermo, MA) and separated on a 150 mm C18 nanoLC column 
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(PepmapAcclaim, 75 µm ID, Thermo, MA) using an Thermo Ultimate 3000 nanoLC 
system (Thermo, MA). H2O with 0.1 % FA and ACN with 0.1% FA were used as solvent 
A and B and operated at 300 nl/min. The peptides were eluted using the following 
gradients:  0-3 min, 1-1% B; 3-6 min, 1-10% B; 6-90 min, 10-70% B; 90-100 min, 70-99% 
B; 100-110 min, 99-1% B; 110-120 min, 1-1% B. After sample loading, the peptides 
were separated and analyzed by an Orbitrap Fusion mass spectrometer (Thermo, MA). 
The samples were analyzed in a data dependent ‘TOPSPEED” mode, in which the mass 
spectrometer collected as many tandem MS spectra as possible within a pre-set duty 
cycle up-limit. The acquired RAW. files were loaded into PEAKS software (Version 7.5, 
Canada) and searched against a mice proteome database downloaded from Uniprot. The 
following database searching parameters were used: precursor mass tolerance, 20 ppm; 
fragment mass tolerance, 0.1 Da; no enzymatic cleavage; variable PTMs including 
acetylation, amidation, phosphorylation, half-disulfide bond, pyroglutamination and Met 
oxidation; maximum number of variable PTM, 3.   
 
5.3.4 Peptide LC-MS analysis 
For each region, 15 individual samples were subjected to LC-MS analysis. The 
samples were reconstituted in 10 µl of 99%/1% H2O/ACN solution with 0.1 % FA. 7 µl 
from each sample was loaded onto nanoLC system coupled with a high resolution Impact 
HD Q-TOF mass spectrometery (Bruker, MA). The LC system and method same as those 
used in peptide LC-MS/MS experiments were utilized. For mass spectra acquisition, the 
Q-TOF was operated at MS1 level only with mass range from 300 to 3000. Data 
acquisition frequency was set at 1 Hz.  
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5.3.5 Peptide quantitation 
The peptide quantitation was performed using Skyline software developed by 
MacCoss lab in University of Washington at Seattle. A Skyline project was built for each 
region of interest. First, for each region, the skyline compatible mzxml file was exported 
from PEAKS using its inbuilt algorithm and then loaded into its corresponding skyline 
project to build a peptide library. The library contained information including identified 
peptides, their m/z. After peptide library construction, LC-MS data files from different 
regions were imported into their corresponding Skyline projects. For peptides contained 
in the library, their extracted ion chromatograms (XIC) were extracted from every single 
imported LC-MS file by skyline. The integrated peak areas of XIC were used for peptide 
quantitation. Three criteria were set to make sure that the correct peak was picked by 
Skyline for quantitation. Firstly, the mass error between the detected m/z in LC-MS 
results and peptide theoretical m/z was less than 20 ppm; secondly, retention time 
difference between LC-MS and LC-MS/MS experiments was less than 5 min; thirdly, the 
Isotope Dot Product score (idopt), which represents similarity between expected and 
observed precursor isotope distribution, was over 0.95. For all the regions except 
hypothalamus, peptides fulfilling all three criteria were kept and quantified. For 
hypothalamus, only criteria 1 and 3 (mass error and idopt score) were employed due to 
the solvent misuse in nanoLCs coupled to Orbitrap and QTOF. For peptides with multiple 
charge states detected, the peak areas for different charge states were summed up. The 
summed peak areas were log2 transformed and a student t test was performed between 
migraine and migraine control and OIH and OIH control respectively. The p value was 
corrected using two methods, both the method introduced by Storey (2002) and the 
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Benjamin-Hochberg method to control the false discovery rate (FDR). The Benjamin-
Hochberg method is more conservative and stringent, while the Storey approach is used 
for many genomics and proteomics experiments. 
 
5.4 Results 
5.4.1 Migraine, migraine control and naïve group 
We first investigated peptide content in each region qualitatively with the goal to 
create region specific peptide lists. Peptides contained in the list that met all the three 
criteria set for peak checking were kept and quantified. The integrated peak areas for 
quantified peptides were not normally distributed.  As data normality is a pre-requisite for 
the t test, we performed log2 transformation on the peak area values. A normality check 
showed that the log2 transformed data has a normal distribution. We then performed a t 
test between any two groups of migraine, migraine control and naïve group. A q value of 
0.25 in Storey approach was adopted as the significance threshold.   
When comparing the migraine group and migraine control, one peptide derived 
from prohormone Secretogranin-2 in the nucleus accumbens was significantly 
upregulated. No peptides that passed q < 0.25 threshold were observed between migraine 
and migraine control in other brain regions of interest. However, prior to p value 
adjustment using Storey approach, there was different number of peptides found to differ 
between migraine and migraine control in all the brain regions except PAG. The q values 
of some of them were close to the threshold.  
The same comparisons were performed between migraine and naïve group and 
migraine control and naïve group. Peptide changes were found between any of these two 
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comparisons in three regions investigated. In the PAG region, 4 neuropeptides were 
changed between the migraine control (vehicle) and naïve group. In the dorsal horn 
region, 51 peptides were found different in the comparison of migraine and naïve group 
and 19 peptides were changed between vehicle and naïve group. Similar results were 
observed in trigeminal nuclei region. 38 and 34 peptides were differentially expressed in 
migraine and vehicle group as compared to naïve group.  
 
5.4.2 OIH, OIH control and naïve group 
Data from OIH, OIH control (vehicle) and naïve group were processed log2 
transformed. Significant hits were discovered through t test with the significance 
threshold set at q value < 0.25.  Significant changes of peptides between OIH and vehicle 
group were observed in three regions, including 6 in the trigeminal nuclei, 22 in the 
dorsal horn and 1 in the RVM. We checked the identity of changed peptide since 
neuropeptides were endogenous chemical messengers. 1 peptide changed in the 
trigeminal nuclei was derived from prohormone Secretogranin-1 and 16 peptides in the 
dorsal horn were derive from 8 different prohormones, including Secretogranin-1, 
Proenkephalin-A, Pro-neuropeptide Y, ProSAAS, Neurotensin/neuromedin N, 
Preprodynorphin, Neurosecretory protein VGF, Cholecystokinin and CGRP.  
Peptide changes were also observed when comparing OIH vs naïve and vehicle vs 
naïve. In the dorsal horn region, 63 peptides were found different between OIH and naïve 
group and 7 peptides were changed between vehicle and naïve group. In the trigeminal 
nuclei region, large difference was seen between vehicle and naïve group. 26 peptides 
passed the FDR correction and were significant different from each other. 1 peptide was 
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different in the comparison of OIH and naïve group. In addition to these two regions, 1 
peptide in PAG was changed between vehicle and naïve group.  
 
5.5 Discussion 
5.5.1 Features of peptide quantitation method used 
In this study, we aimed to discover the peptides that were significantly up-or 
down-regulated in mice exposed to migraine and OIH treatment. Those peptides changed 
are highly likely to participate in the molecular mechanism of migraine and/or OIH. To 
accomplish this goal, we used a LC-MS label-free peptide quantitation strategy 
combining strengths of both Orbitrap and QTOF MS. In this method, the acquisition of 
identification/qualitative and quantitative information was split. Orbitrap fusion MS was 
used for peptide identification since it had an up to 15 Hz MS spectrum collection 
frequency which expanded the peptide coverage.(34) Peptide quantitation was performed 
on QTOF MS at MS1 level only, which provided a wide dynamic range for peptide 
quantitation.(35)  
 
5.5.2 Potential overlapping mechanism of migraine and OIH 
The behavior studies have shown that mechanical pain threshold was significantly 
decreased in mice exposed to NTG, the migraine trigger and morphine, the OIH trigger 
(Figure 5.1).(36, 37) One peptide that we are particularly interested in is CGRP. As 
shown in Figure 5.2.A, the amount of CGRP in the dorsal horn was decreased in both 
migraine and OIH group as compared to their corresponding vehicle group (for migraine 
vs vehicle, p value = 0.0026, q value = 0.35; for OIH vs vehicle, p value = 0.019, q value 
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= 0.21). Although its function in OIH is poorly understood, the CGRP is one of the most 
important molecules underlying migraine.(31) The integral role of CGRP in migraine has 
been discovered and confirmed from three aspects. First of all, the concentration of 
CGRP is elevated in the migraine patients’ serum during migraine attack and its reduced 
after the application of pain relieving chemicals, triptans.(11, 38-41) In addition, it has 
been demonstrated that injection of CGRP into migraine patients could induce migraine 
attack.(42) Finally, the CGRP receptor antagonists and CGRP antibodies have been 
proven capable of reducing and/or aborting the migraine attack, some of which were in 
the clinic trial stage in anti-migraine drug development.(43-45) Due to the known fact 
that CGRP is a key mediator in migraine pathology, it is not surprising to discover CGRP 
in changed peptides through our comparative quantitation approach. On one hand, this 
result adds credibility to our dataset and indicates that the peptide quantitation pipeline is 
capable of capturing actual biological changes in peptides since we are able to pick out 
CGRP from a few hundred of peptides in the sample, which is expected to be changed in 
migraine. On the other hand, the result suggests that CGRP in the dorsal horn is involved 
in both migraine and OIH signaling, which might count for an overlapping molecular 
mechanism between these two pain-related diseases. We also looked into trigeminal 
ganglia and trigeminal nuclei region because previous studies showed that CGRP was 
released upon activation of the trigeminovascular system, which caused vasodilation, 
promoted the release of inflammatory mediators and induced migraine.(46, 47) We 
identified CGRP in both trigeminal ganglia and trigeminal nuclei region. However, no 
difference in the amount of CGRP was observed in these two regions, which could be 
explained from two perspectives. Firstly, it is likely that CGRP has a subtle change in the 
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trigeminovascular system, which is difficult to be captured by our quantitation method. 
Secondly, given the fact that trigeminal ganglia is highly sensitive to pain (48, 49), it is 
possible that CGRP expressed in the trigeminal ganglia is released before detection 
because of repeated animal handling in migraine and OIH triggering process and stress in 
dissection.  
In addition to CGRP, we also found neuropeptide Y (NPY) as another signaling 
molecule functioning in both diseases. The result showed that NPY was decreased in both 
migraine and OIH mice as compared to their vehicle control in the dorsal horn region 
(Figure 5.2.B), although NPY did not pass the FDR control in migraine model (for 
migraine vs vehicle, p value = 0.015, q value = 0.65; for OIH vs vehicle, p value = 0.015, 
q value = 0.20). NPY is a 36 amino acid long peptide amidated at its C-terminal. It 
possesses distinct biological functions at different locations, including appetite and food 
intake, mood regulation like anxiety, stress and depression, and drug addiction. (50-53) 
The role of NPY in migraine pathology is not as well studied as CGRP, but the 
association of NPY-like immunoreactivity with migraine has been found in the 
cerebrospinal fluid (CSF).(54) For hyperalgesia, recent studies showed that NPY has an 
impact on the sensitivity in pain sensation. Smith. P et al. found that the behavioral signs 
of hyperalgesia are reduced by exogenous NPY which binds to presynaptic receptors, 
inhibits the release of CGRP and decreases the activation of neurons in the dorsal 
horn.(55, 56)  In fact, our results correlated well with their findings. It is reasonable to 
speculate that the observed depletion of NPY in the dorsal horn of mice with OIH implies 
a downregulation of NPY expression. Such downregulation affects the inhibition of 
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CGRP release and promotes hyperalgesia, which also explains the decrease of CGRP 
observed in our experiments.   
 
5.5.3 Other peptides involved in migraine or OIH 
Peptides that changed only in migraine or OIH mice model were also discovered, 
which might be disease-specific biomarkers. Table 5.1 and 2 summarized the peptides 
changed in migraine and OIH respectively. In the study of migraine, one peptide from 
Secretogranin-2 in the nucleus accumbens was changed after mice NTG treatment.  
Secretogranin-2 is a large neuroendocrine secretory protein belonging to the granin 
family (57) and some of its known functions include neurotransmitter release regulation 
(58, 59), hormone secretion regulation (60), neuron differentiation (61) and neurite 
outgrowth (62). Many different peptides are cleaved from Secretogranin-2 given its 
sequence length. Some of them, such as secretoneruin, manserin and BM66, have been 
studied and found bioactive in the nervous system in the previous studies.(63-65) The 
peptide changed in the nucleus accumbens corresponds to a short form of secretoneruin 
with the last two amino acid residues NQ at C-terminal removed. The cleavage site is 
located between a serine and an asparagine (SN), which is not a typical prohormone 
processing site. It is difficult to determine whether this peptide is an endogenous 
bioactive peptide or post-mortem degradation product from full length secretoneruin 
based on current results. In addition to this truncated form, the full length secretoneruin 
was also detected in our study. It did pass the significance threshold before Storey FDR 
correction (p value = 0.028), but did not pass the FDR q value threshold. In fact, many 
other neuropeptides, including some opioid peptides and CGRP, NPY mentioned above, 
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had p value below 0.05 but failed in FDR control. Given that only 3 biological replicates 
were available in the current dataset, it is possible that these peptides were indeed 
changed in migraine state and their significance could be further decreased with the 
addition of measurements of more biological replicates.  
In the study of OIH, 29 peptides were differentially expressed in mice after 
morphine injection, which were shown in Table 5.2. 17 of them were neuropeptides 
cleaved from 8 different prohormones. Some changed peptides were derived from the 
same prohormone, for instance, 5 and 2 of these 17 peptides were from the 
Proenkephalin-A (PENK-A) and Cholecystokinin (CCK) respectively. Such observation 
adds credibility to the conclusion that expression of PENK-A and CCK were changed in 
response to morphine injections. PENK-A and Prodynorphin, both detected in the dorsal 
horn, belong to opioid peptide family. The opioid system is one of the critical innate 
systems involved in pain-relieving and the endogenous opioid peptides are related to 
different aspects of pain signaling, including pain formation, transmission, modulation 
and perception.(66, 67) Besides, the presence of opioid peptides in the spinal cord has 
been found decades ago.(68) Therefore, it was reasonable to see changes of opioid 
peptides in the dorsal horn here. We also found levels of two CCK peptides were reduced 
in the dorsal horn. It has been reported that the abundance of CCK peptides, CCK 
receptors and CCK release are altered after nerve injury and inflammation, which are 
related to chronic pain.(69) Besides, the antinociceptive effect of opioids is found to be 
compromised by CCK peptides.(70) It is likely that the decrease in CCK peptides 
corresponds to an elevated release in the dorsal horn, which weakens the endogenous 
antinociceptive system in the organism, enhances pain sensation and facilitates the 
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development of hyperalgesia. We also discovered changed peptides from other 
prohormones, such as Neurotensin, Neurosecretory protein VGF, ProSAAS and 
Secretogranin-1. Evidences have been found which suggested Neurotensin and 
Neurosecretory protein VGF are associated with pain signaling.(71, 72)  
We also found that some non-prohormone derived peptides were changed in mice 
exposed to migraine or OIH treatment. One peptide from eukaryotic translation initiation 
factor 4H was found decreased and increased in dorsal horn and RVM respectively in the 
OIH study. The reason of such change was unclear now and required further investigation. 
Another peptide from myelin basic protein was upregulated in the dorsal horn. Myelin 
basic protein is a critical component for a functional nervous system and plays an 
important role in the axon myelination, a process accelerating axonal impulse 
conduction.(73) It has also been shown to participate in multiple diseases such as 
multiple sclerosis, neuroinflammation and cognitive decline. (74-76) It is not surprising if 
myelin basic protein is also involved in pain-related diseases and can alter pain signaling. 
Besides, we observed a decline of macrophage migration inhibitory factor (MIF) in the 
trigeminal nuclei. The decrease of MIF in the trigeminal nuclei might imply an enhanced 
release of MIF since it is secreted to maintain the function of immune system and tightly 
related to neuroinflammation, which is a condition that coincides with chronic pain.(69, 
77)  
 
5.5.4 Stresses in mice handling and conditioning 
We checked the peptide changes between disease vs naïve and vehicle vs naïve in 
all the regions studied. As mentioned previously, no or few peptide change was observed 
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in hypothalamus, nuclei accumbens, RVM, PAG and trigeminal ganglia between disease 
(migraine or OIH) and corresponding vehicle control group. Similarly, we did not find 
any peptide change between disease vs naïve and vehicle vs naïve within these regions. 
Such results are reasonable since they indicated that no change, at least no peptide change, 
occurred within these regions during NTG or morphine treatment. For trigeminal nuclei 
and dorsal horn where we saw peptide changes between disease and vehicle, differences 
in peptides were also found in the other two comparisons, disease vs naïve and vehicle vs 
naïve. Table 5.3 and 4 showed the summary of peptide changes in the dorsal horn region 
in migraine and OIH model respectively. Differences between disease and naïve were 
greater than between disease and vehicle. To investigate the reason for this phenomenon, 
we calculated the quantitation RSD for peptides changed in the dorsal horn. As shown in 
Table 5.3 and 4, majority of the peptides changed had smallest and largest relative 
standard deviation (RSD) in the naïve and vehicle group respectively. This suggests that 
repeated handling, injection and testing induce stress in mice within disease and vehicle 
group, which affects the peptide level to different extent in each mouse and results in 
large variance in peptide level. For mice in the migraine and OIH group, although these 
mice were treated and tested in the same way as vehicle group, their peptide levels should 
be primarily affected by NTG and morphine, which could lead to the reduction of 
variances in peptide abundance. Although such stress is hard to avoid and eliminate, it is 
worth noting that the targeted analyte pool, peptide in our case, have already changed in 
the vehicle group.  
 
 
- 144 - 
 
5.6 Conclusion and future directions 
Migraine and OIH are two pain-related diseases which shared signaling pathway 
partially and might have an overlapping molecular mechanism.  To discover the peptides 
involved in migraine and/or OIH, we developed a novel label-free peptide quantitation 
strategy, combining the strengths of Orbitrap MS in peptide identification and QTOF MS 
in peptide quantitation. Using this quantitation approach and statistic methods, we found 
30 significant peptide changes in four different brain regions (1 in migraine study and 29 
in OIH study).  Our result showed that CGRP, which is released during migraine attack, 
was also depleted in the dorsal horn in OIH model. Similarly, amount of NPY was 
reduced in both migraine and OIH model. These findings suggested that CGRP and NPY 
might be the common molecule used for pain signaling, underlying overlapping 
mechanism of migraine and OIH. In addition, other pain-related peptides were also found 
changed, such as opioid peptides, CCK, neuroVGF etc.  
The project is still ongoing after we employed mass spectrometry as a great 
exploratory tool to discover the peptide hits involved in migraine and OIH. More 
experiments are underway or planned. Currently, we are preparing more mice in four 
groups (migraine, migraine vehicle control, OIH, OIH vehicle control). In the near future, 
we will isolate the same 7 regions of interest from these mice and quantify peptides using 
the same quantitation approach. Results from this second quantitation experiment can be 
used in multiple ways. On one hand, it validates our current discoveries if same set of 
peptides are found significantly changed again. On the other hand, the results from the 
two sets of peptide quantitation experiments can be combined so that each group has 
more biological replicates.  One issue in our study is that many peptides had p value less 
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than 0.05, but did not pass the FDR control with q value close to the significance 
threshold. Adding more biological replicates into the quantitative measurement might 
further bring down the p value between disease and vehicle group and rescue or 
rediscover the peptide hits we missed in the current dataset. We are also performing 
comparative transcriptomics study now, which is complementary to our quantitative 
peptidomics study. For peptide hits discovered, the mRNA level change of their 
prohormones could validate our results. In addition, synthesized standard of changed 
peptides could be used in animal behavior studies to test whether migraine and OIH could 
be affected by these peptides. 
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5.8 List of Figures and Tables 
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Figure 5.1 Results of pain-stimulation experiment performed during mouse migraine and 
opioid induced hyperalgesia model establishment. Chronic NTG and morphine evokes 
and sustains mechanical hyperalgesia in a dose-dependent manner. A). C57Bl/6J mice 
were treated every second day with NTG (10 mg/kg, ip) or saline for 9 days. Basal 
mechanical responses were recorded 2 hours after injection. B. C57Bl/6J mice were 
injected with morphine (20 mg/kg for day 1-3 and 40 mg/kg for day 4) and saline for 4 
days. Figure provided by Prof. Amynah A. Pradhan at UIC. Unpublished data.  
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Figure 5.2 Quantitation results of Calcitonin gene-related peptide and neuropeptide Y. 
Levels of CGRP (A) and NPY (B) were reduced in mice with migraine and OIH as 
compared to corresponding vehicle control. The p values shown were prior to FDR 
correction. The q values were calculated using Storey’s method and used for FDR control. 
The error bars in panel A and B are standard deviations of signal intensity of CGRP and 
NPY respectively. 
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Table 5.1 Peptides significantly changed (p < 0.05 and q < 0.25) between migraine and 
vehicle group. The only peptide that had a significant difference between migraine and its 
control was found in the nucleus accumbens. 
Regio
n 
Peptide 
Prohormone/precur
sor 
P value q value 
correcte
d p 
value 
log2 fold 
change 
NAc 
TNEIVEEQYTPQS
LATLESVFQELGK
LTGPS 
Secretogranin-2 0.00118 0.1920 0.3014 3.36 
*NAc: nucleus accumbens;  
The log2 transformed fold change is calculated by subtracting log2-transformed average 
intensity of peptide in control from the log2-transformed average intensity of peptide in 
the migraine group. Positive value means a peptide up-regulation in migraine group and 
negative value means a down-regulation in migraine group. 
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Table 5.2 Peptides significantly changed (p < 0.05 and q < 0.25) between OIH and 
vehicle group.  
Regio
n 
Peptide Prohormone/precursor P value q value 
corrected 
p value 
log2 fold change 
TN 
HISPDRVYINYYDMNA
ANVGWNGSTFA 
 
Macrophage migration 
inhibitory factor 
 
0.0257 
 
0.2090 
 
0.8082 
 
-0.760 
 
pyroQYDGVAELDQLLH
Y 
 
Secretogranin-1 
 
0.0271 
 
0.2092 
 
0.8082 
 
1.06 
 
M(acetylation)EMDKRIY
LEL 
 
Acidic leucine-rich 
nuclear phosphoprotein 
32family member A 
 
0.0383 
0.2092 
 
0.8082 
 
0.781 
 
PK(acetylation)KRSS 
 
Protein piccolo 
 
0.0425 
 
0.2092 
 
0.8082 
 
1.58 
 
PLADLNIKDFL 
 
Clathrin coat assembly 
protein AP180 
 
0.0470 
 
0.2095 
 
0.8082 
 
0.975 
 
A(acetylation)AYKLVLIR
HGESAWNL 
Phosphoglycerate 
mutase 1 
0.0496 0.2098 
0.8082 
 
0.668 
 
DH 
DADEGDTLANSSDLLK
ELLGTGDNRAKDSHQQ
ESTNNDEDMS 
 
Proenkephalin-A 
 
0.00190 
 
0.1604 
 
0.2845 
 
-2.36 
 
SHHLAHY(phosphorylati
on)RASEEEPEYGEESRS
Y(phosphorylation) 
 
Secretogranin-1 
 
0.00486 
 
0.1899 
 
0.2845 
 
-3.23 
 
ASQPDVDGFLVGGASL
KPEFVDIINAKQ 
 
Triosephosphate 
isomerase 
 
0.00517 
 
0.1907 
 
0.2845 
 
-1.51 
 
MDELYPMEPEEEANGG
EILA 
 
Proenkephalin-A 
 
0.00804 
 
0.1931 
 
0.3368 
 
-0.88 
 
YGGFMKKMDELYPME
PEEEANGGEILA 
 
Proenkephalin-A 
 
0.00980 
 
0.1995 
 
0.3368 
 
-1.44 
 
PLNQVANPNSAIFGGAR
PREEVVQKEQE 
 
Eukaryotic translation 
initiation factor 4H 
 
0.01238 
 
0.1997 
 
0.3368 
 
-1.13 
 
YPSKPDNPGEDAPAED
MARYYSALRHYINLITR
QRYamide 
 
Pro-neuropeptide Y 
 
0.01476 
 
0.2008 
 
0.3368 
 
-2.46 
 
PFNWDLPEPRSRASKIR
VHPR 
 
Neuromedin-B 
 
0.01743 
 
 
0.2026 
 
0.3368 
 
-1.85 
 
GRPEWWMDYQ 
 
Proenkephalin-A 
 
0.01844 
 
0.2090 
 
0.3368 
 
3.56 
 
SAASAPLVETSTPLRL 
 
ProSAAS 
 
0.01854 
 
0.2121 
 
0.3368 
 
1.36 
 
SC(disulfide)NTATC(disul
fide)VTHRLAGLLSRSG
GVVKDNFVPTNVGSEA
Famide 
 
CGRP 
 
0.01868 
 
0.2131 
 
0.3368 
 
-1.85 
 
IPYIL 
 
Neurotensin 
 
0.01999 
 
0.2139 
 
0.3368 
 
4.54 
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Table 5.2 (cont.) 
 
SSEMARDEDGGQDGD
QVGHEDLY 
 
Preprodynorphin 
 
0.02143 
 
0.2159 
 
0.3368 
 
-1.76 
 
V(acetylation)NPTVFF 
 
Peptidyl-prolyl cis-trans 
isomerase A 
 
0.02577 
 
0.2195 
 
0.3542 
 
-1.15 
 
KARELEQEEEQEAEGSS
VTAQ 
 
CGRP 
 
0.03104 
 
0.2230 
 
0.3794 
 
-0.698 
 
A(acetylation)SQKRPSQR
SKYLATA 
 
Myelin basic protein 
 
0.03372 
0.2263 
 
0.3829 
 
4.28 
 
FENKVPEKQKLFQEDN
GMPVHLKGGASDALLY
RATMALTLGGTAYAIYL
LAMAAFPKKQN 
 
Cytochrome c oxidase 
subunit 7A2  
mitochondrial 
 
0.03481 
 
0.2286 
 
0.3829 
 
-0.987 
 
APPGRPDVFPPPLSSEH
NGQVAEDAVSRPKD 
 
Neurosecretory protein 
VGF 
 
0.03831 
 
0.2288 
 
0.3948 
 
-0.409 
 
RPEWWMDYQ 
 
Proenkephalin-A 
 
0.03947 
 
0.2320 
 
0.3948 
 
3.76 
 
KAPSGRMSVLKNLQSL
DPSHRISD 
 
Cholecystokinin 
 
0.04136 
 
0.2355 
 
0.3956 
 
-1.07 
 
YIQQVRKAPSGRMSVL
KNLQSLDPSHRISD 
 
 
Cholecystokinin 
 
0.04598 
 
0.2376 
 
0.4116 
 
-0.966 
 
LAGLLSRSGGVVKDNF
VPTNVGSEAFamide 
CGRP 0.04677 0.2403 
0.4116 
 
-0.989 
RVM 
PLNQVANPNSAIFGGAR
PREEVVQKEQE 
Eukaryotic translation 
initiation factor 4H 
0.00085 0.0698 0.0772 0.926 
 
* TG: trigeminal ganglia; TN: trigeminal nucleus; NAc: nucleus accumbens; PAG: 
periaqueductal gray; DH: dorsal horn; RVM: Rostral ventromedial medulla; HT: 
hypothalamus. 
The log2 transformed fold change is calculated by subtracting log2-transformed average 
intensity of peptide in control from the log2-transformed average intensity of peptide in 
the migraine group. Positive value means a peptide up-regulation in migraine group and 
negative value means a down-regulation in migraine group. 
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Table 5.3 Summary of peptide changes in the dorsal horn (q<0.25) between migraine, 
vehicle and naïve group. “X” represents the two groups between which a significant 
change was found. The table only contains results from migraine and naïve, vehicle and 
naïve because no peptide change was found between migraine and vehicle group. 
Prohormone Peptide 
Migraine 
and naïve 
Vehicle 
and 
naïve 
Migraine 
std/AVG*
100 
Vehicle 
std/AVG
*100 
Naïve 
std/AV
G*100 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member A 
M[+42]EMDKRIYLEL X 
 
2.60 4.98 2.17 
ATP synthase-coupling factor 6 PKFEVIDKPQS 
 
X 4.47 3.86 1.58 
Beta-hexosaminidase subunit 
beta 
ARLQPALWPFPRSVQMFPR
L 
X 
 
3.31 1.08 1.32 
Calcitonin gene-related peptide 1 VPLRSILESSPGMATL X 
 
2.61 3.02 0.93 
Calcitonin gene-related peptide 1 
MQMKARELEQEEEQEAEGS
SVTAQ  
X 6.71 2.08 1.70 
Cathepsin B IDLPETFDAREQWSN X 
 
0.62 3.71 1.49 
cerebellin-1 SGSAKVAFSAIRSTNH X X 2.56 3.16 1.58 
CGRP 
SC[-1]NTATC[-
1]VTHRLAGLLSRSGGVVKD
NFVPTNVGSEAF[-1] 
X 
 
1.51 1.26 1.91 
Cholecystokinin 
Q[-
17]PVVPAEATDPVEQRAQE
APRRQL 
X 
 
1.44 6.36 2.02 
Chromogranin-A 
LEGEDDPDRSMKLSFRTRA
YGFRDPGPQL 
X 
 
1.51 7.13 2.72 
Chromogranin-A AYGFRDPGPQL X 
 
1.55 8.92 1.27 
Cocaine- and amphetamine-
regulated transcript protein 
Q[-
17]LRAPGAMLQIEALQEVL
KKLKS 
X 
 
3.37 7.38 2.02 
Gastrin-releasing peptide GSHWAVGHLM[-1] X 
 
0.34 9.01 1.54 
Macrophage migration inhibitory 
factor 
HISPDRVYINYY X X 1.12 1.14 2.13 
MCG18019 
Q[-
17]QETAAAETETRTHTLTRV
NLESPGPERVW 
 
X 2.63 2.35 0.83 
Myelin basic protein 
A[+42]SQKRPSQRSKYLATA
STMDH 
X 
 
1.82 1.58 0.45 
Myelin basic protein RFSWGGRDSRSGSPMARR X 
 
2.29 2.68 2.70 
Neuroendocrine convertase 1 LSDDDRVTWAEQQYEKERS X 
 
2.51 4.09 1.81 
Neuroendocrine convertase 2 
Q[-
17]ELEEELDEAVERSLQSILR
KN 
X X 1.78 4.78 0.37 
Neuromedin-B 
ALGMNFSGPAPPIQYRRLLE
PLLQ  
X 3.43 1.82 2.95 
Neurotensin/neuromedin N Q[-17]LYENKPRRPYIL X 
 
1.88 12.0 2.37 
NPY 
YPSKPDNPGEDAPAEDMAR
YYSALRHYINLITRQRY[-1] 
X 
 
3.81 2.63 0.97 
NPY 
SSPETLISDLLMKESTENAPR
TRLEDPSMW 
X X 2.04 2.45 0.52 
Peptidyl-prolyl cis-trans 
isomerase A 
KHTGPGILSM X 
 
0.58 4.22 1.23 
Preprodynorphin 
FAESLPSDEEGENYS[+80]KE
VPEIE 
X 
 
2.41 3.83 2.49 
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Table 5.3 (cont.) 
Preprodynorphin 
FAESLPSDEEGENYSKEVPEI
E 
X 
 
2.30 0.26 1.45 
Preprodynorphin YGGFLRKYP X 
 
4.55 20.8 1.76 
Preprodynorphin YGGFLRKYPK X 
 
1.33 2.57 1.59 
Prepronociceptin VRSLVQV X 
 
1.90 24.8 0.84 
Pre-rRNA-processing protein 
TSR2 homolog 
A[+42]GAAEDVRVLFGAAV
RA 
X X 1.60 1.47 2.00 
Proenkephalin-A VGRPEWWMDYQ X 
 
1.65 3.97 1.56 
Proenkephalin-A 
YGGFMKKMDELYPMEPEEE
ANGGEILA 
X 
 
3.49 2.29 1.92 
Proenkephalin-A YGGFMRRV[-1] X 
 
2.21 4.59 1.01 
Proenkephalin-A SPQLEDEAKEL 
 
X 3.22 3.86 0.54 
Proenkephalin-A SPQLEDEAKELQ 
 
X 2.34 3.37 0.86 
Proenkephalin-A 
MDELYPMEPEEEANGGEIL
A 
X 
 
3.49 2.29 1.91 
Proenkephalin-A 
YGGFMRRVGRPEWWMDY
QKRYGGFL 
X X 6.55 4.60 1.95 
ProSAAS 
ETPDVDPELLRYLLGRILTG
SSEPEAAPAPRRL 
X 
 
6.52 6.59 1.40 
ProSAAS 
VDPELLRYLLGRILTGSSEPE
AAPAPRRL  
X 6.23 6.04 1.24 
ProSAAS 
GEAAGAVQELARALAHLLE
AERQE 
X X 0.32 1.76 1.64 
Protachykinin-1 
DADSS[+80]VEKQVALLKAL
YGHGQISH 
X 
 
2.40 5.07 2.58 
Protachykinin-1 DSFVGLM[-1] X 
 
1.33 7.32 0.40 
Pro-thyrotropin-releasing 
hormone 
DLQRVRGDLGAALDSWIT X 
 
2.49 2.15 5.48 
Secretogranin-1 
GLQYRGRGS[+80]EEDRAPR
P 
X 
 
2.07 3.04 1.21 
Secretogranin-1 GLQYRGRGSEEDRAPRPR X 
 
1.35 1.71 1.71 
Secretogranin-1 
GNPDDSFLEDEGEDRNGVT
LTEK 
X 
 
1.54 8.94 1.98 
Secretogranin-1 LLDEGHYPV X 
 
1.21 10.7 1.38 
Secretogranin-1 SFARAPQLDL X 
 
1.22 7.01 0.88 
Secretogranin-1 
ELENLAAMDLELQKIAEKFS
QR[-1]  
X 5.37 3.92 0.71 
Secretogranin-1 LLDEGHYPVRESPIDT 
 
X 3.02 3.02 1.20 
Secretogranin-1 QYDGVAELDQLLHY X X 1.17 1.77 2.31 
Secretogranin-2 ESKDQLSEDASKVITYL X 
 
2.57 3.16 1.58 
Secretogranin-2 IPVGSLKNEDTPNRQY X 
 
1.38 3.87 0.56 
Secretogranin-2 
IPVGSLKNEDTPNRQYLDED
MLLKVLEYLNQEQAEQGRE
HL 
X 
 
4.32 7.55 1.99 
Secretogranin-2 
IPVGSLKNEDTPNRQYLDED
MLLKVLEYLNQEQAEQGRE
HLA 
X 
 
2.08 5.33 4.16 
Secretogranin-2 ESKDQLSEDASKVITY X X 1.28 1.10 2.17 
Somatostatin 
APSDPRLRQFLQKSLAAATG
KQELAKYFLAELLSEPNQTE
NDALEPEDLPQAAEQDEMR
LELQ 
 X 6.13 2.84 2.01 
Tachykinin-3 DMHDFFVGLM[-1] X 
 
0.98 6.82 1.40 
Triosephosphate isomerase 
ASQPDVDGFLVGGASLKPE
FVDIINAKQ 
X 
 
2.16 5.08 3.04 
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Table 5.3 (cont.) 
Vesicle-associated membrane 
protein  associated protein B and 
C 
AK[+42]VEQVLSLEPQHEL X 
 
0.45 6.75 1.19 
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Table 5.4 Summary of peptide changes in the dorsal horn (q<0.25) between OIH, vehicle 
and naïve group. “X” represents the two groups between which a significant change was 
found.  
Prohormone Peptide 
OIH 
and 
vehicle 
OIH 
and 
naïve 
vehicl
e and 
naïve 
OIH 
std/AV
G*100 
Vehicl
e 
std/AV
G*100 
Naïve 
std/AV
G*100 
Acidic leucine-rich nuclear 
phosphoprotein 32 family 
member A 
M[+42]EMDKRIYLEL 
 
X 
 
3.99 7.96 2.17 
ATP synthase-coupling factor 6 PKFEVIDKPQS 
 
X 
 
1.58 6.26 1.58 
Beta-hexosaminidase subunit 
beta 
ARLQPALWPFPRSVQMFPRL 
 
X 
 
2.95 4.02 1.32 
Calcitonin VPLRSILESSPGMATLSEEE 
 
X 
 
0.79 3.67 0.78 
Calcitonin gene-related peptide 1 
KARELEQEEEQEAEGSSVTA
Q 
X 
  
1.08 0.93 8.13 
Calcitonin gene-related peptide 1 VPLRSILESSPGMATL 
 
X 
 
0.86 4.06 0.93 
Calcitonin gene-related peptide 1 
LAGLLSRSGGVVKDNFVPTN
VGSEAF[-1] 
X X 
 
1.42 2.21 1.20 
Calcitonin gene-related peptide 1 
SC[-1]NTATC[-
1]VTHRLAGLLSRSGGVVKD
NFVPTNVGSEAF[-1] 
X X 
 
3.01 1.60 1.91 
Calcitonin gene-related peptide 1 
MQMKARELEQEEEQEAEGS
SVTAQ  
X X 4.89 3.21 1.70 
Cathepsin B IDLPETFDAREQWSN 
 
X X 2.71 0.64 1.49 
cerebellin-1 SGSAKVAFSAIRSTN 
 
X 
 
0.99 3.58 1.51 
cerebellin-1 SGSAKVAFSAIRSTNH 
 
X 
 
2.04 3.62 0.48 
Cholecystokinin 
KAPSGRMSVLKNLQSLDPSH
RISD 
X 
  
1.88 1.90 2.10 
Cholecystokinin 
YIQQVRKAPSGRMSVLKNL
QSLDPSHRISD 
X 
  
1.77 1.70 2.57 
Chromogranin-A LEGEDDPDRSMKLSFRT 
 
X 
 
0.27 6.03 1.37 
Cytochrome c oxidase subunit 
7A2  mitochondrial 
FENKVPEKQKLFQEDNGMP
VHLKGGASDALLYRATMAL
TLGGTAYAIYLLAMAAFPKK
QN 
X 
  
0.73 1.77 1.41 
Eukaryotic translation initiation 
factor 4H 
PLNQVANPNSAIFGGARPRE
EVVQKEQE 
X 
  
0.50 1.79 5.60 
Gastrin-releasing peptide APVSTGAGGGTVLAKMYP 
 
X 
 
1.85 5.86 1.44 
Gastrin-releasing peptide APVSTGAGGGTVLAKMYPR 
 
X 
 
3.27 8.92 0.65 
Macrophage migration inhibitory 
factor 
AQATGKPAQYIAVHVVPDQL
MTF  
X 
 
4.57 2.10 3.26 
Macrophage migration inhibitory 
factor 
DMNAANVGWNGSTFA  X  0.88 2.96 3.43 
MCG18019 NAPPEPVPPPRAAPAPTHV  X  1.38 4.25 1.00 
MCG18019 
APPGRPDVFPPPLSSEHNGQV
AEDAVSRPKD 
X X X 0.41 0.90 1.43 
Myelin basic protein A[+42]SQKRPSQRSKYLATA X   5.18 7.23 4.40 
Neuroendocrine convertase 1 LSDDDRVTWAEQQYEKERS  X  1.30 5.84 1.81 
- 162 - 
 
Table 5.4 (cont.) 
Neuroendocrine convertase 2 
Q[-
17]ELEEELDEAVERSLQSILR
KN 
 X  1.61 6.16 0.37 
Neuromedin-B PFNWDLPEPRSRASKIRVHPR X   2.86 2.32 2.44 
Neurotensin/neuromedin N IPYIL X   2.58 12.9 5.60 
Neurotensin/neuromedin N Q[-17]LYENKPRRPYIL  X  3.38 16.2 2.37 
NPY 
SSPETLISDLLMKESTENAPR
TRLEDPSMW 
 X  1.32 4.56 0.52 
NPY 
YPSKPDNPGEDAPAEDMAR
YYSALRHYINLITRQRY[-1] 
X X  4.84 0.93 0.97 
Peptidyl-prolyl cis-trans 
isomerase A 
QGGDFTRHNGTGGRSIYGEK
FEDENFILKH 
 X  3.93 1.11 1.20 
Peptidyl-prolyl cis-trans 
isomerase A 
V[+42]NPTVFF X X  6.05 7.88 3.25 
Peroxiredoxin-5  mitochondrial APIKVGDAIPSVEVF  X  2.15 7.05 3.17 
Phosphatidylethanolamine-
binding protein 1 
EWDDYVPKLYEQLSGK  X  0.58 8.47 2.04 
Phosphatidylethanolamine-
binding protein 1 
QAEWDDYVPKLYEQLSGK  X  2.82 6.88 0.97 
Pituitary adenylate cyclase-
activating polypeptide 
GAGENLGGSAVDDPAPLT  X  0.50 2.02 1.30 
Preprodynorphin 
SSEMARDEDGGQDGDQVGH
EDLY 
X   2.19 2.31 3.98 
Preprodynorphin YGGFLRKYP  X  7.36 24.5 1.76 
Preprodynorphin YGGFLRKYPK  X  2.34 4.29 1.59 
Proenkephalin-A GRPEWWMDYQ X   4.40 5.20 5.70 
Proenkephalin-A MDELYPMEPEEEANGGEILA X   0.51 1.00 0.44 
Proenkephalin-A 
FAESLPSDEEGENYS[+80]KE
VPEIE 
 X  1.20 1.70 2.49 
Proenkephalin-A SPQLEDEAKEL  X  3.88 2.78 1.09 
Proenkephalin-A YGGFMRRVGRPEWWMDYQ  X  1.18 4.83 1.16 
Proenkephalin-A 
DADEGDTLANSSDLLKELLG
TGDNRAKDSHQQESTNNDE
DMS 
X X  2.10 1.05 1.14 
Proenkephalin-A 
YGGFMKKMDELYPMEPEEE
ANGGEILA 
X X  1.70 1.41 1.92 
Proenkephalin-A RPEWWMDYQ X  X 7.40 3.31 2.37 
Proenkephalin-A MDELYPMEPEEEANGGEILA  X  1.70 1.41 1.92 
Proenkephalin-A RSPQLEDEAKELQ  X  3.88 2.78 1.09 
Proenkephalin-A SPQLEDEAKELQ  X  0.82 6.42 0.86 
Proenkephalin-A 
YGGFMRRVGRPEWWMDYQ
KRYGGFL 
 X  2.64 4.54 1.95 
Proenkephalin-A 
FAESLPSDEEGENYSKEVPEI
E 
 X X 1.64 1.98 1.45 
Pro-MCH EIGDEENSAKFPI[-1]  X  0.64 11.5 1.56 
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Table 5.4 (cont.) 
ProSAAS SAASAPLVETSTPLRL X   1.59 2.32 3.05 
ProSAAS 
AGDETPDVDPELLRYLLGRIL
TGSSEPEAAPAPRRL 
 X  0.43 5.09 1.40 
ProSAAS 
ETPDVDPELLRYLLGRILTGS
SEPEAAPAPRRL 
 X  2.49 7.55 1.24 
ProSAAS SLSAASAPLVETSTPLRL  X  0.62 1.66 1.12 
ProSAAS 
VDPELLRYLLGRILTGSSEPE
AAPAPRRL 
 X  3.32 14.8 1.50 
Protachykinin-1 
DADSS[+80]VEKQVALLKAL
YGHGQIS 
 X  6.09 7.18 2.08 
Protachykinin-1 DSFVGLM[-1]  X  0.83 9.91 0.40 
Protachykinin-1 
DADSS[+80]VEKQVALLKAL
YGHGQISH 
  X 1.22 1.67 2.58 
Protachykinin-1 
DADSSVEKQVALLKALYGH
GQISH 
  X 1.80 1.26 1.35 
Secretogranin-1 
SHHLAHY[+80]RASEEEPEY
GEESRSY[+80] 
X   3.87 1.66 10.2 
Secretogranin-1 
GLQYRGRGS[+80]EEDRAPR
P 
 X  1.53 5.32 1.21 
Secretogranin-1 
GLQYRGRGS[+80]EEDRAPR
PR 
 X  1.80 10.1 2.25 
Secretogranin-1 
GNPDDSFLEDEGEDRNGVTL
TEK 
 X  0.86 8.53 1.98 
Secretogranin-1 LLDEGHYPVRESPIDT  X  2.14 5.36 1.21 
Secretogranin-1 QYDGVAELDQLLHY  X  2.56 5.98 2.31 
'Secretogranin-1 
ELENLAAMDLELQKIAEKFS
QR[-1] 
 X  2.94 13.1 0.71 
Secretogranin-1 
GLQY[+80]RGRGSEEDRAPR
PR 
 X  2.23 10.1 2.25 
Secretogranin-1 GLQYRGRGSEEDRAPRPR  X  3.67 7.50 1.82 
Secretogranin-2 ESKDQLSEDASKVITY  X  1.32 9.81 2.17 
Secretogranin-2 
IPVGSLKNEDTPNRQYLDED
MLLKVLEYLNQEQAEQGRE
HL 
 X  3.25 3.14 1.99 
Secretogranin-2 SGQLGLPDEEN  X  2.58 23.6 1.40 
Secretogranin-2 ESKDQLSEDASKVITYL  X  0.64 2.84 0.70 
Serine/arginine-rich splicing 
factor 2 
S[+42]YGRPPPDVEGMTSL  X  1.81 2.58 3.62 
Triosephosphate isomerase 
ASQPDVDGFLVGGASLKPEF
VDIINAKQ 
X X  1.88 1.12 3.04 
Vesicle-associated membrane 
protein  associated protein B and 
C 
AK[+42]VEQVLSLEPQHEL  X X 1.49 3.76 1.19 
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Chapter 6 
Purification and structure elucidation of an unknown molecule 
paralyzing the parasitic flatworm, Schistosoma. 
 
6.1 Notes and acknowledgements 
The work presented in Chapter 6 is focused on the isolation and structure elucidation of 
an unknown bioactive compound using a combination of analytical techniques. This 
chapter is adapted from the manuscript in preparation, entitled “Discovery, purification 
and characterization of a natural product paralyzing the infectious stage of the human 
parasite, Schistosoma”, Yang, N.; Gao, J.; Zhu, L.; Yau, P.; Collins, J.J., Lewis, F., 
Sweedler, J.V.; Newmark, P.A. My contribution to this project included the 
determination of the bioactive target, development of the separation protocol and 
elucidation of the structure and stereochemistry of the bioactive target. Dr. Fred Lewis 
initiated this project in the mid-1980s, and Prof. P.A. Newmark re-examined this work, 
building upon Dr. Lewis’s earlier observations. Prof. P.A. Newmark, Dr. Jim Collins, and 
Jiarong Gao prepared samples, established and performed the bioactivity assay used for 
bioactive fraction determination.  Prof. P. Yau, Dr. B.S. Imai and Dr. Y. Chen performed 
1
st
 stage LC separation and assisted in large-scale sample lyophilization. Dr. Lingyang 
Zhu assisted in the NMR spectrum acquisition and provided guidance in spectrum 
interpretation. All the people mentioned above and Prof. Jonathan Sweedler gave helpful 
suggestions in the characterization of the unknown bioactive compound. This work was 
funded by the National Institutes of Health (NIH 2 P30 DA018310 B).  
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6.2 Introduction 
Schistosoma is a group of parasitic flatworm species propagated via freshwater 
environments. Schistosoma causes a disease named schistosomiasis after infecting people 
and other animals, which affects the health of a large population of people, primarily in 
Africa and Southeast Asia. According to recent statistics, 249 million people worldwide 
are affected by Schistosoma now. In addition, over 700 million people have been at risk 
of Schistosoma infection in mid-2003.(1, 2) 
Schistosoma has a complex life cycle, composed of 5 main stages: egg, 
miracidium, sporocyst, cercaria, and the adult worm. In the beginning, eggs hatch into 
miracidia which penetrate into snails. After successive generation inside the snail 
intermediate hosts, the worms are released into freshwater at the infective stage, the 
cercaria. People can get infected after being exposed to contaminated water. Cercariae 
infect the definitive mammalian hosts (i.e., humans) and develop into adult worms, which 
lay large numbers of eggs and cause schistosomiasis.(3, 4) 
Therapies for Schistosoma infection are limited. Currently, schistosomiasis 
treatment exclusively relies on one drug, praziquantel.(5) However, there are two 
challenges associated with praziquantel. Some species have started to develop resistance 
against praziquantel.(6) Besides, patients seek praziquantel treatment after being infected. 
There is no vaccine or preventive drug for Schistosoma infection.(7) 
The current situation could possibly be changed by a discovery made back in the 
1980s. It was found that either rotifer colonization of infected snails or rotifer-
conditioned water could reduce cercariae output, motility and infectivity.(8) Preliminary 
results showed that the rotifer species, Rotaria rotatoria, releases a chemical substance 
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that specifically acts on and paralyzes cercariae, the infective stage of Schistosoma. 
Therefore, this molecule has the potential to be developed into the first preventive drug 
for Schistosoma infection and has remarkable pharmacological significance. Our goal in 
this work was to purify and determine the structure or sequence of this bioactive 
molecule. We established a robust and efficient purification protocol for this bioactive 
molecule to isolate it from the chemically undefined but complex rotifer-conditioned 
culture media. After bioactive compound purification, we used a combination of 
analytical techniques, including mass spectrometry (MS), nuclear magnetic resonance 
(NMR) and molecular modeling to probe its structure and stereochemistry. The results 
showed that the bioactive molecule was a small molecule and had a structure similar to a 
class of known serotonin receptor antagonists.  
 
6.3 Experimental 
6.3.1 Biological activity assay 
Samples to be tested were applied on swimming cercariae. The paralysis of 
cercariae was recorded using a microscope-mounted video camera. Samples processed at 
various stages were tested. If samples contained organic solvents, such as fractions 
collected from liquid chromatography (LC) separation, samples were dried completely 
and reconstituted to desired volume with water prior to the bioassay. The bioassay was 
established by Dr. Fred Lewis and performed by Newmark’s lab. 
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6.3.2 Crude rotifer-conditioned media purification 
Rotifer-conditioned media was filtered through 10,000 and 650 (MWCO) Pall 
Minimate TFF Capsules with Omega membrane (Ann Arbor, MI) and lyophilized to 
dryness. For RP-HPLC, 300 mg of the dried media was dissolved in water and run on a 
RP-HPLC – Merck Chromolith semi-prep RP-18e monolithic column (Darmstadt, 
Germany) at 5 ml/min using a gradient of 100% A to 60% B in 60 minutes.  10 ml. 
fractions were collected and assayed for biological activity. Fractions containing 
biological activity were saved for further study. 
 
6.3.3 Further purification of rotifer media 
The bioactive fractions were pooled, freeze dried with SpeedVac (Savant, MA), 
reconstituted with water and injected into a 4.6mm diameter × 25cm Symmetry column 
(Waters, MA). A Breeze2 analytical LC system (Waters, MA) was employed for 
separation at 0.5 ml/min with the following solvents and gradients: Solvent A, water with 
0.1% formic acid (FA); solvent B, methanol with 0.1% FA; 0—10 min 0—10% B, 10—
30 min 10—35% B, 30—33 min 35—80% B, 33—37 min 80—80% B, 37—40 min 80—
0% B. Eluents were collected manually based on peak elution. All fractions were freeze 
dried, reconstituted with water and analyzed with MALDI MS. Fractions containing 
biological activity were saved for future use. 
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6.3.4 Matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) 
analysis 
For each collected fraction, 1 µl of sample solution was spotted on ground steel 
MALDI target and mixed with 1 µl of alpha-cyano-4-hydroxy-cinnamic acid (CHCA, 
Sigma-Aldrich, MO) solution (10 mg/ml CHCA in 50% acetonitrile solution with 0.005% 
trifluoroacetic acid). Mixed samples were dried at room temperature and subjected to 
MALDI MS analysis.  
 
6.3.5 High-resolution quadrupole time-of-flight mass spectrometry (Q-TOF MS) 
analysis  
1 µl of the bioactive fractions was separated on a Magic 0.1 × 150 mm column 
(Michrom, CA) and analyzed with maXis 4G mass spectrometer (Bruker, MA) using 
previously established method for metabolite study (Aerts et al. 2014). The separation 
was performed at 300 nl/min by use of solvent A (95% water, 5% acetonitrile with 0.1% 
FA) and solvent B (5% water, 95% acetonitrile with 0.1% FA) with the following 
gradient conditions: 0—5 min 4% B, 5—50 min 4—50% B, 50—52 min 50—90% B, 
52—60 min 90% B, 60—70 min 90—4% B, 70—90 min 4% B. 
 
6.3.6 Hydrogen/deuterium (H/D) exchange analysis 
Acidified deuterated methanol (CD3OD, methanol—d4, Sigma—Aldrich, MO) 
was made by adding 1 µl of deuterated FA into 1 ml of CD3OD. 2 µl of the bioactive 
fractions were added into 18 µL of acidified methanol above. 15 µl of the mixture were 
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analyzed by direct infusion into an 11 Tesla FTMS (Thermo Scientific, MA) through 
NanoMate robot (Advion, NY). Full spectra were acquired with resolution set at 100 k.  
 
6.3.7 Nuclear magnetic resonance (NMR) analysis 
Purified bioactive materials were dissolved in 250 µL of CD3OD and transferred 
into a 5 mm Shigemi NMR tube with a glass magnetic plug with susceptibility matched 
to CD3OD on the bottom. All NMR data were collected at 40°C on an Agilent VNMRS 
750 MHz spectrometer equipped with a 5 mm Varian indirect detection probe with z 
gradient capability. Collected NMR data included 1H spectrum, gradient selected 
correlation spectroscopy (gCOSY), total correlation spectroscopy (TOSCY), nuclear 
overhauser enhancement spectroscopy (NOESY) with a mixing time of 500 ms, 
heteronuclear single quantum coherence spectroscopy (1H—13C HSQC) and 
heteronuclear multiple-bond correlation spectroscopy (1H—13C HMBC). The NMR 
spectra were analyzed using Mnova NMR software (Mestrelab Research, Spain). 
 
6.4 Results 
6.4.1 Determination of bioactive compound target 
To find the bioactive molecule, we performed 650 MWCO filtration and two LC 
separations sequentially on the bioactive rotifer culture media. All fractions collected 
from the last LC purification were assayed for biological activity and analyzed using 
MALDI MS. The results from comparative MALDI MS profiling between bioactive and 
nonbioactive fractions showed that peak (M+H, 273.16) was detected exclusively in the 
bioactive fraction (Figure 6.1), which corresponded to the bioactive compound of interest.  
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To further confirm that m/z 273.16 was the bioactive compound we compare the 
amount of m/z 273.16 in the culture media of Philodina acuticornis, another rotifer 
species coexisting with snails that shows no paralyzing activity against cercariae. 1L of 
culture media of Rotaria rotatoria and Philodina acuticornis were processed as described 
in 6.3.2 and 6.3.3. Previous results of bioassay performed on fractions from 2
nd
 LC 
showed that the peak of bioactive compound appeared at 26±0.5 min on chromatograms. 
Therefore, materials eluted from retention time 25 to 27 min from Rotaria rotatoria and 
Philodina acuticornis 2
nd
 LC were collected, dried and reconstituted in 10 µl of water. 1 
µl of reconstituted Rotaria rotatoria and Philodina acuticornis sample were analyzed 
with LC-QTOF MS. The results showed that m/z 273.16 was only observed in Rotaria 
rotatoria sample (Figure 6.2). This matched well with the observation that Rotaria 
rotatoria but not Philodina acuticornis had Schistosoma paralyzing ability. 
 
6.4.2 Determination of the chemical formula and exchangeable proton number of 
the bioactive compound  
 We used high resolution Q-TOF MS to determine the monoisotopic mass for the 
protonated target molecule to be 273.1597 Da. This finding suggested C16H20N2O2 as the 
best-fitting formula. The best-fitting formulas for intense fragments in MS/MS spectra 
had no conflict with C16H20N2O2 in terms of numbers of nitrogen and oxygen atoms 
(Figure 6.3).  
We determined that there is one exchangeable proton in the target molecule 
through H/D exchange MS experiment. A 2Da mass increase was observed before and 
after the deuterium exchange. The most dominant peak in deuterated sample had a m/z of 
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275.1722, corresponding to deuterium singly charged target molecule with one proton 
replaced by deuterium (Figure 6.4). 
 
6.4.3 Structure elucidation through NMR analysis 
We purified and accumulated bioactive compound from 30 liters of rotifer-
conditioned media. The accumulated bioactive materials were analyzed with 1D and 2D 
NMR techniques, which measured both short- and long-range coupling between proton-
proton and proton-carbon.  
In the 1H spectra, peak areas of all non-overlapping peaks were integrated and 
protons (δH  1.34, 3.10, 3.52, 3.56, 3.81, 4.40, 6.86, 6.90 and 7.09 ) showed integer ratio, 
suggesting their signals were from the same compound (Figure 6.5 and Table 6.1). After 
adding the integration of overlapping peaks (δH 2.70, 2.72, 2.77, 2.79), a total number of 
19 protons were discovered, which showed no conflict with the best-fitting formula and 
results from the exchangeable proton experiment. 
HSQC revealed the cross—correlation between directly bonded proton and 
carbon nuclei and determined the number of methyl, methylene and methine groups. As 
shown in Figure 6.6, 19 protons were attached to 11 carbons, including: three methyl 
groups (δC 14.0 ,δH 1.34; δC 41.7 ,δH 2.71; δC 62.2 ,δH 3.81), two methylene groups (δC 
29.0 ,δH 2.79, 3.56; δC  65.8 ,δH 2.70, 3.52) and six methine groups (δC 116.8 ,δH 6.86; δC 
106.6 ,δH 6.90; δC 124.9 ,δH 7.09; δC 76.7 ,δH 3.10; δC 88.2 ,δH 4.40; δC 37.2 ,δH 2.77). The 
other 5 carbons that did not show up in the HSQC spectrum are the quaternary carbons. 
TOCSY revealed that all aliphatic protons except the two methyl groups (δH 2.71 
and 3.81) are from one single spin system (Figure 6.7). Cross peaks were also observed 
- 172 - 
 
among the aromatic proton δH 7.09 and the aliphatic protons (δH 3.56, 2.79 and 3.10), due 
to long-range couplings. Based on the carbon chemical shift, the two methyl groups (δC 
41.7, δH 2.71 and δC 62.2, δH 3.81) should be bound to nitrogen and oxygen, respectively, 
and are isolated protons in agreement with TOCSY data. Using information from the 
spectra mentioned above, the connectivity of neighboring groups was built from COSY 
and HMBC spectrum (Figure 6.8, 9 and 10). The elevated δC, 65.8 and 76.7ppm could be 
explained by the neighboring nitrogen atom in a ring system. Similarly, CH (δC 88.2, δH 
4.40) should be bound to an oxygen due to the significant δC shift towards low field. 
Overall, the aliphatic protons and carbons consist of a dimethylpyrrolidine ring system 
which is further connected to an aromatic group via a CH2 group and an oxygen. 
The connectivity-built aliphatic structure had the formula C7H13NO, which left 
C9H6NO after subtracting from the best-fitting formula. Previous analysis has shown the 
existence of methoxyl group (δC 62.2, δH 3.81). Therefore, the aromatic region was 
composed of C8H3N. HMBC data showed that three aromatic protons were located in 
different rings, implying a fused aromatic ring structure with one nitrogen (Figure 6.10). 
Substituted indole was the most common structure utilized in organisms with the matched 
formula. Besides, HMBC showed that protons on methoxyl group (δH 3.81) and aromatic 
proton (δH 6.90) have crosspeak with carbon (δC 143.1), suggesting they are meta to each 
other. The other proton (δH 6.86) was vicinal to δH 6.90 because of their coupling seen in 
1H and COSY (Figure 6.5 and 8). The aromatic singlet proton δH 7.09 showed cross 
peaks with three aromatic carbons, two of those carbons (δC 120.6 and δC 138.1) had cross 
peaks with proton (δH 6.86) and (δH 6.90) respectively, consistent with an indole 
configuration. HMBC further confirmed C (δC 110.6) was linked to CH2 (δH 2.79 and 
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3.56), and C (δC 143.7) was linked to the CH (δC 88.2 ,δH 4.40) across an oxygen atom.  
Analysis of all cross peaks in HMBC spectrum finally led to two structures (Figure 6.13).   
Results of NOESY experiment support 1 as the final structure due to the presence 
of NOE signal between H (δH 3.81) and H (δH 1.34), which could only be observed 
between protons with short spatial distance (Figure 6.11 and 12). For protons on the three 
consecutive chiral centers, H (δH 4.40) had intense cross peaks with H (δH 2.77), while 
weak signal was observed between H (δH 4.40) and H (δH 3.10) and no signal was 
observed between H (δH 2.77) and H (δH 3.10). This indicated that H (δH 4.40) and H (δH 
2.77) are close to each other and both of them are distant from H (δH 3.10), which 
corresponding to (R, S, S) or (S, R, R) configuration on C (δC 76.7, 88.2 and 37.2). This 
was further supported from NOESY signals between H (δH 2.79, 3.56) and the three H on 
chiral centers. H (δH 4.40) had medium intense signal with H (δH 2.79) but no signal with 
H (δH 3.56). However, it was opposite for H (δH 3.10) which had medium intense signal 
with H (δH 3.56) but no signal with H (δH 2.79).  
Models of (R, S, S) and (S, R, R) were built using Chem3D software and steric 
energy was minimized. Table 6.2 showed the distances between stereochemistry-related 
protons for (S, R, R) and (R, S, S) configurations. The distances for (R, S, S) matched 
with the relative signal intensity in NOESY data, while the observed NOESY signal 
relative intensity conflicted with proton-proton distances in (S, R, R) configuration. For 
example, the distances between H (δH 4.40) and H (δH 2.79, 3.10) were 4.379 and 1.948 Å 
measured for S, R, R configuration, while experimental NOESY signal between H (δH 
4.40) and H (δH 2.79) was stronger than that between H (δH 4.40) and H (δH 3.10). This 
result suggests that the bioactive compound is highly likely to adopt (R, S, S) 
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configuration, which can be confirmed after synthesis of the determined structure. 
(Figure 6.14) 
 
6.5 Discussion 
Rotaria rotatoria is able to specifically paralyze parasitic flatworm, Schistosoma 
at its infective stage. We used a wide range of analytical and modeling methods to 
elucidate the structure and stereochemistry of this unknown bioactive compound secreted 
by Rotaria rotatoria. The structure determined through NMR matches well with chemical 
formula and exchange proton number determined through MS-based experiments. 
Compounds with similar structures to the bioactive compound of interest were found 
through literature search. One of these similar compounds is ergoline. Ergoline and many 
of its derivatives bind to serotonin receptors with sub-µM potency.(9, 10) Besides, a 
patent has been filed for a class of compounds possessing affinity for serotonin receptor. 
Our determined structure is similar to their compounds with methoxyl group instead of 
methyl group at C2 position and methyl group at C14 instead of C15.(11) It is interesting 
that recent studies on Schistosoma suggested that the serotonin receptor is involved in the 
parasite's muscle contraction and affects its motility in both sporocyst and adult stages. 
Applying serotonin on sporocysts and suppressing serotonin receptors in adult worms 
using RNAi can increase and decrease parasite motility, respectively.(12, 13) Given these 
two facts, it is likely that the secreted bioactive compound also causes Schistosoma 
paralysis by binding to its serotonin receptors. Since the bioactive compound only 
appears effective on cercariae, a subtype of serotonin receptor exclusively or densely 
expressed at this life-cycle stage should be the receptor accounting for the paralysis.  
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Knowing the structure of the bioactive compound is the first step in understanding 
the mechanism of Schistosoma paralysis and development of preventive drug against 
Schistosoma infection. Many experiments are planned and can be performed in the future, 
such as synthesizing bioactive compound, testing its potency on serotonin receptors, 
elucidating the mode of action and optimizing bioactive compound.  
 
6.6 Conclusion and future directions 
In summary, we developed a robust three-stage separation protocol that efficiently 
isolates an unknown natural product secreted by rotifers from a complex chemical 
background. We determined the structure of the unknown molecule through MS and 
NMR techniques and revealed its stereochemistry by combining NMR with molecular 
modeling. Based on the structure homology, we speculate that the molecule executes its 
biological function by binding to serotonin receptors in the cercariae. On one hand, our 
work demonstrates the application of combining analytical and virtual methods in the 
discovery and characterization of natural products. On the other hand, the work has a 
biological and pharmacological impact, which can facilitate the understanding of 
Schistosoma infection and movement at molecular level and could be a start for the 
development of an alternative therapy in Schistosoma-associated diseases. 
Currently, a few follow-up studies are underway. We are collaborating with Prof. 
Marchant’s lab at University of Minnesota to test purified bioactive material on 
Schistosoma serotonin receptors expressed in human cells. The compound appears to be a 
partial agonist, weakly activating one subtype of Schistosoma serotonin receptors. Similar 
tests will be performed on the subtype of Schistosoma serotonin receptors highly 
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expressed during cercariae stage. In addition, we are collaborating with Prof. Bjorn C. G. 
Soderberg’s group at West Virginia University to synthesize the structure we determined, 
which we can test using the bioassay. His lab has also successfully synthesized the 
serotonin antagonists reported in the Japanese patent, which are structurally similar to our 
determined structure. We will also test these two compounds on cercariae. These follow-
up studies will help us confirm the structure of the bioactive molecule as well as the 
receptor it acts on.  
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6.8 List of Figures and Tables 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Comparative MALDI profiling of fractions collected from 2
nd
 HPLC. (A). 
CHCA matrix blank. (B). Fraction before bioactive fraction. (C). Bioactive fraction. m/z 
273.20 exclusively present in bioactive fraction is pointed out with a red arrow.  (D). 
Fraction after bioactive fraction.  
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Figure 6.2 Extracted ion chromatograms of m/z 273.1600 in Rotaria rotatoria and 
Philodina acuticornis culture media. Eluent between 25 and 27 min on the 2
nd
 LC of 
Rotaria rotatoria and Philodina acuticornis culture media were collected, dried, 
reconstituted to 10 µl. 1 µl of reconstituted  Rotaria rotatoria and Philodina acuticornis 
fractions were analyzed with nanoLC-QTOF MS. Extracted ion chromatograms of m/z 
273.1602±0.005 Da of Rotaria rotatoria and Philodina acuticornis culture media after 
2
nd
 LC were shown. Red: Rotaria rotatoria sample. Blue: Philodina acuticornis sample. 
The compound of 273.16 Da was exclusively only secreted by Rotaria rotatoria and 
present in Rotaria rotatoria culture media.  
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Figure 6.3 MS and tandem MS of the bioactive compound acquired using high-
resolution Q-TOF analysis. The best-fitting formula of the precursor ion was C16H21N2O2. 
The best-fitting formula of intense peaks matches with the target molecule in terms of the 
number of C, H, N and O atoms.  
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Figure 6.4 Isotopic pattern of m/z 273.1600 molecule before and after deuterium 
exchange. FTMS determined the accurate monoisotopic mass of the target molecule and 
revealed its isotopic pattern. (A) Before deuterium exchange, 273.1597 was determined 
to be the monoisotopic mass of the target molecule.  (B) After deuterium exchange, m/z 
of the base peak increased to 275.1722. The isotopic pattern suggested the presence of 
one exchangeable proton in the target.  
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Figure 6.5 1H NMR spectrum of the target molecule. 
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Figure 6.6 
1
H—13C HSQC NMR spectrum of the target molecule. 
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Figure 6.7 TOCSY NMR spectrum of the target molecule. 
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Figure 6.8 COSY NMR spectrum of the target molecule. 
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Figure 6.9 
1
H—13C HMBC NMR spectrum of the target molecule (aliphatic region). 
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Figure 6.10 
1
H—13C HMBC NMR spectrum of the target molecule (aromatic region). 
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Figure 6.11 NOESY NMR spectrum of the target molecule. (Aliphatic region) 
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Figure 6.12 NOESY NMR spectrum of the target molecule. (Aromatic region) 
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Figure 6.13 Final two structures determined from NMR experiments except NOESY. 
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Figure 6.14 Target molecule structure determined through NMR data. NOESY resolved 
the relative stereochemistry of three chiral centers and narrowed down possible 
configuration to (R, S, S) or (S, R, R) at C12, 13, 14 positions. Left: (R, S, S); Right:(S, R, 
R). 
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Table 6.1 Summary of proton and carbon signals from 1H, COSY, HSQC, HMBC and 
NOESY.  
 
 13C 1H  
Positio
n 
δC 
(detected
) 
δC 
(predicted
) 
mult
. 
δH Peak 
area 
mult. COS
Y 
HMBC NOESY 
1 116.8 110.4 CH 6.86 1.12 d  6 3, 5 18 
2 143.1 148.2 C       
3 143.7 143.1 C       
4 120.6 120.3 C       
5 138.1 132.5 C       
6 106.6 103.7 CH 6.90 1.00 d  1 2, 4  
7 110.6 110.8 C       
8 124.9 123.0 CH 7.09 1.00 s  4, 5, 7 11,11’ 
9   NH       
10   O       
11 29.0 32.5 CH2 2.79  Overl
ap 
11’, 
12 
7, 8,12,13 8,11’,13 
11’ 29.0 32.5 CH2 3.56 1.04 dd  11, 
12 
4,7,8,12,1
3 
8,11,12 
12 76.7 72.1 CH 3.10 1.16 br 11, 
11’, 
13 
 11’,13,14,17,18 
13 88.2 84.5 CH 4.40 1.05 dd  12, 
14 
3,11,15 11,12,14,17 
14 37.2 38.9 CH 2.77  Overl
ap 
13, 
15’, 
17 
15,17 12,13,15’,17 
15 65.8 62.6 CH2 2.70  Overl
ap 
15’ 12  15’,17 
15’ 65.8 62.6 CH2 3.52 1.08 dd 14 12,13 14, 15,17,18 
16   N       
17 14.0 14.6 CH3 1.34 3.01 d  14 13, 14, 15 12,13,14,15,15’,2
0 
18 41.7 43.7 CH3 2.71  s  12, 15 12,15’ 
19   O       
20 62.2 56.1 CH3 3.81 2.98 s  2 17 
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Table 6.2 Summary of NOSEY and molecular modeling data. (A). The relative signal 
intensity of crosspeaks in NOSEY spectrum. (B). Model for (S, R, R) configuration was 
established. Steric energy and proton-proton distances were measured based on the 
established model. (C). Model for (S, R, R) configuration was established. Steric energy 
and proton-proton distances were measured based on the established model. 
 
 
A. NOE signal relative intensity of protons at chiral centers and nearby carbons.  
 
 H11(2.79ppm) H11’(3.56ppm) H12(3.10ppm) H13(4.40ppm) 
H11(2.79ppm)     
H11’(3.56ppm) s    
H12(3.10ppm) N m   
H13(4.40ppm) m N w  
H14(2.77ppm) N N w s 
s, strong; m, medium; w, weak; N, none.  
 
B. Calculated H-H spatial distance (Å) from energy minimized model for (C12, 13, 14; S, 
R, R) configuration. The minimized steric energy was 110.8652 kcal/mol. 
 
 H11(2.79ppm) H11’(3.56ppm) H12(3.10ppm) H13(4.40ppm) 
H11(2.79ppm)     
H11’(3.56ppm) 1.709    
H12(3.10ppm) 2.623 1.969   
H13(4.40ppm) 4.379 3.637 1.948  
H14(2.77ppm) 4.709 4.671 3.312 2.346 
 
C. Calculated H-H spatial distance (Å) from energy minimized model for (C12, 13, 14; R, 
S, S) configuration. The minimized steric energy was 35.5899 kcal/mol. 
 
 H11(2.79ppm) H11’(3.56ppm) H12(3.10ppm) H13(4.40ppm) 
H11(2.79ppm)     
H11’(3.56ppm) 1.799    
H12(3.10ppm) 3.098 2.477   
H13(4.40ppm) 2.500 3.690 3.080  
H14(2.77ppm) 3.938 4.977 3.857 2.255 
 
 
 
